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ABSTRACT
The in vitro efficacy and mechanism of action of two purine analogues, arprinocid and 
its in vivo metabolite arprinocid-1 -N-oxide, were investigated against T. gondii 
tachyzoites using two contrasting approaches. Firstly, a global proteomics approach was 
undertaken for the analysis of proteins expressed in the tachyzoite stage of T. gondii, as 
a preliminary to analysing differences between arprinocid-1-N-oxide-resistant and - 
sensitive parasites. Secondly, a biochemical approach to investigate purine transporters 
of T. gondii as possible conduits or targets for arprinocid and arprinocid-1-N-oxide.
Initial work using ^H-uracil growth uptake to measure the growth of tachyzoites enabled 
the measurement of the basic anti-parasitic properties of the compounds. The IC50 
values for arprinocid and arprinocid-1-N-oxide were 22.4 ± 5.0 p.M and 0.061 ± 0.028 
juiM, respectively. Both compounds were specific to T. gondii at therapeutic 
concentrations and acted irreversibly within a short period of time.
High-resolution two-dimensional electrophoresis (2-DE) using the pH ranges 4-7 and 6- 
11 reproducibly separated over 1,000 polypeptides, whilst further separations using 
narrow range gels suggested that at least 3,000-4,000 polypeptides should be resolvable 
by 2-DE using multiple single pH unit gels. Peptide mass fingerprint (PME) data 
acquired by MALDI-time-of flight mass speetrometry, enabled unambiguous protein 
identifications to be made where full gene sequence information was available. 
However, interpretation of the T. gondii EST database using PMF data was less reliable. 
In contrast, peptide fragmentation data, acquired by MALDI-post-source decay mass 
spectrometry, proved a successful strategy for the putative identification of proteins 
using the T. gondii EST database. Moreover, peptide fragmentation data permitted the
iii
identification of T. gondii proteins based on peptide homology to known proteins from 
other organisms. The data demonstrated that proteomic analyses are now viable for T. 
gondii and other protozoa for which there are good EST databases, even in the absence 
of complete genome sequence. Work presented in this thesis demonstrated the 
usefulness of proteomics for the investigation of strain variation, protein changes as a 
consequence of genetic manipulation, and protein expression differences between 
arprinocid-1-N-oxide-sensitive and -resistant T. gondii lines. Detailed analysis of these 
drug-sensitive and -resistant mutants indicated that they reproducibly differed in only 
one protein, although it is suspected that further analysis using narrow range IPG strips 
may yield more differences. Unfortunately, this differentially expressed protein remains 
unidentified probably because of the incompatibility of silver-staining with mass 
spectrometry analysis.
Although proteomics is a powerful collection of tools for the investigation of biological 
questions, currently it is in an early development phase. In contrast, classical 
biochemical approaches, such as the oil-stop technique for measurements of purine 
transport, are more standardised. Characterisation of purine transport in T. gondii 
resulted in the identification of a high affinity transporter for hypoxanthine (TgHTl; Km 
= 0.91 ± 0.19 p,M) and low affinity transporters for inosine (TglTl; 656 ± 259 qM) and 
adenosine (TgATl; Km = 105 ± 22 piM). No saturable transport of [^H]-adenine was 
observed. The discovery of a hypoxanthine transporter with a 100-fold higher affinity 
for substrate than the purine nucleoside transporters indicates that TgATl may not be 
the main carrier responsible for purine salvage in this organism. Both arprinocid and 
arprinocid-1-N-oxide inhibited TgATl with high affinity (K; = 3.3 ±1.1 pM and Ki =
10.4 ± 3.4 pM, respectively), suggesting that these drugs may be substrates for, or
inhibitors of, this transporter. Although their exact mechanisms of action remain to be 
elucidated, neither drug acts on T. gondii by interfering with the hypoxanthine-xanthine- 
guanine-phosphoribosyltransferase (HXGPRT)-mediated purine salvage.
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Chapter 1: Introduction
CHAPTER 1 
Introduction
1.1 Toxoplasma gondii and toxoplasmosis
Toxoplasma gondii, an intracellular coccidian parasite belonging to the phylum 
Apicomplexa, is an important pathogen affecting both humans and animals. Over 500 
million people are infeeted with T. gondii (Denkers and Gazzinelli, 1998). Although 
infection in humans is common, disease is rare and usually confined to risk groups, such 
as the immunocompromised for whom toxoplasmosis represents a life-threatening 
disease. Infection with T. gondii has been pinpointed as a common cause of central 
nervous system defects in AIDS patients, for example, toxoplasmic encephalitis. 
Toxoplasmosis also causes more than 3000 congenital infections per year in the USA 
alone (Joiner and Dubremetz, 1993). In addition to human infections, the economic 
impact to the farming industry is considerable and may be pereeived on two levels. 
Firstly, the direct loss of livestock due to abortion storms (see Section 1.4.3), and 
secondly, meat products from Toxoplasma-infQcXcd livestock, such as sheep, goats and 
pigs, are a risk to human health.
The mainstay of treatment for human toxoplasmic encephalitis, a combination of 
pyrimethamine and sulfadiazine, has severe side effects often resulting in poor patient 
compliance. Furthermore, the lack of therapeutic agents to treat the tissue cyst stage of
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T. gondii, which is responsible for the recrudescence of disease, is of great concern due 
to the persistence of the parasite in the host. In combination with a world-wide increase 
in the number of AIDS patients, the incidence of toxoplasmosis is certain to rise. 
Therefore, continued research into the biology and biochemistry of T. gondii is essential 
to improve our understanding of Toxoplasma and toxoplasmosis. This will provide 
information that is pivotal for the identification of novel therapeutic targets and 
ultimately for the development of new, improved ?inii~Toxoplasma drugs.
1.2 Life cycle
1.2.1 Historical perspective
T. gondii parasites were first described by Nicolle and Manceaux (1908) in the blood, 
spleen and liver of a North African rodent, Ctenodactylus gondii. At this time the 
biology of this newly described parasite, originally named Leishmania gondii, was 
poorly understood, resulting in confusion over its classification. However, this new 
species lacked a kinetoplast, in contrast to Leishmania species, and so in 1909 was 
renamed Toxoplasma gondii. Toxoplasma is derived from two Greek words, Toxon = 
bow or arc; and plasma = form, and is descriptive of the crescentic shape of the 
intracellular form of the parasites.
Soon after the discovery of T. gondii, researchers began to investigate its life cycle and 
the routes of transmission. Early work had demonstrated that T. gondii was an obligate 
intracellular parasite which invaded nucleated cells and produced fatal infections in 
mice, guinea pigs, rabbits and chickens (Sabin and Olitsky, 1937). Transmission of T. 
gondii using mice-to-mice contact experiments were negative until small numbers of
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animals were allowed to feed on other mice recently deceased due to infection with T. 
gondii (Sabin and Olitsky, 1937). This led to the realisation that transmission via 
contaminated tissue was possible.
The first theory of Toxoplasma transmission suggested the cause of parasitaemia was a 
blood-sucking insect (Woke et a i, 1953). An insect responsible for transmission was 
not discovered. A few years later tissue cysts were identified in pork and subsequently 
linked with toxoplasmosis (Weinman & Chandler, 1956). These cysts were resilient to 
extremes of temperature and to strong acids (for example gastric juices), thereby 
supporting the idea that they are an important form of Toxoplasma and could be 
involved in transmission via ingestion (Jacobs et a l, 1960). However, this theory was 
insufficient to explain how vegetarians or herbivores became infected.
Speculation grew on the possible involvement of a nematode, Toxocara cati, in 
transmitting T. gondii from cat faeces. Initial work demonstrated that the faeces of a cat, 
infected with Toxocara cati two months prior to being infected with T. gondii tissue 
cysts (derived from murine infections), resulted in experimental transmission of 
toxoplasmosis to mice (Hutchison, 1965). Hutchison, (1967) proposed that Toxoplasma 
was contained within the ova of T. cati and was released when larval worms hatched in 
the intestine of a warm-blooded host. This hypothesis was further substantiated by the 
demonstration that filtration of T. cati ova destroyed the infectivity of the suspension 
(Hutchison, 1967). However, it was not realised that Toxoplasma oocysts tend to 
aggregate onto large particles, such as faecal debris, that are too big to pass through the 
filter (Frenkel et a l,  1969). Moreover, infection by T. gondii had previously been 
shown to be possible in the absence of T cati (Dubey, 1968). Thus doubt was cast on 
the nematode theory.
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Hutchison (1965) observed oocysts in the faeces of cats, but because they were similar 
to the genus Isospora they were not considered to be associated with Toxoplasma. The 
oocyst, originally described as a "new cystic form of Toxoplasma,'^ was shown to be 
responsible for transmission of T. gondii from cat faeces without, as previously thought, 
the involvement of nematodes (Hutchison et al., 1969; Work and Hutchison, 1969). 
Work and Hutchison (1969) showed that there was a correlation between the number of 
oocysts given to mice and the severity of infection. Freshly excreted faecal oocysts did 
not transmit toxoplasmosis to mice but if oocysts were left at room temperature for 2-3 
days to allow sporulation, transmission of toxoplasmosis could occur. Cats excreted 
oocysts approximately 3 weeks (prepatent period) after being fed faecal oocysts from 
infected cats, 3 - 5  days after being fed tissue cysts from an infected mouse and 9 - 1 1  
days after being fed tachyzoites (Frenkel et ah, 1970). Similar observations were 
reported by Dubey et a l,  (1970). The discovery of the Toxoplasma oocyst led to the 
complete life cycle being fully understood and the realisation that infections could occur 
from tachyzoites, ingestion of tissue cysts or contamination from faecal oocysts. The 
complete life cycle was published by Hutchison et a l, (1971) (Figure 1.1). The life 
cycle comprises two distinct parts, (i) the sexual cycle, which only occurs in cats and 
felidae, the definitive hosts of T. gondii, and (ii) the asexual cycle, which occurs in any 
warm-blooded mammal or bird (Miller et a l, 1972). During each of these cycles the 
parasites undergoes distinct developmental changes.
1.2.2 Sexual cycle
Toxoplasma gondii infection of cats is by ingestion of one of the infective stages, i.e. 
tachyzoite, bradyzoite or sporozoite. Regardless of the route of infection, a common 
pathway exists in which parasites first undergo schizogeny and then gametogeny
Chapter 1: Introduction
SEXUAL CYCLE ASEXUAL CYCLE
Cats & other felidae Warm blooded animals and birds
BRADYZOITE 
(tissue cysts)
à VSporogony & 
Gametogony
TACHYZOITE
Sporozoite in oocysts
ENVIRONMENT
After Evans, 1993
Figure 1.1. Simplified life cycle of Toxoplasma gondii. The life cycle 
may be considered in two parts (i) sexual cycle, which occurs in cats 
and other felidae resulting in excretion of oocysts, containing 
sporozoites, in the faeces (ii) asexual cycle, which occurs in warm­
blooded animals and birds. Tachyzoites are the rapidly dividing form 
of Toxoplasma and are characteristic of acute infection. Bradyzoites 
are the slowly dividing form and are characteristic of latent chronic 
infections. In immunodeficient hosts, re-activation of bradyzoites into 
tachyzoites causes recrudescence of disease.
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(Dubey and Frenkel, 1972; Hutchison et a l, 1971). However, the prepatent period (the 
time from infection to production of oocysts) varies depending on the source of 
infection (refer to Section 1.2.1; reviewed (Dubey, 1998).
1.2.2.1 Schizogony
The transmission of Toxoplasma is enhanced by the resistance of the oocysts to 
environmental factors (Yilmaz and Hopkins, 1972) and by the shedding of millions of 
oocysts (Jackson and Hutchison, 1989). The production of such a large number of 
oocysts is achieved by the multiplication of Toxoplasma by a process known as 
schizogony. Schizogony occurs in the epithelial cells of the small and large intestines of 
the cat and is a process whereby the nucleus of the mother cell repeatedly divides 
resulting in multiple daughter cells.
1.2.2.2 Gametogony
The development of the sexual stages of Toxoplasma, known as gametogony, occurs 
between 3 and 15 days post-infection. Male gametocytes, containing between 6 and 21 
gametes, are few in number ( 2 - 4  %) compared with the total number of mature 
gametocytes. Each male gamete is elongated in appearance and contains two flagella, 
presumably used to help move towards female gametes. Fertilisation results in the 
production of a zygote, which is enclosed within a tough oocyst wall. Oocysts move 
through the small intestine and are excreted in faeces where they then undergo 
sporulation (Dubey and Frenkel, 1972).
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1.2.2.3 Sporulation
Enclosed within the oocysts two sporoblasts form, which subsequently mature into two 
binucleate sporocysts. Inside each sporocyst, four sporozoites are produced resulting in 
a total of eight sporozoites inside a single oocyst. Sporulated oocysts may be formed 
within 24 h after being excreted in cats' faeces and may remain infective for up to one 
year outdoors in temperate climates (Yilmaz and Hopkins, 1972). Cats tend to be 
relatively clean animals and often bury their faeces, thus the warm moist texture of the 
soil may serve to increase viability of the oocysts and consequently increase the 
likelihood of transmission to a new host. Infection with oocysts may occur via a variety 
of routes including, contaminated vegetables, animal feed and grazing pastures or from 
accidental ingestion of oocysts during cleaning of cat litter trays.
1.2.3 Asexual cycle
The asexual cycle of T. gondii can be considered as two stages. Firstly, the production 
of tachyzoites which are characteristic of acute infection, and, secondly, the production 
of bradyzoites or tissue cysts present during latent chronic infection (Figure 1.1).
1.2.3.1 Tachyzoites
Infection of a new host with oocysts results in the release of sporozoites that may then 
enter the gastrointestinal tract and transform into tachyzoites. Subsequently, parasites 
disseminate via the bloodstream to organs and tissues within the body whereby they can 
invade any nucleated cell. Parasite replication takes place by a process of “internal 
budding,, called endodyogeny, derived from the Greek words: endon = within/inside;
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dyo = two; and genesis = birth (Goldman et a l, 1957). Endodyogeny is a process by 
which a mother cell divides to produce two identical daughter cells, the parent being 
destroyed in the process (Goldman et a l, 1957).
T. gondii tachyzoites have highly developed organelles (rhoptries, micronemes and 
dense granules) which allow entry into the target cell by an active process rather than by 
phagocytosis. Invasion consists of many individual steps that occur individually or 
concurrently. The main processes involve attachment of the apical end of the parasite to 
the host cell surface, excretion of microneme and rhoptry proteins from specific 
organelles located at the apical end of the parasite, followed by the release of dense 
granules and vacuole formation (reviewed Dubremetz et a l, 1998; Joiner and 
Dubremetz, 1993). The complete process occurs in less than 15 - 40 s (Werk, 1985). It 
is hoped that understanding the precise and complex mechanisms involved in invasion 
will lead to the discovery of new chemotherapeutic targets.
1.2.3.2 Microneme proteins
Micronemes are organelles, located at the apical end of T. gondii tachyzoites, that 
release proteins that play a role in host-cell invasion (reviewed by Soldati et a l, 2001; 
Tomley and Soldati 2001). To date, 30 microneme proteins have been identified from 
Cryptosporidium, Eimeria, Neospora, Plasmodium, Sarcocystis and Toxoplasma 
(Tomley and Soldati, 2001), including the recently discovered T. gondii microneme 
protein, TgMIClO (Hoff et a l, 2001). Considerable sequence homology in the adhesive 
domains of microneme proteins exists between these genera, suggesting that invasion 
processes may be conserved at the molecular level (Tomley and Soldati, 2001).
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The identification of thrombospondin-related adhesive protein (TRAP) in Plasmodium 
sporozoites (Robson et al., 1988) was central to the identification of homologues in T. 
gondii (Wan et al., 1997). Like TRAP, TgMIC2 contains thrombospondin (TSP) repeats 
and similarly is considered to be important in host-cell attachment and invasion. During 
apical attachment to the host cell, TgMlC2 is distributed across the host cell membrane 
during invasion, but is not incorporated into the parasitophorous vacuole (Carruthers et 
al., 1999; Carruthers and Sibley, 1999). TgMICl contains two (degenerate) TSP repeats 
with low homology to TRAP, suggesting that these proteins are also functionally similar 
(Fourmaux et al., 1996). Other conserved functional structures, including I-domains, 
epidermal growth factor (EGF)-domains and apple domains, have been identified 
(reviewed Tomley and Soldati, 2001). TgMICS contains five EGF domains which are 
potentially involved in protein-protein interactions and thus may act as a link between 
parasite and host cell (Garcia-Reguet et a l, 2000). TgMIC4 consists of six conserved 
apple domains, each of which has four tandemly repeated structures that are stabilised 
by three internal disulphide bonds (Brecht et a l,  2001). The exact role of these apple 
domains remains to be elucidated, and thus far TgMIC4 is the only T. gondii microneme 
protein identified to have these domains. Recently another microneme protein, 
TgMIClO, has been identified. This lacks homology to any previously identified 
microneme protein, except one found in Neospora caninum, and may therefore indicate 
the presence of a new family of microneme proteins (Hoff et a l, 2001). Its role is yet to 
be determined.
The secretion of microneme proteins is regulated by cytoplasmic free Ca^  ^ in the 
parasite (Carruthers and Sibley, 1999). Release of intracellular Ca^^ by NH4 CI or 
thapsagargin treatment was shown to trigger microneme release from extracellular 
tachyzoites, suggesting that intracellular Ca^ "^  stores are sufficient to initiate invasion
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processes (Carruthers and Sibley, 1999). The recently defined acidocalcisome, found in 
bacteria, fungi, algae and protozoa contains millimolar concentrations of Ca^ "^  and 
although the majority of this Ca^^ is bound, it may be an essential source of free Ca^ "^  
required for release of micronemes (Docampo and Moreno, 2001). Since the 
acidocalcisome is not present in mammalian cells, it offers the exciting prospect of 
being a parasite-specific drug target. The acidocalcisome is membrane-bound, which 
will presumably cause difficulties in the design of drugs that can penetrate this barrier. 
However, this organelle, in addition to being a source of calcium, also has a range of ion 
pumps and proton exchangers, which also may be targeted (Docampo and Moreno, 
2001). The exact nature and function of these pumps is not known but are thought to be 
involved in the regulation of pyrophosphates, polyphosphates and other cations 
(Docampo and Moreno, 2001). Whether these functions are essential to the parasite 
survival remains to be seen.
Some microneme proteins are proteolytically processed to an active form before being 
released from the parasite (Carruthers et al 2000). For example, prior to the secretion of 
TgMIC2 (115 kDa), the C-terminus and V-terminus domains are sequentially removed 
by two distinct proteases found on the parasite surface (termed MPPl and MPP2).
The mechanism by which microneme proteins reach their designated organelle is not 
known. However, all micronemes are synthesised with an W-terminal signal sequence 
that is presumably involved in translocation of the protein (Tomley and Soldati, 2001). 
The extracellular adhesive domains of microneme proteins have been shown to interact 
with specific receptors on the surface of the host cell, and although the exact nature of 
these receptors is still unknown, lectins, laminins and glycans are thought to be 
important (Tomley and Soldati, 2001).
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1,2.33 Rhoptry proteins
The initial contact between T. gondii tachyzoites and a host cell triggers the release of 
proteins from rhoptry organelles (reviewed Dubremetz et al., 1998). Rhoptry proteins, 
in particular penetration enhancing factor (Lycke et al., 1975), later renamed rhoptry 
protein ROPl, are found in the parasitophorous vacuole. Although their function is not 
certain, it is feasible that they are involved in the construction of this vacuole. One 
hypothesis is that rhoptry proteins may contribute to the formation of small pores in the 
vacuolar membrane which allow free exchange between the host cytoplasm and the 
vacuolar space (Schwab et al., 1994). Current opinion on whether the parasite or the 
host cell contributes the material for the formation of the vacuole membrane has been 
extensively reviewed by Dubremetz and co-workers (1998), but the question remains 
largely unanswered. Capacitance of the host cell during invasion by T. gondii has been 
recorded by patch clamping and shown not to increase, and since capacitance is 
correlated with cell surface this would suggest that vacuoles consist primarily of 
invaginated host cell outer membrane (Suss-Toby et al 1996). During vacuole closure, 
capacitance is decreased which would indicate a drop in host cell surface area as the 
vacuole pinches off from the host cell membrane (Suss-Toby et al 1996). According to 
Suss-Toby and co-workers (1996), up to 18.5 % of material for the vacuole is parasite 
derived.
1.2.3.4 Dense granule proteins
Proteins released from dense granule organelles (GRA), during and subsequent to 
invasion of host cells, are thought to be involved in structural modifications of the 
parasitophorous vacuole (reviewed Cesbron-Delauw, 1994). These modifications are
11
Chapter 1: Introduction
unknown but are thought to be necessary for T. gondii survival. At least eight dense 
granules have been identified (Cesbron-Delauw, 1994). Several dense granule proteins, 
GRAl, GRA2, GRA4, GRA6 and GRA7 are all targeted to the vacuolar space, whilst, 
GRA5 is associated with the vacuole membrane and GRA3 is targeted to both (Fischer 
et al., 1998; Labruyere et al., 1999; Lecordier et al., 1993; Mercier et a l, 1993). A 
mutant T. gondii line lacking GRA2 was shown to invade fibroblasts and macrophages 
in vitro but exhibited reduced virulence in mice, thus demonstrating that GRA2 (and 
perhaps other GRA proteins) may be important in T. gondii pathogenesis (Mercier et 
al, 1998).
1.2.3.5 Surface antigens
The surface of T. gondii tachyzoites and bradyzoites is a complex entity being covered 
by many glycosyl-phosphatidylinositol (GPI)-anchored proteins (reviewed Lekutis et 
al., 2001). Currently, there are 21 known surface antigens belonging to two main 
families, (i) surface antigen 1 (SAGl) and (ii) surface antigen 2 (SAG2). The SAGl 
family consists of GPI-anchored proteins with 12 conserved cysteine residues of SAGl 
and approximately 30 % (or more) overall homology (Manger et a l, 1998). The SAG2 
family consists of those proteins related to the SAG2 antigen and have an incomplete 
set of cysteine residues and a low overall homology (approximately 20 %) (Lekutis et 
al., 2000). In addition, SAG2 family proteins are smaller proteins, approximately 200 
amino acids, compared with SAGl family antigens which contain over 300 amino acids 
(Lekutis et a l, 2001).
The expression profile of many of the SAG genes has not been fully analysed, and 
although much work has been performed to determine which antigens are expressed in 
tachyzoites and/or bradyzoites, little is known about surface proteins found in the sexual
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stages of T. gondii. To date eight surface antigens (SAGl, SRSl, SRS2, SRS3, SAG2A, 
SAG2B, SAG5B and SAG5C) have been found to be expressed only within tachyzoites 
and five SAG antigens (BSR4, SAG2C, SAG2D, SAG 4A and SAG5A) have been 
found to be expressed only within bradyzoites (Lekutis et a l, 2001). SAG3 has been 
identified in both tachyzoites and bradyzoites (Cesbron-Delauw et al., 1994). The most 
likely reading frame of SRS5 contains four stop codons and a frame shift, indicating 
that it is a pseudogene; SRS5 is not expressed in either the tachyzoite or bradyzoite 
stage (Lekutis et al., 2001).
The roles of SAG proteins are not completely understood but they are thought to be 
involved in host cell invasion, immune regulation, virulence and in the intracellular 
survival of parasites. One theory is that SAG proteins are used to adhere to host cells 
and that the vast array of antigens expressed by T. gondii may explain, to some extent, 
its ability to invade a wide range of nucleated cells (Boothroyd et a l, 1998). Analysis of 
surface proteins present in species with a more limited host range, such as Neospora, 
could give vital clues. Antibodies raised against SAGl have been shown partially to 
block T. gondii invasion (Mineo et a l, 1993) and more recently a knockout mutant of 
SAGl has been shown to have reduced virulence compared to parental wild-type 
control infections (Lekutis et a l, 2001). Similarly, a SAG3 null mutant was also less 
virulent than wild-type strains (Dzierszinski et a l, 2000). The creation of a double 
knockout of SAGl and SAG3 has been attempted but failed, indicating that at least one 
of these proteins is required for invasion (Dzierszinski et a l, 2000). Further studies 
using single or double SAG gene knockout mutants are needed to elucidate which genes 
are essential and to obtain a more complete understanding of the host-parasite 
relationship. It seams feasible that differential expression of SAG genes between T.
13
Chapter 1: Introduction
gondii life stages will be important in tachyzoite-bradyzoite transition and therefore 
gene deletions in tissue-cyst forming strains could give valuable insights critical to drug 
or vaccine development strategies.
1.2.3.6 Bradyzoites
In immunocompetent hosts, tachyzoites are converted to bradyzoites which form cysts 
in a wide variety of tissues (especially the brain and skeletal muscle). They may persist 
for the lifetime of the host, thus acting as a reservoir of latent infection. The 
recrudescence of acute infection in immunodeficient hosts is of clinical significance, for 
example among AIDS patients over 95% of toxoplasmic encephalitis cases are due to 
the reactivation of Toxoplasma bradyzoites (Luft and Remington, 1992). Currently, 
there is no licensed drug proven to destroy or reduce the foimation of tissue cysts. This 
is perhaps a consequence of the inability for sufficient concentrations of therapeutic 
agents to cross the blood-brain-barrier and/or to penetrate the cyst wall. Better 
understanding of the signalling pathways involved in tachyzoite-bradyzoite 
interconversion is critical and is likely to be important for the discovery of therapeutic 
targets against the bradyzoite stage.
The timing of tachyzoite-bradyzoite interconversion is dependent on the immune 
response (McCabe & Oster, 1989; Subauste and Remington 1993), although the extent 
of the involvement of the immune response in controlling interconversion is unknown. 
During this transition, it is likely that changes in metabolism and gene expression occur 
thus enabling T. gondii to adapt to a different environment. As discussed above, it is 
known that stage-specific antigens are expressed. Experimental evidence suggests that 
in vitro conversion of tachyzoites to bradyzoites occurs in response to external stress
14
Chapter 1: Introduction
conditions. For example, (i) incubation of tachyzoites with gamma interferon (Bohne et 
al., 1993), (ii) incubation with mitochondrial inhibitors, such as oligomycin or 
antimycin A (Bohne et a l,  1993), (iii) culture in acidic (pH 6.8) or alkaline (pH 8.2) 
media (Bohne et a l, 1994; Soête et a l, 1994) and (iv) culture of tachyzoites at 43°C 
(Soête et a l, 1994).
Obtaining large quantities of bradyzoites is more difficult than for tachyzoites, and this 
is reflected in our current limited knowledge of this life-stage. However, the study of 
bradyzoites in vitro is now possible and should greatly contribute to our knowledge over 
the coming years. Recently, bradyzoite development has been linked to a family of heat 
shock proteins (hsp) and although the implications of this are unknown, future studies 
using gene knockouts should help elucidate the roles of hsps (Soête et a l,  1994). 
Interestingly, a bradyzoite-specific antigen, BAGl/hsp30 (BAG5), has C-terminal 
homology to hsps from plants that have been implicated in differentiation events, such 
as seed formation (Soête et a l, 1994). Despite BAG5 being specific for bradyzoites, it 
is not an essential gene for cyst formation since null mutants were able to form cysts in 
vivo, albeit at a reduced frequency (Zhang et a l, 1999). It would, therefore, appear that 
several genes are involved in cyst formation, and that alternative proteins are able to 
compensate for the lack of BAGS. The complexity of the process is indicated further by 
the asynchronous differentiation of bradyzoites and existence of intermediate stages that 
express both tachyzoite- and bradyzoite-specific antigens (Soête et al., 1993). Recent 
evidence suggests that cyclic nucleotide signalling pathways are involved in stress- 
induced tachyzoite-bradyzoite conversion (an increase in cAMP induces bradyzoites 
formation) (Kirlonan et a l, 2001).
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1.3 Virulence
The severity of toxoplasmosis is related to both the virulence of the infecting strain and 
to host factors. In mice, some strains readily undergo conversion from the tachyzoite 
stage to the bradyzoite stage resulting in latent infections (such as the Beverly strain), 
whilst virulent strains remain in the tachyzoite form causing acute infections (for 
example RH T. gondii). Phylogenetic analysis, using restriction fragment length 
polymorphisms (RFLP), indicate that three clonal lineages exist. There are (i) Type 1 
which are virulent in mice, (ii) Type II which are predominantly found in human 
infections and (iii) Type III which are predominantly found in animal infections 
(reviewed Sibley and Howe, 1996). However, recent evidence from sequencing loci of 
antigenic proteins suggests that only two clonal lineages exist and that the predominant 
genotypes arise from a genetic mixing of two distinct ancestral lines (Grigg et al, 
2001). The Fi progeny of a cross between mice avirulent type II and mice avirulent type 
III T. gondii strains produced progeny that were three logs more virulent than the 
parental generation, thereby indicating virulence may occur by recombination of alleles 
at two or more loci (Grigg et al, 2001). Strains that are virulent in one species may be 
avirulent in another, and vice-versa. These strain variations are important in disease 
manifestation and clinical treatment. Understanding, these differences should lead to 
better treatment strategies and development of vaccines. For example, the S48 T. gondii 
strain is not able to produce tissue cysts (Wilkins et a l, 1987) and has been successfully 
tested as a Toxoplasma vaccine, Toxovax™ (Buxton, 1993).
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1.4 Incidence of disease
1.4.1 Immunocompromised host
The vast majority of acute infections in immunocompetent humans are asymptomatic 
and treatment is not warranted. However, onset of disease may be severe in 
immunocompromised hosts (AIDS, cancer chemotherapy and organ transplant patients) 
and consequently treatment is necessary. The predominant disease manifestation is 
toxoplasmic encephalitis (TE). In the USA one third of all seropositive AIDS patients 
will develop TE whilst in Europe it is estimated that 25-50% of seropositive AIDS 
patients will develop TE (Luft and Remington, 1992).
1.4.2 Congenital infection
Toxoplasma infection is only passed on to the foetus during pregnancy if the woman is 
infected after conception and the likelihood of foetal transmission is increased the later 
on in the pregnancy that infection is acquired (McCabe and Oster, 1989). Infections 
during pregnancy are usually asymptomatic and therefore the only method to detect a 
risk of foetal infection is by screening. However, political views on screening for 
toxoplasmosis in pregnancy vary. In France and Austria congenital toxoplasmosis is 
considered more of a public health hazard and both countries operate screening 
programmes, whilst in the UK and USA routine screening is not performed. In France, 
87 % of pregnant women are seropositive to Toxoplasma whilst only 20 % of women in 
the UK are seropositive (Chatterton, 1992).
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1.4.3 Domestic animals and cats
Many studies have been performed to assess the prevalence of Toxoplasma in domestic 
animals, but the results have shown high variability between different regions and 
different studies (reviewed Jackson and Hutchison, 1989; Evans 1992). Infections in 
horses and cattle generally result in few clinical symptoms, however, infections in 
ruminants can lead to abortions (Esteban-Redondo and Innes, 1997). In the past cases of 
toxoplasmosis in cattle were probably misdiagnosed, and instead may have been 
Neospora caninum, a closely related protozoan parasite (Dubey and Lindsay, 1993). 
Although infections in humans may occur from ingestion of tissue cysts from 
contaminated meat, the natural life cycle of infection is probably cat-rodent-cat 
transmission (Webster fl/., 1994).
The exact prevalence of infection in cats is unknown, although it appears that cats only 
excrete oocysts once in their lifetime (Dubey, 1970). In a survey of prevalence in cats in 
Scotland, 19 % were found to have significant antibody titres (>1:10) and exclusion of 
young cats from the data set (infection is more prevalent in older cats) indicated that 
stray cats are more susceptible to infection than domestic cats (Jackson et al, 1987).
Congenital infection in sheep is a serious cause of loss of lambs due to abortion storms, 
stillbirth, mummification or neonatal death (Jackson and Hutchison, 1989). High losses 
(up to 80 % of sheep) have been recorded in Norway, with similar high rates of 
prevalence and abortion in Britain (up to 68 % prevalence). New Zealand and Australia 
(Jackson and Hutchison, 1989; Evans, 1992). Such severe losses are a significant 
economic drain to farmers and the farming industry.
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Although cattle are susceptible to infection by T. gondii, disease rarely develops 
(Esteban-Redondo and Innes, 1997). As mentioned above, many cases of abortion in 
cattle were most likely to have been caused by N. caninum. Prevalence of T. gondii in 
cattle may be up to 25 % in some countries such as The Netherlands; in Scotland 
prevalence is reported to be less than 7 % (Jackson and Hutchison, 1989). Prevalence in 
pigs is generally lower than infection in sheep. Only three studies have been carried out 
on prevalence of toxoplasmosis in pigs in Britain, with a range of 4 - 12 %, although 
this may be higher in other countries (Evans, 1992). Studies of the prevalence of 
antibodies in goats estimated infection between 7 % to 20 % in California (Jackson and 
Hutchison, 1989).
1.5 Clinical and experimental treatment strategies
Chemotherapy of important human and veterinary coccidosis, including Toxoplasmosis, 
has been recently reviewed (Haberkom, 1999; Coombs et al., 1997). Currently there are 
only a few drugs that are licensed for the treatment of toxoplasmic encephalitis (TE). 
The first choice treatment for TE is usually a combination of pyrimethamine (a 
substituted phenylpyrimidine) and sulfadiazine (sulphonamide analogue) (Figure 1.2). 
However, the long-term therapy required and the adverse side effects mean that over 50 
% of patients withdraw from medication (Haverkos, 1987). There is no proven licensed 
therapy against the tissue cyst stage of T. gondii, which is responsible for the 
recrudescence of disease. Many potential therapeutic drugs that have been shown to kill 
tachyzoites in vitro or in vivo do not affect tissue cysts. The reasons for the limited 
success of the treatment of bradyzoites remain unclear but may be related to the cyst 
wall acting as a barrier thereby preventing access of the drugs. Further research into the 
biology and biochemistry of coccidia is needed to identify new drug targets and to
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design novel inhibitors that have greater specificity for T. gondii and also destroy or 
reduce tissue cysts.
Treatment of congenital and ocular toxoplasmosis has been more successful. The most 
commonly used drugs are spiramycin used for the prevention of congenital infections 
and clindamycin used for the treatment of ocular toxoplasmosis (see below).
The mechanisms of action of many dinii-Toxoplasma drugs are largely unknown but 
may be classified under four headings, (i) folic acid antagonists (ii) protein synthesis 
inhibitors (iii) purine analogues (iv) miscellaneous. The following is not an extensive 
list of compounds that have been tested against T. gondii, but is a discussion of previous 
and current work related to the development of 2caT\-Toxoplasma drugs that is intended 
as an indication of areas of interest for future drug development. In particular, attention 
will be paid to the purine analogues, arprinocid and arprinocid-1 -N-oxide, which are a 
main focus of this thesis.
1.5.1 Folic acid antagonists
In contrast to mammalian cells, T. gondii has all the enzymes necessary for de novo 
folate synthesis thus providing possible targets for ?iVit\-Toxoplasma chemotherapy 
(Kovacs et a l, 1989). Pyrimethamine selectively binds to DHFR thereby inhibiting the 
conversion of dihydrofolate to tetrahydrofolate and ultimately reducing nucleic acid 
synthesis (Figure 1.3). Although this reaction occurs in mammalian and protozoan cells, 
the two enzymes are distinct (Kovacs et a l, 1990) and consequently pyrimethamine has 
2000-fold greater specificity for DHFR of the parasite than for the equivalent human 
enzyme.
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Figure 1.2. Anti-folate chemotherapeutic drugs. Pyrimethamine, which inhibits 
dihydrofolate reductase (DHFR), in combination with a sulfonamide analogue is the 
mainstay of treatment of toxoplasmic encephalitis. Sulfadiazine is the most commonly 
used sulfonamide, although recently sulfadoxine has been successfully tested, p- 
Aminobezoic acid (pABA) is a precuisor of for the synthesis of dihydropteroate (see 
Figure 1.3). Trimetrexate and analogues of 6,7-disubstituted 2,4-diaminopteridine are 
novel compounds which selectively inhibit DHFR.
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De novo folate synthesis in Toxoplasma gondii
Hydroxymethyldihydro-
pterinpyrophosphate
Dihydropteroate ^  ^  
synthase
Thymidylate
(dUMP)
Dihydro Dteroate
j??-Aminobenzoic acid 
(pABA)
Thymidylate
synthetase
glutamate
Dihydrofolate synthetase
f
7,8-Dihydrofolate
Dihydrofolate 
reductase
Tetrahydrofolate
Serine
hydroxymethyl- 
transferase
5,10-Methylenetetrahydrofolate
serine
glycine
Uridylate
(dUMP)
Figure 1.3. De novo folate synthesis in T gondii. Folate synthesis 
pathway is shown above the centre dotted line. The precursor for 
synthesis is GTP which is metabolised in a four-step reaction to 
hydroxymethyldihydropterinpyrophosphate (omitted from figure). 
The product of folate synthesis, dihydropteroate, is subsequently 
converted to dihydrofolate, reduced and methylated. The cycle is 
completed by the formation of thymidylate. Key enzymes are written 
in italics. Dihydrofolate reductase and thymidylate synthetase are 
part of a single bifunctional enzyme. The two enzymes, each marked 
by a cross (X), are the chemotherapeutic targets of the 
pyrimethamine and sulfonamides (refer to text).
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In clinical therapies, the activity of pyrimethamine is usually enhanced by the co­
administration of a sulphonamide drug. Sulphonamides are synthetic analogues of para- 
aminobenzoic acid (pABA), a precursor for the synthesis of dihydropteroate, and 
competitively inhibit dihydropteroate synthase (Figure 1.3). Although sulphonamides 
do not kill Toxoplasma they act synergistically with pyrimethamine, presumably 
because both drugs act against a common metabolic pathway but it may also be because 
some of the pterin substrate binds to sulfonamides forming complexes that inhibit 
dihydrofolate synthetase (Barrett et a l, 1998). There are many sulfonamide compounds 
with proven efficacies including sulfanilamide, sulfapyridine and sulfathiazole (Sabin 
and Warren, 1942). However, sulfadiazine (Figure 1.2) is usually the sulfonamide of 
choice for the treatment of toxoplasmosis (Sheffield and Melton, 1975). Other, newer 
sulfonamides have been synthesised such as sulfadoxine (Figure 1.2) and 
sulfametopyrazine which have longer half-lives and thus need only be administered 
once a week. The combination of sulfadoxine and pyrimethamine, Fansidar, is 
commonly used for treatment of chloroquine-resistant malaria.
As mentioned above, the side effects of pyrimethamine-sulfadiazine long-term 
treatment are often so severe that withdrawal from therapy is common. When the two 
compounds are administered together they result in depression of bone marrow 
production causing leukopenia (abnormally low white blood cell count), megaloblastic 
anaemia (abnormally large red blood cells) and thrombocytopenia (abnormally low 
platelet count). However, co-administration of folinic acid may reverse some of these 
effeets (folic acid antagonises the toxic effects of pyrimethamine). Pyrimethamine is 
teratogenic and therefore cannot be used during the first trimester of pregnancy. 
Sulphonamides tend to cause a wide range of side effects primarily due to excessive and
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unwanted protein binding which invokes an immune response causing hypersensitivity 
and fever. Other adverse reactions to sulfonamides include bone marrow suppression 
(discussed above), crystalluria, nephrolithiasis (kidney stones) and renal failure 
(McCabe and Oster, 1989); Joss, 1992).
Apart from the severe side effects of pyrimethamine-sulfadiazine treatment, resistance 
of some protozoan parasites to therapy is an increasing problem. Point mutations in 
enzymes have been shown to decrease the ability of drugs to bind to their target 
enzymes. For example, mutations in Plasmodium falciparum dihydropteroate synthase 
and dihydrofolate reductase result in resistance to sulfadoxine and pyrimethamine, 
respectively (Wang et a l, 1997). Similar mutations conferring resistanee to antifolates 
in T. gondii have been observed under laboratory conditions (Reynolds and Roos, 
1998). However, pyrimethamine resistance in T. gondii is rare, probably because drug- 
resistance mutations are unlikely to pass from one human to another. Should there be an 
increase in resistance to antifolate therapy in toxoplasmosis, the mainstay of treatment, 
pyrimethamine and sulfadiazine, would be rendered inadequate (Reynolds and Roos, 
1998).
Other anti-folate compounds have been shown to be effieacious by inhibiting DHFR 
and thus are promising chemotherapeutic agents. Trimethoprim-sulfamethoxazole (co- 
trimoxazole) (Figure 1.2) has been shown to be effective during clinical trials (Norrby et 
a l ,  1975) and more recently the combination trimethoprim-piritrexim has been 
demonstrated to inhibit in vitro growth of T. gondii tachyzoites (Derouin and Chastang, 
1989). Epiroprim, an analogue of trimethoprim, has been shown to be effective alone or 
in combination with dapsone in reducing brain cysts (Brun-Pascaud et a l, 1996; Chang 
et a l, 1994). Trimetrexate ( I C 5 0  = 1 . 4  nM), an analogue of piritrexim, was 600-fold
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more active against DHFR enzyme compared with pyrimethamine and has been shown 
to be efficacious in vitro and in vivo (Allegra et a l, 1987). Other newer compounds that 
have been shown to inhibit T. gondii DHFR, such as analogues of 6,7-disubstituted 2,4- 
diamino-pteridines (Jackson et a l,  1996) (Figure 1.2), 2,4,-diamino-5-methyl-5- 
deazapteridines (Piper et a l, 1996) and di- and tri-cyclic 2,4-diaminopyrimidines (Lau 
et a l, 2001), may prove superior to trimetrexate and piritrexim.
1.5.2 Protein synthesis inhibitors
Spiramycin (Figure 1.4) is a macrolide antibiotic, i.e. it contains a macrocyclic lactone 
ring structure. Spiramycin is unsuitable for the treatment of cerebral toxoplasmosis 
because it is unable to penetrate into the cerebrospinal fluid (CSF), but because it does 
accumulate within tissues, particularly the placenta, spiramycin may be used for the 
prevention of congenital toxoplasmosis. Spiramycin is available in Europe for the 
treatment of pregnant women with acute Toxoplasma infection, although its efficacy has 
never been proved (Derouin et a l, 2000). However, the success of treatment is a 
contentious issue; most studies use incomparable control groups and thus the potential 
benefits of treatment versus the side-effects of treatment are difficult to conclude 
(Wallon et a l,  1999). Clindamycin (Figure 1.4), structurally very different to 
spiramycin, is a highly lipophilic compound that is used mainly to treat ocular 
toxoplasmosis (McCabe and Oster, 1989). There are few adverse reactions to treatment 
except when prescribed in large doses (McCabe and Oster, 1989). Clindamycin has 
been demonstrated to reduce parasite invasion, possibly by reducing protein synthesis in 
extracellular parasites (Blais et a l, 1993b).
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Figure 1.4. Structures of (a) spiramycin and (b) clindamycin. 
Spiramycin is used to prevent congenital toxoplasmosis whilst 
clindamycin is used against ocular toxoplasmosis. Spiramycin is 
actually composed of 3 compounds, spiramycin I (R = H), 
spiramycin II (R = COCH3) and spiramycin III (R = COCH2CH3).
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Of the newer macrolides, based on semisynthetic derivatives of 14- and 15-membered 
macrolides, azithromycin, clarithromycin and roxithromycin have been shown to have 
increased bioavailability and therefore more persistent levels of drug in serum and 
tissues may be achieved (Kirst and Sides, 1989). Moreover, these newer macrolides 
penetrate polymorphonuclear leukocytes, macrophages and lymphocytes, which is 
particularly important in the treatment of intracellular pathogens, such as T. gondii. 
Azithromycin has been shown to be concentrated inside mouse macrophages at up to 
2.7 mM, well above therapeutic levels (IC50 = 140 p,M; IC90 = 334 \iM) and well above 
concentrations needed to inhibit protein synthesis; azithromycin (53 piM) inhibited 
[^^S]-methionine incorporation by 67 % compared with controls (Blais et a l, 1993). 
Azithromycin has been shown to be effective both in vitro against tachyzoites and tissue 
cysts (Chang and Pechere, 1988; Huskinson-Mark et a l, 1991) and in treating murine 
toxoplasmosis (Chang et a l, 1989). Clarithromycin has been shown to be effective both 
in vitro (Chang and Pechere, 1988) and in murine models of toxoplasmosis (Chang et 
a l, 1988). The exact mode of action of macrolide antibiotics is not completely known, 
although recent evidence suggests that targeting to the plastid organelle results in 
inhibition of protein synthesis (Beckers et a l, 1995). Recently, a combined treatment of 
azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS 
patients has undergone phase I and II clinical trials (Jacobson et a l, 2001). Results 
demonstrated that whilst the combination was safe, there was a significant relapse rate 
and severe side effects in patients receiving higher doses of drugs.
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1.5.3 Purine analogues
Toxoplasma gondii is incapable of de novo purine synthesis (Perrotto et a l, 1971) and 
as such relies on purine transporters and salvage enzymes (the details of these pathways 
will be discussed in Chapter 6). Consequently, these uptake mechanisms provide 
potential chemotherapeutic targets for the design of novel dtnii-Toxoplasma compounds. 
Since several of the enzymes involved are speeific to T. gondii, a suitable level of 
parasite specificity may be obtained, resulting in the ability to administer low doses 
with fewer side effects. The purine analogues, arprinocid and arprinocid-1 -N-oxide, 
have both been shown to be effective against T. gondii tachyzoites when tested in vitro 
and in vivo (Luft, 1986; Pfefferkorn et a l, 1988), and against Neospora caninum 
(Lindsay et a l, 1994) and Cryptosporidium parvum (Rehg and Hancock, 1990). These 
compounds are discussed in more detail in Sections 1.7.1 - 1.7.5. Another purine 
analogue, 2',3'-dideoxyinosine, has been shown to reduce the numbers of T. gondii cysts 
within cerebral tissue and re-infeetion experiments with these tissue cysts showed that 
they had lost their viability (Sarciron et a l, 1997). Although, the mechanism of action is 
not known, it is feasible that interference with essential purine metabolic pathways 
results in parasite death. A recent study of purine metabolism in the brains of mice 
infected with a tissue-cyst forming strain of T. gondii tissue cysts showed that treatment 
with 2',3'-dideoxyinosine resulted in an increase in activity of purine enzymes in 
cerebral tissue, in particular adenosine deaminase (Gherardi et a l, 1999). The 
implications of this are not known although it suggests that 2',3'-dideoxyinosine targets 
purine metabolic enzymes.
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1.5.4 Miscellaneous compounds
Among the first compounds to be tested against T. gondii were lasalocid and monensin, 
both polyether antibiotics. They have both been proven to be potent inhibitors of T. 
gondii tachyzoites in vitro (Melton and Sheffield, 1975) and monensin was also 
effective in reducing faecal oocyst production in cats (Frenkel and Smith, 1982). 
Treatment of domestic cats using monensin may reduce human infections and 
congenital transmission but this strategy would have no impact on transmission from 
stray cats. Monensin and lasalocid have been shown to be effective in reducing the 
viability of Eimeria tenella sporozoites (Long and Jeffers, 1982) and have activity 
against Cryptosporidium parvum (Armson et a l, 1999).
During the early 1970's the active antimalarial ingredient, artemisinin (alternative name: 
qinghaosu), of the Chinese herb qinghao, was isolated (Figure 1.5). Artemisinin belongs 
to a class of compounds called trioxanes that have been found to be rapid acting, highly 
effective antimalarials with low host toxicity (reviewed van Agtmael et a l,  1999; 
Dhingra et a l, 2000; Olliaro, 2001; Olliaro et a l, 2001; Posner and Meshnick, 2001). 
Interestingly, the use of qinghao for malaria fever dates back to 340 A.D (cited Ke et 
a l, 1990). Artemisinin acts on the early trophozoite and schizont stages of malaria, and 
also against gametocyte development, resulting in reduced transmission. Moreover, 
more than two million patients have been treated with artemisinin (Olliaro et a l, 2001) 
and no incidence of resistanee has been reported (Olliaro, 2001). Holfels et al, (1994) 
postulated that artemisinin may act via free radicals, although their exact mechanisms of 
action are still a mystery and of great scientific debate. Malaria-infected erythrocytes 
digest haemoglobin thus releasing haem in the process, a toxic substance for the parasite 
that is neutralised by polymerisation to haemazoin. Haem, or more
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specifically Fe^ ,^ catalyses the breakdown of the peroxide bridge of artemisinin (Figure
1.5), leading to the formation of free radicals. These free radicals are toxic to malaria 
parasites (van Agtmael et al., 1999). The precise mechanism whereby free radicals are 
formed and how they exert their action remains unclear. Several semi-synthetic 
analogues of artemisinin, for example dihydroartemisinin, artemether, arte ether and 
artesunate have been demonstrated to have greater efficacy and better drug solubilities 
than artemisinin (van Agtmael et al., 1999). Several of these derivatives and also 
second-generation completely synthetic 1,2,4-trioxanes display in vitro anti-Toxoplasma 
activity, however further work is necessary to determine their usefulness as drugs 
(Chang et a l, 1989; Ke et a l, 1990). Cloned T. gondii mutants resistant to artemisinin 
have been demonstiated to be cross-resistant to dihydroartemisinin and artemether, but 
not deoxyartemisinin (derivative of artemisinin containing a reduced endoperoxide 
bond) and pyrimethamine, suggesting resistance is specific to artemisinin and its 
endoperoxide-bond-containing derivatives (Berens et a l, 1998). One resistant clone was 
found to be avirulent for mice and offered protection against lethal challenge from a 
wild-type strain, whilst another clone resulted in the formation of unusually large 
vacuoles. Together, these clones will be useful for investigation of the mechanism of 
action of artemisinin and for studies of parasitophorous vacuole formation and virulence 
factors (Berens et at., 1998).
Hydroxynaphthoquinones, in particular atovaquone (Figure 1.5), have been shown to be 
effective against tachyzoites in vitro and significantly reduce the numbers of brain tissue 
cysts in murine models of toxoplasmosis (Araujo et a l, 1991; Khan et a l, 1998). There 
was no synergistic effect when atovaquone was combined with pyrimethamine, 
sulfadiazine, clarithromycin or minocycine (Romand et a l,  1993) although another
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publication presented evidence that the combination of atovaquone and pyrimethamine 
was synergistic (Araujo et a l, 1993). Atovaquone combined with proguanil has recently 
been licensed, as a drug called Malarone, for the treatment of malaria, however 
resistance to this combination has already been reported. Mutations in the parasite 
cytochrome b, where the drug is thought to bind and inhibit mitochondrial electron 
transport, have been found to confer resistance resulting in a 9000-fold reduction in 
sensitivity to atovaquone (Korsinczky et a l, 2000).
Another class of compounds, the triazines, including diclazuril and toltrazuril (Figure
1.5) have been shown to be effective against T. gondii both in vitro and in murine 
models (Lindsay and Blagbum, 1994). The mechanism of action of triazines is not 
completely known, however, one report has suggested that toltrazuril primarily affects 
the respiratory chain (Harder and Haberkom, 1989), although it was reported that one 
target of triazines is the chlorophyll a-Dl complex located within the apicoplast 
(Hackstein e ta l,  1995).
1.6 Novel drug targets
1.6.1 Apicoplast
T. gondii parasites contain three distinct genomes, (i) nuclear genome, (ii) 
mitochondrial genome and (iii) 35 kb extrachromosomal DNA. The latter, identified by 
in situ hybridisation and electron microscopy, is localised to a discrete organelle 
surrounded by four bilayer membranes, termed the apicoplast, and has a structure 
similar to chloroplast genomes (Kohler et a l, 1997). The function of this organelle, 
thought to be acquired by endosymbiosis of green alga, is largely unknown although it
32
Chapter 1: Introduction
is certain that the parasite replicates the 35 kb DNA during endodyogeny. Therefore, the 
apicoplast is likely to be a source of novel chemotherapeutic targets (discussed below) 
(Kohler et al., 1997; McFadden and Roos, 1999).
T. gondii bradyzoites as well as tachyzoites have been shown to contain a 
morphologically similar plastid organelle (Roberts et a l, 1998) allowing the possibility 
of identifying chemotherapeutic targets in both life stages, to which a single drug may 
act. However, inevitably, designing therapeutic agents that readily cross the tissue cyst 
wall remains a challenge.
Ciprofloxacin, a quinolone analogue (Figure 1.5), has been shown to inhibit replication 
of the T. gondii tachyzoite apicoplast genome, clearly validating this organelle as a 
potential chemotherapeutic target (Fichera and Roos, 1997). Furthermore, the same 
characteristic kinetics of delayed parasite death (described below) that have been 
demonstrated for some protein synthesis inhibitors, including clindamycin, also occur 
with ciprofloxacin indicating that these compounds all act upon the apicoplast (Beckers 
et a l, 1995; Fichera et a l, 1995). Parasites treated with ciprofloxacin or clindamycin 
replicate normally at the beginning of treatment but in the subsequent invasion round 
replication is severely disrupted, giving rise to the phenomenon of delayed parasite 
death. Concentrations of clindamycin over 1000 times greater than its IC50 against 
tachyzoites do not inhibit parasite growth in the first round of replication, however, 
different treatment do affect the speed of replication upon entry into a second host cell 
(Fichera et a l, 1995). The reasons for continued parasite survival in the presence of 
what would appear to be a malfunctioning apicoplast is a mystery but perhaps the 
damage to the apicoplast only manifests itself during some function required for correct 
invasion of a new cell, like, for instance, parasitophorous vacuole formation.
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A fusion protein consisting of the nuclear-encoded apicoplast acyl-carrier protein (ACP) 
and the green fluorescent protein (GFP) results in the targeting of GFP to the apicoplast. 
Transient expression of this construct containing a fragment of ROPl, named ACP- 
GFP-mROPl, inhibits apicoplast segregation (He, et al., 2001). It was noted that a 
parasite within a vacuole replicates normally but the apicoplast is only segregated into 
one of the two daughter cells. This process is repeated in the next generation, i.e. only 
one granddaughter cell acquires the apicoplast. Parasites with and without apicoplasts 
grow normally, although the apicoplasts in some cells grow abnormally large, indicating 
a loss of cell cycle control. Parasites lacking an apicoplast were sorted by FACS and 
used successfully to re-infect cells. Although vacuoles were formed, replication ceased. 
This work further substantiates the 'delayed death' effect seen with ciprofloxacin or 
clindamycin and illustrates the importance of the apicoplast in establishing a functional 
parasitophorous vacuole (He et al., 2001). The ability to generate apicoplast deficient 
isolates will allow further characterisation of this organelle and should also provide a 
convenient system for testing whether or not potential chemotherapeutic agents are 
targeted to the apicoplast.
In contrast to the work of Fichera et al. (1995), one study found that ciprofloxacin was 
toxic to host cells and that a related compound, trovafloxacin, had increased specificity 
both in vitro and in vivo with no host cell toxicity (Khan et a l, 1996). An assessment of 
the structure-activity relationships of quinolones and fluoroquinolones confirmed the 
potency of trovafloxacin against T. gondii (Gozalbes et a l, 2000) and a later report 
suggested that this compound may be important for treatment of malaria (Hamzah et a l, 
2000).
34
Chapter 1: Introduction
The exact function of the apicoplast is not known, although its genome has been 
sequenced for P. fa lciparum  and for T. gondii (Wilson et al., 1997; 
http://www.sas.upenn.eduAjkissing/toxomap.html). The apicoplast does not encode all 
of the genes required for protein synthesis and no proteins are apparently involved in 
the functioning of the apicoplast, but rather nuclear-encoded proteins possess peptide 
leader sequences that target proteins to the apicoplast (reviewed (Gleeson, 2000); this 
makes it more difficult to determine the exact functions of the apicoplast. The diseovery 
that herbicides were effective against some Apicomplexa led to the identification of the 
apicomplexan shikimate pathway, a source of amino acid synthesis. As such, the 
shikimate pathway is of potential significance in the discovery of novel therapeutic 
targets. Other pathways such as isoprenoid biosynthesis (Section 1.6.3) and fatty acid 
synthesis (Section 1.6.4) have been located to the apicoplast and demonstrated to be 
attractive chemotherapeutic targets.
1.6.2 Shildmate pathway
Roberts et al. (1998) published evidence for the presence of a shikimate pathway in 
Apicomplexan parasites. The shikimate pathway is conserved in plants, algae, bacteria 
and fungi, and is responsible for the synthesis of aromatic compounds including the 
aromatic amino acids, phenylalanine, tyrosine, and tryptophan, in addition to the 
synthesis of ubiquinone and pABA. All of these compounds are formed from the 
'branch' product of the shikimate pathway, chorismate, which is formed from the 
condensation of phosphoenolpyruvate and erythrose-4-phosphate (Figure 1.6). In total 
seven enzymes are utilised, initially forming 3-deoxy-<^-arabinoheptulosonate-7- 
phosphate, which is sequentially metabolised to 3 -dehydroquinate, 3-dehydroshikimate,
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Figure 1.6. Shikimate pathway present in Apicomplexa. Chorismate, 
formed in a seven-step process from phosphoenolpyruvate and 
erythrose-4-phosphate, is then used in the formation of aromatic amino 
acids, ubiquinone and pABA.
36
Chapter I: Introduction
shikimate, shikimate-3-phosphate, 5-enol pymvylshikimate-3-phosphate and finally 
chorismate (Figure 1.6).
Glyphosate (Y-(phosphonomethyl)-glycme), also known as RoundUp® or 
Tumbleweed®, is a selective inhibitor of 5-enolpyruvyl shikimate-3-phosphate (EPSP) 
synthase, was found to inhibit the growth of T. gondii, P. falciparum  and C. parvum 
thereby indicating the presence of a functional shikimate pathway (Roberts et al., 1998). 
Furthermore, addition of pABA to the medium reversed the effects of glyphosate 
against T. gondii, P. falciparum but not C. parvum. The reasons for the non-antagonistie 
effect of pABA against glyphosate treatment of C. parvum are unknown, but may be 
because of poor transport or the involvement of the shikimate pathway in other 
obligatory metabolic pathways (Roberts et al., 1998).
Enzymes involved in the synthesis of chorismate are potential chemotherapeutic targets. 
Furthermore, mammalian cells do not have a shikimate pathway and therefore drugs 
should be specific to the Apicomplexa. Fluorinated analogues of shikimate, an 
intermediate in the shikimate pathway, have been found to inhibit the in vitro growth of 
P. falciparum  (McConkey, 1999). Chorismate synthase, the final enzyme in the 
shikimate pathway, has considerable homology with chorismate synthases from several 
species, including P. falciparum  (49.7 %) and Saccharomyces cerevisiae (49.6 %), 
although chorismate synthases from T. gondii and P. falciparum have unusually long 
insertions (Roberts et al., 1998). The function of these insertions is not known, but 
clearly the distinct homology between the enzymes of some Apicomplexa may allow 
the development of common treatments against malaria, toxoplasmosis and coccidiosis. 
Moreover, many patients with immune deficiencies are susceptible to simultaneous 
infection with opportunistic pathogens, such as Pneumocystis carnii and
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Mycobacterium tuberculosis, which also have shikimate pathways, thus permitting the 
attractive prospect of developing drugs with broad-spectrum activities.
In plants the shikimate pathway is localised in the chloroplast whilst in fungi and 
bacteria the enzymes are localised in the cytoplasm. Recent evidence suggests that the 
apicomplexan shikimate pathway is present within the cytoplasm because the amino 
terminal leader sequence that target nuclear-encoded proteins to the plastid, present in 
plants, are absent from apicomplexan chorismate synthases (Keeling a / . ,  1999). 
Recently, P. falciparum  chorismate synthase was shown to be dispersed within the 
parasite cytoplasm, and not located discretely within the apicoplast (Fitzpatrick et al., 
2001).
1.6.3 Isoprenoid biosynthesis
Another important function of the plastid is isoprenoid biosynthesis (Jomaa et al., 1999; 
Vial, 2000). Isoprenoid synthesis is an important pathway in protein prénylation, 
ubiquinone-related electron transport systems and A-glycosylation of proteins. It was 
long assumed that Apicomplexa were unable to synthesise isopentenyl diphosphate 
(IPP), since they lack enzymes of the acetyl-CoA/mevalonate (MYA) pathway present 
in mammals (Figure 1.7). In bacteria, plants and algae, IPP synthesis is MVA- 
independent and occurs via l-deoxy-D-xylulose 5-phosphate (DOXP). Condensation of 
pyruvate and glyceraldehyde-3-phosphate by DOXP synthase and subsequent 
conversion to 2-C-methyl-D-erythritol 4-phosphate by DOXP reductoisomerase results 
in the formation of IPP (Figure 1.7). Database mining of sequences on chromosome 14 
o f P. falciparum from the Malaria Genome Project, suggested the existence of DOXP
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Figure 1.7. Apicomplexan and mammalian isoprenoid biosynthesis. In both 
apicomplexan and mammalian systems, isoprenoid biosynthesis occurs from 
isopentenyl diphosphate (IPP) and its isoform dimethylallyl diphosphate. In 
mammals, the condensation of two molecules of acetyl-CoA results in the 
formation of mevalonate, which is then converted to IPP in a three enzyme step 
(Vance, 1993). In contrast, apicomplexan IPP is synthesised from pyruvate and 
glyceraldehyde 3-phosphate (Vial, 2000). Not all of the enzymes in this pathway 
have been identified. Abbreviation; HMG-CoA, |3-hydroxy-|3-methylglutaryl- 
CoA; PP, pyrophosphate.
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synthase and DOXP reductoisomerase homologous genes. Moreover, analysis of these 
sequences identified plastidial targeting sequences, and transient expression in T. gondii 
of a construct encoding the leader peptide of DOXP-reductoisomerase fused with GFP 
co-localised with extranuciear plastid DNA, strongly indicating the presence of a 
functional IPP pathway in the apicoplast (Jomaa et al., 1999). In addition, in vitro and in 
vivo P. falciparum growth was inhibited by fosmidomycin and FR-900098 (a derivative 
of fosmidomycin), compounds which are known to inhibit DOXP-reductoisomerase. 
The presence of isoprenoid biosynthesis in P. falciparum suggests that apicomplexan 
IPP synthesis is a potential chemotherapeutic target, and since parasite and mammalian 
IPP synthesis pathways are divergent, these drug targets are likely to be parasite 
specific. It would be interesting to elucidate whether inhibitors of isoprenoid 
biosynthesis exhibit the same 'delayed-death' phenotype observed with other inhibitors 
of apicoplast function, for example ciprofloxacin.
1.6.4 Fatty acid biosynthesis
Fatty acid biosynthesis is important in cell growth, and since the apicomplexan fatty 
acid synthesis pathway (Type II) is distinct from the mammalian pathway (Type I), it is 
therefore an attractive parasite-specific drug target (reviewed Coombs and Müller, in 
press). One major difference in these pathways is that enzymes of the Type I fatty acid 
synthesis are present as a complex, whereas. Type II enzymes exist as mono functional 
proteins. Triclosan, commonly found in toothpaste and other household goods, inhibits 
T. gondii and P. falciparum growth by inhibiting the Fab I (enoyl-acyl carrier protein 
(ACP) reductase) step of fatty acid biosynthesis (Heath et al., 1999; McLeod, 2001). As 
further evidence of the presence of Type II fatty acid biosynthesis in Apicomplexa, 
thiolactomycin, an inhibitor of FabB, FabF ((3-ketoacyl-ACP synthase II and FabH ([3-
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ketoacyl-ACP synthase III) in E. coli, also inhibits the in vitro growth of P. falciparum 
(Waller et al, 1998), and in addition aryloxyphenoxyproprionate and cyclohexadione 
herbicides inhibit T, gondii growth by interacting with acetyl-CoA carboxylase (ACC) 
(Zuther et al., 1999). It would be interesting to elucidate whether or not lipids 
manufactured by the fatty acid synthesis pathway contribute to parasitophorous vacuole 
formation, and perhaps consequently whether this would be related to the 'delayed- 
death' phenotype described above.
1.7 Arprinocid
1.7.1 Activity against chicken coccidiosis
A new class of chemical compounds were synthesised in the early 1970’s, 6-amino-9- 
(substituted benzyl)-purines (Lire et a l, 1974). Unpublished observations identified one 
compound in particular, 6-amino-9-(2-chloro-6-fluorobenzyl)-purine (MK-302) later 
known as arprinocid (Figure 1.8a), as having anticoccidial activity (cited Miller et al.,
1977).
The efficacy of arprinocid was proven against Eimeria species infections in broiler 
chickens and the most effective dose determined to be 75 parts per million (ppm) 
(Kilgore et a l, 1976). The final weights of drug-treated infected chickens were 
significantly greater than untreated-infected control birds. Moreover, none of the 
medicated chickens showed any evidence of coccidiosis (Kilgore et a l, 1976). A 
similar, but larger scale, study of battery chickens infected with Eimeria tenella also
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Figure 1.8. Structures of (a) arprinocid and (b) arprinocid-1-N-oxide.
42
Chapter 1: Introduction
concluded that arprinocid could exert complete control of coccidiosis (McManus e ta l,  
1976).
A structural analogue of arprinocid, 6-amino-9-(2, 6 -dichlorobenzyl)-purine (L- 
628,914), was shown to have a similar efficacy, compared to arprinocid, against E. 
tenella infections in broiler chickens (Miller et a l,  1977). Both compounds reduced 
mortality, lesions and oocyst production resulting in an increased growth rate (Miller et 
a l,  1977). As well as decreased oocyst production, both arprinocid and L-628,914 
reduced the sporulation of oocysts (Tamas et a l, 1978). Treatment ofE.  tenella-mÎQciQà. 
chickens with 70 ppm arprinocid completely inhibited oocyst production, and although 
oocyst production occurred to a limited extent with lower doses of arprinocid, 
sporulation was less than 5 % of controls (Tamas et a l, 1978). Similar observations 
were made with L-628,914 (Tamas et a l, 1978). Despite higher concentrations of 
arprinocid, compared to L-628,914 (45 ppm), being needed to control infections, the 
maximum tolerated concentration for arprinocid was 1.5 times greater than for L- 
628,914 (Miller et a l, 1977). The increased tolerance of chickens to arprinocid 
presumably resulted in the lack of interest of L-628,914, although other factors, such as 
cost of synthesis, may have been a consideration.
Results from a subsequent much larger study confirmed the potential of arprinocid as an 
anticoccidial drug (Olson et a l, 1978). Arprinocid was shown to prevent mortality, 
reduce lesions, inhibit oocyst production and improve weight gain, comparable to 
uninfected controls, in battery chickens infected with 20 field isolates of E, tenella, E. 
acervulina, E. necatrix, E. maxima and E. brunetti (Olson et a l , 1978). Furthermore, 
arprinocid showed no cross-resistance with other drug-tolerant isolates (Olson et a l,
1978). Seven marketed anticoccidials (amprolium and ethopabate, robenidine, clopidol,
43
Chapter 1: Introduction
zoalene, monensin, nicarbazine and lasalocid) were tested for comparison and all 
isolates, with the exception of one E. tenella isolate, were insensitive to one or more of 
the drugs tested (Olson et a l, 1978).
In order to confirm the potential of arprinocid as an anticoccidial drug, a large scale 
study was conducted to evaluate the activity of arprinocid under floor-pen conditions, 
thus allowing the collection of data in situations that would simulate commercial use 
(Kilgore et a l, 1978). Eight such trials of arprinocid against Eimeria coccidiosis in 
broiler chickens were performed at various locations within the United States and, in 
agreement with previous small-scale studies, arprinocid-treated birds (70 ppm) had 
significantly reduced lesions, increased feed efficiency and improved weight gain 
compared with control birds (Kilgore et a l, 1978). The same conclusions about the 
efficacy of arprinocid were also made subsequent to similar large-scale trials of 
arprinocid, conducted in France, Germany and England, against artificially induced and 
natural coccidial infections in broiler chickens ((Schindler et a l, 1979). Arprinocid 
controlled coccidiosis (as judged by prevention of mortality, reduced lesions and 
increased weight gain) and was shown to have equal, or greater efficacy, than four 
commercially available products; halofuginone, monensin, nicarbazine and Pancoxin® 
(amprolium, ethopabate and sulfaquinoxaline). In addition, unpublished results from a 
study with 99 isolates of Eimeria from 9 European countries (cited (Schindler et a l,
1979) and data from three trials in South Africa (Schroder et a l, 1980) confirmed the 
efficacy of arprinocid.
Heat stress in poultry is an occasional but severe problem, especially in hot climates, 
resulting in mortality that is often enhanced by anticoccidial drugs such as nicarbazin. 
Several floor-pen experiments, coinciding with hot summer temperatures, were
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conducted to study the heat tolerance of a number of drugs, including arprinocid. 
Nicarbazin treatment of birds resulted in a heat related mortality of 59 % compared to 
12 % for arprinocid and 13 % for unmedicated controls, further indicating the potential 
of arprinocid as a safe and effective anticoccidial drug (Keshavarz and McDouglad, 
1981).
In addition to the remarkable efficacy of arprinocid in controlling chicken coccidiosis, 
arprinocid was found to have little toxicity (Keshavarz and McDougald, 1982). Five 
separate battery trials were conducted in which test drugs were used at up to three times 
the recommended levels. The general health of chickens was only impaired at 
concentrations of arprinocid 2.5 to 3 times normal dosages, although the increased 
mortality seen was not significantly different from control chickens (Keshavarz and 
McDougald, 1982). Inconsistencies in the preparation of chicken feeds may result in 
varying doses causing drug toxicity problems, in addition to coccidiosis. The finding 
that arprinocid has little toxicity at high doses is advantageous since many other 
compounds, such as nicarbazine, cause severe growth depression above therapeutic 
concentrations.
1.7.2 Morphological effects of arprinocid on Eimeria
Arprinocid was reported to have 3 distinct effects on oocysts: (i) reduction in the 
number of excreted oocysts; (ii) decreased sporulation; and (iii) oocysts that did 
sporulate were less viable (Ruff et a l, 1978). The ability of arprinocid to reduce 
sporulation appeared not to be a direct effect on oocysts themselves, since oocysts from 
untreated infected chickens sporulated as normal when incubated in drug-treated 
sporulation medium (Tamas e t a l ,  1978). Consequently, the drugs were thought to
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interfere with sporulation by acting against either the micro- or macrogametes or 
zygotes.
Arprinocid (70 ppm) inhibited the development of first- and second-generation 
schizonts and altered the structure of the wall-forming bodies of macrogametes 
(McManus et al., 1980). More detailed investigations of macrogamete structure using 
electron microscopy, however, concluded that there was little morphological change in 
type I wall forming bodies, although type II wall forming bodies became granular in 
appearance and ceased to develop further (Pittillo et a l, 1981). Normal development of 
second-generation schizonts results in complete merogony (Ball et a l, 1985). In chicks 
treated with arprinocid (70 ppm) two days after infection with E. tenella, large masses 
of the residual cytoplasm were found to be vacuolated and surrounded by unusually 
small schizonts. These effects could account for the reduction in oocyst numbers after 
arprinocid treatment (Ball et al., 1985).
1.7.3 Mechanism of action of arprinocid and arprinocid-l-N-oxide
Urine taken from chickens dosed with arprinocid was analysed and a compound, 16 
atomic mass units heavier than the parent drug, was identified as 6-amino-9-(2-chloro-
6 -fiuorobenzyl) purine-1-N-oxide (arprinocid-l-N-oxide) (Jacob et a l,  1978) (Figure 
1.8b). This urinary metabolite of arprinocid was later demonstrated, using an 
arprinocid-l-N-oxide resistant strain, to be the active in vivo metabolite of arprinocid 
(Pfefferkorn et al., 1988). Other active metabolites have never been identified. Chicken 
and dog liver microsomes have been shown to convert arprinocid to arprinocid-l-N- 
oxide whilst mouse liver microsomes incubated with arprinocid predominantly gave 2 - 
chloro-6 -fluorobenzyl alcohol (Wolf et al., 1978). Unpublished observations have
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shown that 2 -chloro-6 -fluorobenzyl alcohol is inactive against chicken coccidiosis 
(cited Wang et al., 1979a) (discussed further in Section 1.7.5).
Multiplication of E. tenella tachyzoites (trophozoites) in chickens was inhibited by 
arprinocid (60 ppm), even when treatment was delayed by 72 h post-infection. No 
change in the activity of arprinocid was observed after the addition of up to 1 0 0 0  ppm 
adenine or adenosine to the diet, suggesting that there was no competition between drug 
and these substrates (Wang et al., 1979a).
Arprinocid (67 p,M) had no detectable effect on cow milk xanthine oxidase, chicken 
liver hypoxanthine-guanine phosphoribosyl transferase (HGPRT), chicken liver 
adenosine deaminase, pig nucleoside phosphorylase and E. tenella cAMP 
phosphodiesterase (Wang et al., 1979a). Arprinocid also had no inhibitory effects on 
other NADH/NADPH-dependent dehydrogenases found in E. tenella unsporulated 
oocysts, for example glutamate dehydrogenase and isocitrate dehydrogenase (Wang et 
al., 1979a). However, arprinocid did exert a potent inhibition of E. tenella dihydrofolate 
reductase (Kj = 3 pM) by competing with NADPH, and inhibited glucose-6 -phosphate 
dehydrogenase (Ki = 90 pM) in E. tenella by competing with NADP (Wang et al., 
1979a).
Based on the assumption that arprinocid may inhibit E. tenella dihydrofolate synthesis, 
experiments were conducted to measure DNA synthesis in the presence of drug (Wang 
et al., 1979a). Uptake of [^H]-adenine and [^"^C]-uracil by E. tenella schizonts was not 
affected by arprinocid. However, in contrast arprinocid (67 pM) resulted in a reduction 
in the incorporation of [^H]-hypoxanthine into DNA of the host cell and parasite 
indicating that perhaps the mechanism of action of arprinocid was by inhibition of
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hypoxanthine transport (Wang et al., 1979a). Although, the activity of arprinocid and 
arprinocid-l-N-oxide was not affected by the presence of hypoxanthine (Pfefferkorn et 
a l, 1988).
In E. tenella, nucleic acid metabolism only occurs intracellularly - which poses 
difficulties for direct experimental analysis of isolated parasites. Therefore, further 
studies on the activity of arprinocid were conducted mainly using uninfected host cells. 
The mechanism of action of arprinocid was thought to be blockade of the hypoxanthine- 
guanine salvage pathway since 67 pM arprinocid inhibited hypoxanthine, guanine and 
inosine incorporation by 64 %, 58 % and 43 %, respectively (Wang et al., 1979a). High 
voltage paper electrophoresis of purine nucleotides labelled with [^H]-hypoxanthine 
demonstrated that arprinocid had no affect on any specific nucleotide (XMP, IMP, 
ADP, ATP, GDP or GTP) but reduced the incorporation of [^H]-hypoxanthine into all 
nucleotides in HeLa cells (Wang et al., 1979a). It is not Imown whether this effect is 
significant to the anti-coccidial activity of arprinocid. The inhibition of inosine 
incorporation could either be as a result of the conversion of inosine to hypoxanthine by 
inosine phosphorylase or perhaps there is a common receptor site (or transporter) for 
which hypoxanthine, inosine and guanine compete that is blocked by arprinocid. There 
was no change in the incorporation of radiolabelled uridine, thymidine, and adenine.
Subsequent work provided further evidence for arprinocid inhibition of hypoxanthine 
transport (Wang et a l, 1979b). Although, arprinocid (0.5 mM) had no noticeable effect 
on hypoxanthine-guanine phosphoribosyltransferase (HGPRT) in HeLa cells, arprinocid 
acted as a potent competitive inhibitor of hypoxanthine transport (Ki = 33 pM) and 
guanine transport (Ki = 79 pM) (Wang et a l,  1979b). Arprinocid showed no effect 
against adenine transport (K i = 4.4 mM) (Wang et a l, 1979b) which confirmed a
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previous report that adenine does not alter the efficacy of arprinocid (Wang et al., 
1979a). However, these effects do not necessarily correlate with activity against the 
parasite.
Wang and co-workers (1979 a and b) concluded that arprinocid was the active 
compound against coccidia based on two distinct observations. Firstly, since metabolic 
activity in the allantoic cavity of embryonic eggs is minimal, metabolism of arprinocid 
to arprinocid-l-N-oxide would be unlikely. The higher activity of arprinocid compared 
to arprinocid-l-N-oxide in embryonic eggs therefore suggested that arprinocid was the 
active form (Wang et al., 1979a). Secondly, inhibition of hypoxanthine-guanine 
ti'ansport by arprinocid-l-N-oxide was only half that of arprinocid (Wang et al., 1979b). 
However, Latter and Wilson (1979) postulated that arprinocid-l-N-oxide was the active 
compound against coccidia based on the observation that arprinocid was active in chick 
liver cultures but not in chick kidney cells (Latter and Wilson 1979). As mentioned 
above, chicken liver microsomes can metabolise arprinocid to arprinocid-l-N-oxide 
(Wolf et al., 1978), a compound which was active in both chick kidney and liver cells 
(Latter and Wilson, 1979). Moreover, tissue residue levels of chicks fed arprinocid-l-N- 
oxide correlated with the ICso of arprinocid-l-N-oxide against E. tenella (Wang and 
Simashkevich, 1980). Specifically, chickens medicated with [^"^C]methylene-arprinocid 
(70 ppm) for 22 h were found to have (i) 0.64 ppm (2.1 pM) arprinocid and 0.33 ppm 
(1.1 pM) arprinocid-l-N-oxide in their livers, and (ii) 0.42 ppm (1.4 pM) arprinocid and 
0.3 ppm (1 pM) arprinocid-l-N-oxide in the intestines (Wang and Simashkevich, 1980). 
The I C 5 0  of arprinocid against E. tenella in vitro was determined as 67 pM and the Ki 
for inhibition of hypoxanthine transport is 33 pM (see above), both values far higher 
than the levels of drug found with tissues of medicated chickens. In contrast, the I C 5 0  of
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arprinocid-1 -N"0 xide against Æ". tenella in vitro was determined as 1 pM, a level much 
closer to the chicken tissue residue levels (Wang and Simashkevich, 1980). Hence, it 
was evident that arprinocid-l-N-oxide was in fact the active compound in vivo.
The activity of arprinocid or arprinocid-l-N-oxide against HeLa cells may not translate 
into a similar effect on the parasite and therefore HeLa cells are not a good model for 
studying anticoccidial activity. For example, uptake of arprinocid by HeLa cells is not 
altered by the presence of hypoxanthine suggesting that hypoxanthine transport is not 
involved in its activity (Wang & Simashkevich, 1980). In contrast, second generation 
schizonts of E. tenella grown in chick kidney epithelial cells and incubated in 67 mM 
arprinocid resulted in a decreased incorporation of hypoxanthine (53 %) indicating that 
arprinocid interferes with hypoxanthine transport (Wang & Simashkevich, 1980).
Arprinocid-l-N-oxide (67 pM) only decreased hypoxanthine incorporation in HeLa 
cells by 19 % which could not explain its potent inhibition of the growth of E. tenella 
(Wang & Simashkevich, 1980), suggesting that arprinocid-1-N-oxide may have an 
alternative mechanism of action. Wang et al., (1981) presented evidence that the 
activity of arprinocid-l-N-oxide may be related to interference with microsomal 
metabolism. HeLa cells incubated with high doses of arprinocid-l-N-oxide (67 pM) 
resulted in the dilation of the rough endoplasmic reticulum (ER) and vacuole formation 
which were prevented by SKF-525A, an inhibitor of microsomal metabolism (Wang et 
al., 1981). Furthermore, arprinocid-l-N-oxide, but not arprinocid, has been shown to 
bind to cytochrome P450 (Wang et al., 1981). From the evidence published by Wang 
and co-workers (1981) it appears that arprinocid-l-N-oxide undergoes microsomal drug 
metabolism. However, no further metabolites of arprinocid-l-N-oxide have been
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discovered and more importantly it is not known whether T. gondii has cytochrome 
P450 enzyme.
1.7.4 Development of resistance to arprinocid
The first published report on the development of resistance to arprinocid came two 
years after it was first used commercially in controlling coccidiosis in broiler chickens. 
In 1981, in England, after an outbreak of coccidiosis occurred, E. tenella was isolated 
and tested for sensitivity to arprinocid. There was no significant difference in weight 
gain, mortality, and oocysts sporulation, between arprinocid treated (60 ppm) infected 
chickens and unmedicated infected chickens (Chapman, 1982). Previously arprinocid 
had already been shown to be highly effective at 60 ppm and 70 ppm against E. tenella 
(Olson et a l, 1978; Schindler et aL, 1979). A similar experiment was repeated using a 
range of concentrations of arprinocid and it was concluded that this particular isolate 
was arprinocid resistant (Chapman, 1982). Shortly after the publication of this work a 
letter was published stating results that did not support the theory of a rapid onset of 
coccidial resistance to arprinocid, and that this drug could be highly beneficial if used in 
rotation with other drugs (Voeten, 1982). A more detailed study was needed.
The efficacy of arprinocid against Eimeria  isolates obtained from areas where 
arprinocid had previously been used was compared to the efficacy from sites where 
arprinocid had not been used, and shown to be effective against Eimeria species only 
from areas where the drug had never been used. Isolates from areas where arprinocid 
had been used for 5-7 successive flocks were resistant (Chapman, 1983).
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Chapman (1982, 1983) showed that the development of resistance to arprinocid in 
Eimeria isolates was a major problem and around this time it was withdrawn from use. 
However, it was not known if the resistance was stable. If this was not the case, then 
strategies for increasing the “life,, of a drug could be implemented, possibly by using 
the drug in rotation with 1 or more compounds (Chapman, 1986; Voeten, 1982). 
Unpublished observations indicated that it was possible to induce resistance by 
continuous passage in chickens medicated with increasing concentrations of drug 
(Chapman, 1986). Resistance to 150 ppm arprinocid was found to be stable whereas 
resistance to arprinocid 60 ppm (recommended level) was found to be unstable 
(Chapman, 1986). The question must be raised though, if resistance is unstable in the 
field then maybe arprinocid could be re-introduced under a new drug regime? This 
question has never been addressed because arprinocid was taken off the market.
1.7.5 Activity of arprinocid and arprinocid-l-N-oxide against T. gondii
Arprinocid was shown to be effective in mice infected with T. gondii tachyzoites (Luft, 
1986) although in the light of evidence published by Latter and Wilson (1979) and 
Wang and Simashkevieh (1980) (refer Section 1.7.3) the effects were most likely to be 
due to metabolism to arprinocid-l-N-oxide. Whilst mice infected with 2 x 1 0 ^  RH T. 
gondii tachyzoites and treated 2 h later with 50 p,g/day arprinocid survived for a 
significantly longer period of time compared with untreated infected mice, overall 
mortality was unchanged (Luft, 1986). In contrast, mice infected with 2 x 1 0 ^  RH 
tachyzoites and treated with 1 mg/day arprinocid were completely protected, although 
Toxoplasma was found in the brain of 58% of those mice treated with 100 pg/day 
arprinocid (Luft, 1986). Unfortunately, Luft did not make clear what was meant by
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Toxoplasma in the brain and whether this referred to tissue cysts. Nonetheless, 
arprinocid was effective against murine models of Toxoplasma and was demonstrated to 
have better efficacy than pyrimethamine (Luft, 1986).
Pfefferkorn et al (1988) published further evidence that arprinocid-l-N-oxide was the 
active metabolite of arprinocid using a drug-resistant mutant. A mutant isolate, R- 
ANO^-1, resistant to arprinocid-l-N-oxide, was obtained by chemical mutagenesis 
using ethylnitrosourea and subsequent passage in the presence of drug (Pfefferkorn et 
al, 1988). This resistant line was 16- to 20-fold less sensitive to arprinocid-l-N-oxide 
than the parental RH line, but just as sensitive to arprinocid in vitro. However, whilst 
arprinocid was effective in treating mice infected with RH T. gondii tachyzoites, it was 
not effective against toxoplasmosis in mice infected with R-ANO^-1, suggesting that in 
vivo metabolism to arprinocid-l-N-oxide occurs and that this 1-N-oxide is the active 
form (Pfefferkorn et al 1988). Where this metabolism takes place is unknown. The most 
obvious place would be in the liver of the host animal, however, mouse liver 
microsomes incubated with arprinocid predominantly gave 2 -chloro-6 -fluorobenzyl 
alcohol, which was found to be inactive against chicken coccidiosis (Wolf et a l, 1978). 
One possibility is that the parasite, itself, may have drug-metabolising enzymes.
An in vitro method was developed for evaluating the effect of drugs on T. gondii tissue 
cysts and bradyzoites using a fluorescent dye that changes colour depending on the 
viability of the bradyzoites (discussed further in Chapter 3). Treatment of intact tissue 
cysts and released bradyzoites with 10 |ag/ml arprinocid-l-N-oxide for 6  days resulted 
in deformed bradyzoites (Huskinson-Mark et a l, 1991). The authors did not describe 
this deformity. Whilst this evidence suggests that arprinocid-l-N-oxide may eradicate
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the cyst stage of Toxoplasma, further work in animal models is essential to draw 
conclusions.
1.8 Identification of novel drug targets: a global approach
Chemotherapy is the mainstay of treatment of many animal and human diseases, 
including toxoplasmosis. The search for new drugs relies on the identification of novel 
targets, preferably essential biochemical pathways present in parasites and absent in 
their mammalian hosts. One recent example, is the identification of the shikimate 
pathway in Plasmodium species and Toxoplasma gondii as discussed above (Section 
1.6 .2).
The process of identification of novel biochemical pathways is rapidly changing. 
Biochemical techniques, such as kinetic assays of recombinant enzymes or HPLC 
analysis of enzyme activity, are directed at characterising parasite enzymes or proteins 
that differ between parasites and mammalian cells. In addition to these techniques, 
recent advances in bioinformatics and reverse genetics (Soete et a l, 1999), together 
with high-throughput differential gene analysis (Humphery-Smith and Blackstock, 
1999), have made possible a rational approach to the identification of drug targets.
1.8.1 Gene sequencing
The expansion of genome databases, such as the Malaria Sequencing Project 
(Anonymous, 2001), and expansion of expressed sequence tag (EST) databases, 
particularly for T. gondii tachyzoite and bradyzoites genes (Ajioka, 1998a; Manger et 
al,, 1998), have enhanced our ability to discover previously unidentified genes. In
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particular, the identification of genes that are conserved between Apicomplexa not only 
suggests the presence of common pathways, but allows the prospect of designing broad- 
range chemotherapeutic agents (Ajioka et al., 1998b), At present there are over 16, 000 
T. gondii ESTs available (http://www.ebi.ac.uk/parasites/paratable.html), from both 
tachyzoite and bradyzoite stages, therefore providing valuable information on genes 
expressed during stage transition. For example, searching the T. gondii EST database 
allowed the discovery of some microneme proteins based on homology to P. falciparum 
TRAP (reviewed Tomley and Soldati, 2001). However, whilst mining EST databases 
may prove fruitful, it has the disadvantage that many essential genes may be under­
represented.
1.8.2 Reverse genetics
The high frequency of stable transformation coupled with the haploid genome of T. 
gondii tachyzoites makes this parasite a suitable model for investigation of gene 
function by reverse genetics (Roos et al., 1994). The feasibility of creating mutant T. 
gondii lines with specific gene deletions, modified genes or expressing additional genes, 
permits the exploration of many important biological questions. For example, questions 
related to protein trafficking, host cell invasion and drug resistance. The T. gondii 
hypoxanthine-xanthine-guanine-phosphoribosyltransferase (HXGPRT) and uracil 
phosphoribosyl transferase genes were cloned (Donald et a l, 1996; Donald and Roos, 
1995, respectively). Both enzymes are parasite-specific and were therefore thought to be 
good candidates for dmg targeting. However, null mutants were found to be viable 
(Donald et a l, 1996; Donald and Roos, 1995). The use of HXGPRT vectors for 
targeting specific genes whose function is unknown has also been demonstrated, by 
using mycophenolic acid or 6 -thioxanthine as positive or negative selection,
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respectively (Donald and Roos, 1998). Other T, gondii genes have been deleted, 
including GRA2 and SAG3 which resulted in decreased virulence in mice (Mercier et 
al., 1998; Dzierszinski et al., 2000, respectively), and the gene encoding for the BAGl 
bradyzoite antigen which resulted in decreased in vivo cyst formation (Zhang et al., 
1999).
The green fluorescent protein (GFP) from the jellyfish Aequorea victoria, may be 
expressed as a fusion protein in T. gondii, thereby allowing the visualisation of protein 
trafficking. For example, secretion of surface antigens, and real time studies of protein 
movement have been investigated (Striepen et al., 1998, 2001; Kim et a l, 2001). 
Extracellular tachyzoites or infected host cells expressing GFP fusion proteins can be 
readily be sorted by FACS, facilitating a convenient selection strategy (Striepen et a l, 
1998). Moreover, targeting studies in deletion mutants allows the elucidation of those 
genes essential for parasite survival (Striepen et a l, 2001).
Although the list of available reverse genetics techniques for T. gondii is growing, 
currently there is no system that allows inducible control of gene expression, thus 
limiting the study of essential genes (Soldati, 1996). An inducible expression system 
has been developed for the protozoan parasite, Trypanosoma brucei, utilising the 
tetracycline repressor system of Escherichia coli (Wirtz and Christine, 1995), but this 
system in not available for T. gondii yet. The hormonally regulated Cre-lox system, 
which has been used successfully in mammalian cells for inducible gene targeting, has 
been stable expressed in T. gondii taehyzoites (Brecht et a l, 1999). However, the fusion 
between Cre recombinase and a mutated progesterone receptor binding domain 
(CrePRl) was active even in the absence of hormone, thus preventing this as a system 
for gene regulation in T. gondii.
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1.8.3 Differential gene expression
Whilst molecular biology and reverse genetics techniques can be suceessful in 
identifying and validating gene targets, they usually allow for only one gene at a time to 
be analysed. The wealth of information that has become available recently due to 
sequencing projects, such as the P. falciparum  sequencing project, renders these 
techniques insufficient to mine this wealth of information optimally.
Methodologies for the quantification of mRNA using hybridisation techniques such as 
Northern Blotting or by reverse transcription polymerase chain reaction (RT-PCR) are 
also limited to just a few genes per assay. However, developments in PCR technology 
have led to quantification of mRNA on a larger scale. Differential display-PCR is a 
relatively simple and inexpensive technique for identifying differentially expressed 
genes and potential drug targets. However, the large number of false positives/negatives 
that are obtained can reduce its efficiency. Serial analysis of gene expression (SAGE) 
tends to be less error prone but requires large amounts of high quality starting material. 
This technique has been proven effective in studies of gene expression in normal versus 
cancer cells (Zhang et a l, 1997).
In the last decade, the development of high-throughput methods based on gene-chip 
technologies has allowed many thousands of genes to be analysed simultaneously. DNA 
array hybridisation allows the simultaneous analysis of tens of thousands of genes. 
Individual cDNA (or oligonucleotide) sequences are imprinted as spots onto a solid 
support, typically a nylon membrane or glass slide. After hybridisation of labelled 
mRNA to the array, the intensity of the label associated with each spot directly
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correlates with the level of expression of that mRNA. Double labelling experiments 
permit the identification of differentially expressed mRNA sequences.
Genetic techniques, such as insertional mutagenesis and gene deletion, are not however 
redundant, neither are the classical biochemical analyses. Instead, these approaches are 
likely to be more directed to genes/proteins of interest that were identified by chip- 
based technologies. The cost of array-based technology has been beyond the finance of 
many research groups but hopefully this will ehange. The technology is exciting and, 
when more readily available, will provide rapid analysis of parasite gene expression.
Analysis of the protein expression by two-dimensional electrophoresis (2-DE) will 
complement these other approaches. Recent advances enabling reproducible separation 
of proteins (Chapter 4) allows not only global analysis of gene produets expressed by an 
organism (or tissue), but also gives detailed information about co- and post-translational 
modifications, such as phosphorylation and glycosylation. These ehanges, not 
detectable at the mRNA level, are of tremendous importance in understanding 
biochemical processes within a cell. Furthermore, proteins of interest may be identified 
by using mass spectrometry data to search protein or genome databases (Chapter 5). 
This, therefore, allows the validation of an increased/decreased expression of a gene at 
the protein level. Moreover, comparison of protein expression changes in healthy versus 
diseased cells can give vital information about the onset of disease. The applications of 
these techniques are wide and have particular benefits for investigation of the 
mechanism of action of drugs and drug-resistance.
There is no doubt that classical biochemical and genetic techniques have added a 
tremendous wealth of knowledge to the study of Apicomplexa. Developing global
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techniques aimed at analysing many hundreds or thousands of genes/proteins 
simultaneously are also powerful techniques, but their full potential is yet to be realised. 
The question is not which techniques will take over, but, rather, how will we be able to 
integrate the techniques in a more rational approach to the more rapid identifleation and 
validation of drug targets.
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1.9 Aims of project
The overall focus of this study was to provide information on the action against 
Toxoplasma gondii of arprinocid and arprinocid-l-N-oxide. The availability of drug- 
sensitive and -resistant lines facilitated the investigation and was a central theme to the 
thesis. The following were the main approaches and objectives of this thesis.
1) Efficacy of arprinocid and arprinocid-l-N-oxide
a) To examine the sensitivity of T. gondii tachyzoites to arprinocid and arprinocid- 
l-N-oxide and investigate the sensitivity of two mutant T, gondii lines resistant 
to arprinocid-l-N-oxide.
b) To investigate whether the effects of arprinocid and arprinocid-l-N-oxide 
against T. gondii were directed specifically towards the tachyzoites or dependant 
on disruption of normal host cell metabolism.
c) To investigate whether or not arprinocid and arprinocid-l-N-oxide interfere with 
the HXGPRT-mediated salvage of purines.
d) To analyse the relative efficacy of arprinocid and arprinocid-l-N-oxide against 
T. gondii using different dose regimens.
2) Two-dimensional electrophoresis (2-DE) analysis and mass spectrometric
identification of T. gondii tachyzoite proteins.
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a) To develop the tools necessary for the reproducible, high-resolution separation 
of T. gondii taehyzoite proteins by 2-DE, and apply these techniques to 
investigate acquisition of drug-resistance.
b) To create a preliminary 2-D gel map of T. gondii tachyzoite proteins using 
MALDI mass spectrometry in combination with protein and EST database 
searching.
c) To use mass spectrometry techniques to identify a protein differentially 
expressed between the drug-sensitive and -resistant parasites.
3) Purine transport in T. gondii tachyzoites
a) To characterise nucleoside/nucleobase transporters in T. gondii as likely 
conduits for the transport or targets of arprinocid and arprinocid-l-N-oxide.
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CHAPTER 2
General Materials and Methods
The purpose of this Chapter is to describe general materials and methods including 
parasite maintenance, protein estimation, preparation of protein and DNA, and 
statistical analysis. Detailed methods for in vitro drug assays, two-dimensional 
electrophoresis of T. gondii proteins, mass spectrometric identification of T. gondii 
proteins, and membrane transport, are described in Chapters 3, 4, 5 and 6 , respectively.
2.1 Materials
2.1.1 Toxoplasma gondii tachyzoites
The following Toxoplasma gondii isolates were kindly supplied by E.R. Pfefferkorn 
(Dartmouth College, New Hampshire, USA): (i) a cloned parental line "pRH", (ii) an 
arprinocid-1-N-oxide-resistant mutant "ARP^ 5-86" derived from pRH (Pfefferkorn et 
aL, 1988) and (iii) an arprinocid-1-N-oxide-resistant mutant "ANO^", also derived from 
pRH (Rickets Pfefferkorn, 1993). For convenience ARP^ 5-86 T. gondii will be 
referred to as ARP^. The following T. gondii strains were also used: (iv) T. gondii 
strain, RH (Sabin, 1941), (v) incomplete vaccine line, S48 (Wilkins et a l, 1987) and 
(vi) a cloned line of RH lacking the hypoxanthine-xanthine-guanine-phosphoribosyl-
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transferase (HXGPRT) gene (Donald et a l, 1996). A summary of the above T. gondii 
lines is given in Table 2.1.1.
Table 2.1.1. Description of Toxoplasma gondii lines available for analysis.
T. gondii strain Description Cloned Reference
pRH Parental RH line of 
ARP"  ^and ANO"^
Yes Pfefferkorn et a l, 1988
ARP‘^ Arpinocid-1 -N-oxide- 
resistant mutant
Yes Pfefferkorn et a l, 1988
ANO^' Arpinocid-1 -N-oxide- 
resistant mutant
No Ricketts and Pfefferkorn, 
1993
S48 Vaccine strain No Wilkins et a l, 1987
RH Virulent strain No Sabin, 1941
RH-HX HXGPRT knockout 
mutant derived from 
RH
Yes Donald et a l, 1996
2.1.2 Culture medium and solutions
(i) Iscove's Modified Dulbecco's Medium (Life Technologies) used for cell culture 
was supplemented with 5 % (v/v) foetal calf serum (PCS) and 100 U/ml penicillin and 
100 [ig/ml streptomycin sulphate. Culture medium was filter sterilised using a 0.2 pim 
membrane pore-size Sartolab® V500 filter (Sartorius, Surrey, UK) connected to a 
diaphragm-based vacuum pump. Unless stated otherwise, the abbreviation IMDM refers 
to filter sterilised supplemented medium containing PCS and antibiotics.
(ii) HEPES buffered balanced salt solution for washing cell monolayers prior to 
trypsinisation was made as follows: 140 mM sodium chloride, 5 mM potassium 
chloride, 5 mM D-glucose, 10 mM HEPES and 0.001 % phenol red. The buffer was 
adjusted to pH 7.5 using 5 M sodium hydroxide and filter sterilised as described above.
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(iii) Suspension medium for the cryopreservation of T. gondii tachyzoites and host 
cells consisted of Iscove's Modified Dulbecco's Medium supplemented with 10 % (v/v) 
PCS, 100 U/ml penicillin and 100 ^g/ml streptomycin sulphate and 12.5 % (v/v) 
DMSO. Suspension medium was filter sterilised using syringe filters.
All solutions were stored at 4°C for a maximum of one month.
2.1.3 Drugs and chemicals
Arprinocid (6-amino-9-(2-chloro-6-fluorobenzyl)-purine), arprinocid-l-N-oxide (6 - 
amino-9-(2-chloro-6-fluorobenzyl) purine-1-N-oxide), and adenosine-N-oxide were 
kindly donated by Pfizer Ltd, Kent, UK. They were supplied in powder form and 
dissolved in 100 % dimethysulphoxide (DMSO). Aliquots at various concentrations 
were stored at -20°C. Por in vitro experiments using compounds dissolved in DMSO, 
drugs were diluted to a final concentration of 1 % DMSO, which had no noticeable 
effect on Vero cells or T. gondii tachyzoites as judged by visual analysis of control 
cultures incubated in 1 % DMSO.
Laboratory chemicals used were the best available. Chemicals and their suppliers are 
listed in Table 2.1.2. All buffers and reagents were made using double-distilled- 
deionised water (dddHiO), except those used for two-dimensional electrophoresis 
which were made using 18 Megohm (18 MQ) ultrapure water (Millipore, UK).
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Acetonitrile Sigma, Dorset, UK
Acetic acid (glacial) BDH, Poole, UK
Acrylamide PAGE solution, 40 % (PlusOne™) Amersham Pharmacia 
Biotech, Bucks, UK
Adenine Sigma, Dorset, UK
[2, 8 -^H]-Adenine (32.2. Ci/mmol) NEN, Hounslow, UK
Adenosine Sigma, Dorset, UK
[2-^H]-Adenosine (25 Ci/mmol) Amersham Pharmacia 
Biotech, Bucks, UK
Adenosine-N-oxide Pfizer Ltd, Kent, UK
Agarose, Seakem LE BMA, ME, USA
Ammonium bicarbonate BDH, Poole, UK
Ammonium persulphate (PlusOne™) Amersham Pharmacia 
Biotech, Bucks, UK
Angiotensin I Sigma, Dorset, UK
Arprinocid
(6-amino-9-(2-chloro-6-fluorobenzyl)-purine) Pfizer Ltd, Kent, UK
Arprinocid-1 -N-oxide
(6-amino-9-(2-chloro-6-fluorobenzyl) purine-1 -N-oxide) Pfizer Ltd, Kent, UK
n-Butanol BDH, Poole, UK
di-n-butylphthalate BDH, Poole, UK
Caleium chloride BDH, Poole, UK
CHAPS (PlusOne™) Amersham Pharmacia 
Biotech, Bucks, UK
Coomassie Brilliant Blue R250 Sigma, Dorset, UK
a-Cyano-4-hydroxycinnamic acid Aldrich, Dorset, UK
Dilazep Sigma, Dorset, UK
Dimethylsulphoxide Sigma, Dorset, UK
Dipyridamole Sigma, Dorset, UK
Dithiothreitol (PlusOne™) Amersham Pharmacia 
Biotech, Bucks, UK
Ethanol (Anal^) Bamford Laboratories, 
Rochdale, UK
Ethylenediaminetetraacetic acid (EDTA) Fisher Scientific, Leics, 
UK
Foetal Calf Serum Labtech, Sussex, UK
Formaldehyde BDH, Poole, UK
D-Glucose Fisher Scientific, Leics, 
UK
Glutaraldehyde BDH, Poole, UK
Glycerol, 87 % (PlusOne™) Amersham Pharmacia 
Biotech, Bucks, UK
Glycine (PlusOne™) Amersham Pharmacia 
Biotech, Bucks, UK
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HEPES Fisher Scientific, Leics, 
UK
[8 "^H]-Hypoxanthine (32.0 Ci/mmol) Amersham Pharmacia 
Biotech, Bucks, UK
Iscove's modified Dulbeccos medium Life Technologies, 
Paisley, UK
Immobiline drystrip cover fluid (PlusOne™) Amersham Pharmacia 
Biotech, Bucks, UK
Immobiline pH gradient buffers 
(3-1 ONE, 4-7L, 6-1IL and 5.5-6.7L)
Amersham Pharmacia 
Biotech, Bucks, UK
Inosine Sigma, Dorset, UK
[2 , 8 -^H]-inosine (33.4 Ci/mmol) Moravek Biochemicals, 
Ca, USA
oc-Iodoacetamide Calbiochem, Germany
Magnesium chloride Riedel de Haën, Germany
Magnesium sulphate Sigma, Dorset, UK
Methanol (Anal^ )^ BDH, Poole, UK
N-N'-Methylene-bisacrylamide solution, 2 % (PlusOne^") Amersham Pharmacia 
Biotech, Bucks, UK
Mineral oil (light) Sigma, Dorset, UK
Monensin Sigma, Dorset, UK
MOPS (USB) Amersham Pharmacia 
Biotech, Bucks, UK
Papaverine Sigma, Dorset, UK
Penicillin G sodium / streptomycin sulphate (100 U/ml / 
1 0 0  p,g/ml)
Life Technologies, 
Paisley, UK
Phenol red BDH, Poole, UK
Phosphate Buffered Saline (tablets) Sigma, Dorset, UK
Potassium earbonate BDH, Poole, UK
Potassium chloride BDH, Poole, UK
Potassium tetrathionate Sigma, Dorset, UK
Scintillation fluid (Ecoscint A) National Diagnostics, 
Hull, UK
Silver nitrate Sigma, Dorset, UK
Silver stain kit, protein (PlusOne™) Amersham Pharmacia 
Biotech, Bucks, UK
Silver stain kit, protein Genomic Solutions
Sodium acetate Sigma, Dorset, UK
Sodium chloride Riedel de Haën, Germany
Sodium dihydrogen phosphate BDH, Poole, UK
Sodium dodecyl sulphate (PlusOne™) Amersham Pharmacia 
Biotech, Bucks, UK
Sodium hydrogen carbonate Riedel de Haën, Germany
Sodium hydroxide Riedel de Haën, Germany
Sodium thiosulphate Sigma, Dorset, UK
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[methyl-^H]-Thymidine (6.7 Ci/mmol) NEN, Hounslow, UK
TEMED (PlusOne™) Amersham Pharmacia 
Biotech, Bucks, UK
Tris base (PlusOne™) Amersham Pharmacia 
Biotech, Bucks, UK
Triton X-100 Sigma, Dorset, UK
Trypsin-EDTA (Ix) Life Technologies, 
Paisley, UK
Trichloracetic acid BDH, Poole, UK
Trifluoracetic acid Sigma, Dorset, UK
Trypsin, sequence grade (modified) Promega, Southampton, 
UK
Uracil Sigma, Dorset, UK
[5, 6 -"H]-Uracil (45.0 Ci/mmol) Amersham Pharmacia 
Biotech, Bucks, UK
Urea (PlusOne™) Amersham Pharmacia 
Biotech, Bucks, UK
Versine Media Services, 
University of Glasgow, 
UK
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2.2 Methods
2.2.1 Culture of Vero cells aud Toxoplasma gondii
T. gondii tachyzoites were maintained by twice-weekly serial passage using African 
Green Monkey kidney fibroblasts (Vero eells) as host cells. Cells and parasites were 
grown in filter sterilised IMDM in 25 cm  ^ (T25) or 75 cm  ^ (T75) vented tissue culture 
flasks (Greiner, Germany) at 37°C in a 5 % CO2 humidified incubator.
Confluent uninfected host cells were detached from the surface of culture flasks by 
washing the cell monolayer twice in HEPES saline for 1 min (5 ml for a T25, 10 ml for 
a T75) and incubating the cells in versine : trypsin (4 : 1) for approximately 5 min at 
37"C. Gentle tapping of the flask aided the removal of cells from the flask surface. 
Cells were eentrifuged at 1500 x g for 5 min at 4°C and resuspended at a density of 2 x 
10*^  eells/ml IMDM. Cells were re-seeded at 1 x 10  ^ (total) in 5 ml IMDM for a T25 
flask and 4x10^ (total) in 15 ml medium for a T75 flask. Vero cells were infected 24 h 
later at a parasite-to-cell ratio of 3:1 and 4:1 for a T25 and T75, respectively. 
Tachyzoites were harvested 3 or 4 days later using a sterile cell scraper (Greiner). Cells 
and parasites were counted using an improved Neubauer hemacytometer (Weber 
Scientific Ltd, UK).
2.2.2 Preparation of T. gondii tachyzoites for proteiu or DNA extraction
Tachyzoites were separated from host cells by filtration through 47 mm diameter 3 pm 
pore-size Nuclepore® polycarbonate filters (Whatman, UK). Filtered tachyzoites,
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typically containing less than 0 . 1  % host cell contamination as judged by microscopic 
observation, were washed twice in PBS (pH 7.4) by centrifugation at 1500 x g for 20 
min at 4°C. Tachyzoites were given a final wash in PBS (pH 7.4) and pelleted by 
centrifugation at 16,000 x g for 3 min at 4°C.
2.2.3 Protein estimation (BCA assay)
Protein content estimations were performed using a BCA Protein Assay kit (Pierce Ltd, 
UK). Working Reagent was prepared by combining 50 parts Reagent A with 1 part 
Reagent B. Bovine Serum Albumin protein standards (10 pi) were made by serial 
dilutions from a stock of 2 mg/ml. Each standard, blank or unknown sample was 
prepared in triplicate and pipetted into the appropriate microtitre plate wells. Working 
Reagent (200 pi) was added to each of the wells and the samples mixed on a shaker for 
1 min. Samples were incubated at 37°C for 1 h and absorbances read at 560 nm in a 
Titertek Multiskan® MCC/340 microtitre plate reader (Labsystems & Flow 
Laboratories, Finland). A standard curve of blank-corrected absorbances of known 
standards versus protein concentration was plotted and used to calculate unknown 
protein concentrations.
2.2.4 Preparation of genomic DNA from T. gondii tachyzoites
DNA from T. gondii parasites was extracted from a minimum of 2 x 10  ^ filter-purified 
and washed tachyzoites (as described in paragraph 2.2.2) using the GenomicPrep Cells 
and Tissue DNA Isolation kit (Amersham Pharmacia Biotech, UK). Parasites were 
resuspended in a final volume of 40 pi PBS (pH 7.4) and gently mixed with 600 pi Cell
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Lysis Buffer. RNAse A (3 pi) was added and mixed by inverting 25 times. Samples 
were incubated at 37°C for 1 h, cooled to room temperature and vortexed vigorously for 
20 s in the presence of 200 pi Protein Precipitation Solution. Following centrifugation at 
16,000 X g for 3 min, the supernatant (containing the DNA) was decanted into a clean
1.5 ml capped tube. Isopropanol (600 pi) was added and mixed by inverting 50 times 
before being centrifuged at 16000 x g for 1 min. The sedimented DNA was washed in 
70 % ethanol, air dried and dissolved in 100 pi water.
2.2.5 Cloning and sequencing of gene fragments
DNA was amplified using the polymerase chain reaction (PCR) on a Dyad™ DNA 
Engine (MJ Research Inc, USA). DNA samples were separated by electrophoresis in a 1 
% agarose gel using Ix TBE buffer containing 0.5 pl/ml ethidium bromide and 
visualised on a UV transilluminator. These techniques were performed by Ms Janice 
Brock. Sequencing was performed directly on the PCR fragment at the Molecular 
Biology Service Unit at Glasgow University.
2.2.6 Cryopreservation of T. gondii tachyzoites and Vero cells
r. gondii tachyzoites and Vero cells were stored in liquid nitrogen using 
dimethysulphoxide (DMSO) as a cryoprotectant. Freshly harvested tachyzoites were 
washed twice in IMDM containing 10 % (v/v) FCS by centiJfugation at 1500 x g for 10 
min at 4°C and resuspended in suspension medium at a density of 1 x 10^/ml. Detached 
Vero cells were washed as above and resuspended in suspension medium at a density of 
1 X lOVml. Aliquots (1 ml) were pipetted into cryotubes, which were placed in a
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polystyrene box insulated with cotton wool and cooled slowly to -80°C. Vials were 
catalogued and immersed in liquid nitrogen for long-term storage.
Cryopreserved tachyzoites were removed from liquid nitrogen and thawed rapidly in a 
clenched fist. One vial of taehyzoites was used to infect two T25 flasks of Vero cells. 
Parasite growth was monitored daily and cells passaged as required until the normal 3-4 
day eye le of invasion of host cells, replication and lysis occurred.
2,2.7 Statistical analysis.
Equations and methods for statistical analysis were obtained from Fowler and Cohen 
(1992).
2.2.7.1 Measurement o f variance
Statistical variance (.s^ ) was calculated according to the formula below
n - l
where 2  “  the sum of, x = data value, x = mean of x, and n = number of samples. 
Standard deviation (s) was caleulated by taking the square root of variance.
2.2.7.2 F-test analysis
Prior to performing a Student's /-test for significance in difference between means of 
two samples, data were analysed to test for equal or unequal variance. A two-tailed F-
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test was performed using the following equation, where the degrees of freedom are (ni - 
1 ) and (nz - 1 ) for samples 1 and 2 , respectively.
F -  greater variance 
lesser variance
2.2.7.3 Student's t-Test fo r  comparing the means o f samples
Comparison of the means of two small samples (under 30 observations) was performed 
using a two-tailed /-test (unequal or equal variance depending on result from F-test) in 
which the mean difference between two samples was divided by the standard error of 
the difference. Calculated / values were compared with a standard table of distribution 
of / under the appropriate degrees of freedom. The equation below, where degrees of 
freedom = (ui + nz)- 2, was used to calculate / manually. T values were checked using 
Microsoft Excel 97. P values of 0.05 were considered significant.
fn^  - 1 ) - ^ /  +  («2 ~  1) * *^ 2^  ^  ^n^+nA
 ^ («1 + «2 “  2 ) ^  ^ «1 -«2 y
2.2.7.4 Student's t-Test fo r  comparing the means ofpaired samples
Analysis of the means of matched pairs was performed using a paired two-tailed /-test. 
The difference between matched pairs was determined as 'd.' The equation is given 
below, where n is the number of matched pairs and (n - 1 ) is the degrees of freedom.
y d
-  ( ^ d f  ) / ( / î - l ) ]
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CHAPTER 3
Evaluation of the in Vitro Effects of Arprinocid 
and Arprinocid-1-N-oxide on T. gondii Growth and Survival
3.1 Introduction
Understanding the mode of action of drugs and the mechanism of acquisition of drug- 
resistance is crucial to the development of new anti-coccidials with increased potency 
and specificity (Luft and Remington, 1992). In vitro investigations into the efficacy of 
novel therapeutic compounds is an important step in designing improved drugs and 
combination therapies. In addition, the testing of chemical analogues allows the 
identification of chemical structures that have increased affinity and greater specificity 
for parasites, thus enabling rational drug design. In vitro investigations are invaluable 
studies and are comparatively inexpensive for high-throughput screening of large 
numbers of compounds.
For some coccidia, including Eimeria spp and Cryptosporidium, the comparative 
difficulty in growing life stages in vitro makes the assessment of anti-coccidial agents 
problematic. By contrast, measurement of the incorporation of ^H-uracil, which 
specifically labels intracellular T. gondii parasites, has been successfully used to analyse 
quantitatively the in vitro growth of tachyzoites (Mack and McLeod, 1984; Pfefferkorn 
and Pfefferkorn, 1977a). Although this technique may also be used to measure the
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growth of Eimeria tenella first generation schizonts, ^H-uracil is not incorporated into 
mature schizonts and merozoites, possibly due to reduced RNA synthesis in these later 
stages (Schmatz et a l, 1986). Furthermore, the asynchronous growth of Eimeria  
parasites makes interpretation of the results difficult. The in vitro assessment of drugs 
against Cryptosporidium parvum  has been performed semi-quantitatively either by 
manually counting parasite life stages (Armson et a l, 1999; Theodos et a l,  1998) or by 
using monoclonal antibodies specific to intracellular stages of C. parvum  and 
immunofluoreseence microscopy (Perkins et a l, 1998). However, manual counting of 
parasites is tedious and not suitable for high-throughput analysis, although it should be 
mentioned that microscopic analysis is invaluable in interpreting data from quantitative 
assays. In contrast, T. gondii tachyzoites can be grown in tissue culture allowing 
quantitative in vitro drug-screen assays to be performed with relative ease and therefore 
is an excellent model for testing potential anticoecidial agents in vitro. Likewise, 
analysis of compounds against T. gondii tissue cysts in vitro is possible. Tissue cysts 
may be obtained by (i) extraction from brains of infected mice (Huskinson-Mark et a l, 
1991); (ii) infection of murine brain cells/human fibroblasts with bradyzoites obtained 
from brain cysts (Ricard et a l, 1999a, b; Sahm et a l, 1997); or (iii) decoquinate- 
induction of tachyzoite infected fibroblasts (Lindsay et a l, 1998). The measurement of 
drug-activity against tissue cysts may be performed by using a fluorescent stain 
(acridine orange-ethidium bromide) which changes colour depending on the viability of 
the cyst (Huskinson-Mark et a l,  1991). Results may be confirmed by inoculating mice 
with the drug-treated tissue cysts and monitoring time to death (Araujo et a l, 1991).
Several methods of quantitatively measuring the efficacy of BXiti-Toxoplasma drugs 
have been developed. In addition to the ^H-uracil assay, enzyme-linked-immuno-
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sorbent-ass ays (ELISA) have been performed to test for inhibitors of T. gondii and 
Neospora caninum growth (Derouin and Chastang, 1988; Lindsay et a l, 1994). 
Recently, a microtitre colorimetric assay has been developed using a strain of T. gondii 
expressing bacterial (3-galactosidase providing a non-radioactive alternative to the ^H- 
uracil incorporation assay (McFadden et a l, 1997). An alternative and more 
sophisticated method, allows the measurement of the percentage of infective cells and 
number of intracellular tachyzoites by flow cytometry using a monoclonal antibody 
against cell surface antigen, for example T. gondii SAGl (Gay-Andrieu et a l, 1999). 
Recently a flow cytometry approach has been applied to C. parvum sporozoite viability 
(Giacometti et a l, 2000). Whilst these techniques avoid the use of radiolabelled 
precursors and can be readily automated, ELISA-based screens require additional 
experiments to determine the effect of compounds on host cells and flow cytometric 
quantification methods require the use of expensive FACScan equipment which is not 
available to many researchers.
An understanding of the biological and biochemical differences between parasites and 
their hosts is not only of great importance in the development of new antiparasitic 
drugs, but can also be exploited in the design of drug screen assays. For example, as 
mentioned above, the measurement of the incorporation of ^H-uracil that specifically 
labels intracellular T. gondii and not extracellular tachyzoites or host cells. This assay 
was discovered accidentally during a series of investigations into resistance to 5- 
fluorodeoxyuridine (Pfefferkorn, 1978; Pfefferkorn and Pfefferkorn, 1977b). In the late 
1970's, subsequent to the study of an enzyme defect in a mutant T. gondii strain resistant 
to 5-fluorodeoxyuridine, it was proposed that deoxyuridine was incorporated by T. 
gondii (Pfefferkorn and Pfefferkorn, 1977b). In a subsequent study, it was discovered
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that the mutant strain was unable to incorporate radiolabelled uracil, deoxyuridine, or 
uridine and consequently it was thought that uridine kinase, an enzyme responsible for 
the conversion of uridine to UMP, was absent. However, uridine kinase activity could 
not be detected in wild-type parasites. Thus, the previously published salvage pathway 
was modified (Figure 3.1) (Pfefferkorn, 1978). Uptake of ^H-uracil by intracellular T, 
gondii can only occur after permeating the host outer membrane and therefore uracil 
must be available to the host cell. Since uracil is not utilised by the host cell, a parasite- 
speeific salvage enzyme was thought to be responsible. Further work concluded that a 
40-fold higher activity of uridine phosphorylase in infected cells compared to 
uninfected cells was responsible for the conversion of uridine to uracil. 
Autoradiographic analysis of the uptake of ^H-uracil indicated that nearly all the 
radio lab el was associated with intracellular tachyzoites and that there was no reverse 
flow into the host cell. Once the intracellular parasite has incorporated uracil it is 
converted to UMP by uracil phosphoribosyl transferase, an enzyme absent in 
mammalian cells. ^H-uracil is specifically incorporated into T. gondii nucleic acids in 
proportion to the number of parasites and therefore can be used as a measure of 
tachyzoite growth (Pfefferkorn and Pfefferkorn, 1977a). The ^H-uracil assay has been 
used in many studies to assess the efficaey of ^ni\-Toxoplasma compounds. For 
example, rifapentine (Araujo et a l, 1996), naphthoquinones analogues (Khan et a l, 
1998) and synercid (Khan et a l, 1999a). It is used in this chapter as the principle tool to 
evaluate the in vitro effects of arprinocid and, its in vivo metabolite, arprinocid-l-N- 
oxide on T. gondii tachyzoites.
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cytidine >uridine
uracil
deoxycytidine— ► deoxyuridine
uridine-5
-►monophosphate
(UMP)
1 - cytidine deaminase
2 - uridine phosphorylase
3 - uracil phosphoribosyltransferase
Figure 3.1. Pyrimidine salvage pathways present in T. gondii tachyzoites. The end 
product, uridine-5’-monophosphates (UMP), is used directly in the formation of nucleic 
acids. Uridine phosphorylase catalyses the reversible phosphor lysis of uridine and 
deoxyuridine to form uracil which is salvaged by T. gondii and converted to UMP by the 
enzyme, uracil phosphoribosyltransferase. Neither of these enzymes are present in 
mammalian cells and consequently these cells are unable to utilise uracil for RNA and 
DNA synthesis.
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3.2 Aims
Arprinocid has been shown to be effective against both chicken coccidiosis (Miller et 
a l,  1977) and murine toxoplasmosis (Luft, 1986; Pfefferkom et a l, 1988). Previous 
work suggested that the activity of arprinocid was related to inhibition of hypoxanthine 
transport (Wang et a l, 1979a; Wang et a l, 1979b). The production of an arprinocid-1- 
N-oxide-resistant T. gondii strain allowed further investigation of the mechanism of 
action of arprinocid (Pfefferkom et a l, 1988) and led to the conclusion that arprinocid- 
1-N-oxide was the active in vivo metabolite of arprinocid. Furthermore, hypoxanthine 
was shown not to alter the efficacy of either compound. However, the mechanism of 
action of arprinocid and arprinocid- 1 -N-oxide remains to be elucidated.
The main objectives of work presented in this chapter were to
(i) Examine the sensitivity of pRH T. gondii tachyzoites to arprinocid and 
arprinocid-1-N-oxide, and investigate the decreased sensitivity of two mutant T. gondii 
strains (ARP^ and ANO^) to arprinocid-1-N-oxide.
(ii) Compare the IC50 values of arprinocid and arprinocid-1-N-oxide with those for 
adenosine-N-oxide and monensin,
(iii) Investigate whether the effects of arprinocid, arprinocid-1-N-oxide, adenosine- 
N-oxide or monensin against T. gondii were specific to tachyzoites as a consequence of 
the dismption of normal host cell metabolism.
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(iv) Analyse the efficacy of arprinocid and arprinocid-1-N-oxide against a mutant T. 
gondii line lacking the gene encoding for HXGPRT (RH-HX ) to investigate whether 
these compounds interfere with the HXGPRT-mediated salvage of purines.
(v) Analyse the efficacy of arprinocid and arprinocid-1-N-oxide when T. gondii 
tachyzoites were treated using different dose regimes.
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3.3 Methods
3.3.1 /«  vitro activity of drugs on T. gondii tachyzoites.
Vero cells (2 x 10"^  cells/well) were incubated in 24-well plates overnight to form 60 % 
confluent monolayers and were infected with freshly harvested tachyzoites using a 
tachyzo ite-to - cell ratio of 3:1. In order to measure the effects of both invasion and 
replication of T. gondii, compounds were added to cell cultures 1 h before infection, 
unless otherwise stated. Cultures were incubated for 24 h, 48 h, or 72 h, at 37°C in a 5 
% CO2 humidified incubator. Subsequently, the cultures were radiolabelled by the 
addition of 5 qCi [5, 6-^H]-uracil per well and then further incubated for 4 h at 37°C. 
The 24-well plates were then chilled for 3 min at -20°C and the cell monolayers fixed to 
the bottom of the wells by the addition of 1 ml of ice-cold 0.6 N trichloroacetic acid 
(TCA) per well. After incubating on ice for 1 h, the TCA solution was removed and 
excess soluble radiation washed away by immersing the plates in a cold water bath 
overnight. Plates were air-dried for 5-10 min and the TCA precipitate dissolved by the 
addition of 0.5 ml of 0.1 N sodium hydroxide per well. After incubation of the 24-well 
plates at 37°C for 1 h, 0.25 ml of the liquid phase was removed from each well and 
added to 3 ml scintillation fluid that was acidified to neutralise the sodium hydroxide (3 
\il glacial acetic acid per 3 ml scintillant). Experiments were conducted in triplicate. 
Counts per minute (CPM) were recorded from both infected and uninfected Vero cells 
(background) using a 1219 RockBeta Spectral scintillation counter (LKB Wallac, 
Finland).
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3.3.2 In vitro activity of drugs on host Vero cells.
The sensitivity of Vero cells to the drugs was assayed by measuring ^H-thymidine 
incorporation, a similar technique to the measurement of ^H-uracil incorporation into 
tachyzoites (Pfefferkom et a l, 1988). Uninfected Vero cells (2 x 10"^ ) were incubated in 
24-well plates in the presence of dmg for 48 h. The cultures were radiolabelled by the 
addition of 5 jxCi [^H]-thymidine per well and incubated for 6 h at 37°C. ^H-thymidine 
incorporation was quantified as described above.
3.3.3 Graphical analysis.
Dose-effect curves were plotted as percentage of control ^H-uracil incorporation against 
dmg concentration (pM) using FigP version 2.98 (Biosoft, UK) and I C 5 0  values 
calculated by FigP using the sigmoidal curve-fit equation below;
V = Min + (Max - Min)
1 + ( (X  / X5o)^ - P)
Bar-charts were drawn using Microsoft® Excel 97. Other graphs were drawn using 
GraFit version 4.0.14 (Erithacus Software Ltd, UK).
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3.4 Results
3,4.1 Reproducibility of the ^H-uracil assay
The reproducibility of the ^H-uracil assay was measured using triplicate 24-well plates 
and measuring the incorporation of ^H-uracil into T. gondii tachyzoites during a 4 h 
period 48 h after infection of Vero cells. The mean counts per minute (CPM) ± s.d. (n = 
24) from each 24-well plate were (i) plate 1 - 4289 ± 287 (ii) plate 2 - 4435 ±315 (iii) 
plate 3 - 4514 ± 299. Mean CPM values ± s.d. for corresponding wells (n = 3) from 
each plate are displayed in Figure 3.2a. A frequency histogram showed that 75 % of 
observations fell within 1 s.d. of the mean and that 95 % of observations fell within 2 
s.d of the mean (Figure 3.2b). On this basis it was concluded that the data were 
normally distributed. It was assumed that the residual observations (< 5 %) were equally 
divided at either end of the distribution and therefore Student's f-Test statistics were 
calculated as two-tailed.
The calculated values of F  (P = 0.05) for data between plates 1 and 2, between plates 2 
and 3 and between plates 1 & 3 were 1.21, 1.11 and 1.09, respectively. Since these 
values were below the critical value of F  (P = 0.05) the samples were assumed to be 
from populations of similar variance. Student's ^-Test analysis (assuming equal 
variance) showed that there was no significant difference (P > 0.05) in the means of the 
groups of data. A similar more sensitive test for matched pairs, whereby the well 
positions from one plate were fixed against the well positions from a second plate (wells 
were assumed to be numbered 1 to 24, from top left to bottom right) was performed. 
The calculated values of t between plates 1 and 2, between plates 2 and 3 and between
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Figure 3.2. Reproducibility of ^H-uracii assay used to measure 
growth of T. gondii tachyzoites (a) Parasites and host cells were 
grown in replicate 24-well plates and ^H-uracil incorporation 
measured during a 4 h period 48 h after infection of Vero cells. 
Data are the mean ± s.d. (n = 3) of uracil uptake in each well 
(numbered consecutively from top left to bottom right). Dotted 
line is mean of 72 wells, 4412 ± 310 (b) Frequency histogram of 
the distribution of the data from all observations (n = 72).
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plates 1 and 3 indicated there was no significant difference in the means (P > 0,05). As a 
final test, row and column reproducibility within each plate was measured. There was 
no significant difference between rows of plates (P > 0.05) or between columns of 
plates (P > 0.05).
3.4.2 Growth rate of 5 different strains of T. gondii
Growth curves of five sti'ains of T. gondii, pRH, ARP* ,^ ANO* ,^ RH-HX" and S48, were 
quantified by measuring ^H-uracil incorporation during a 4 h period at 0 h, 4 h, 24 h, 48 
h and 72 h relative to the time of infection of Vero cells (Figure 3.3a). All five T. gondii 
strains exhibited similar growth rates up to 24 h. However, the continued growth of 
parasites varied between strains. At 48 h post-infection, compared with 24 h post­
infection, ^H-uracil uptake by pRH and ARP^ T. gondii tachyzoites increased by 
approximately 30 % whilst, for ANO^, ^H-uracil uptake decreased. For the same time 
period ^H-uracil incorporation by RH-HX and S48 T, gondii increased by 188 % and 
176 %, respectively.
A concurrent experiment to the ^H-uracil growth assay, using 25 cm  ^ tissue culture 
flasks and exactly the same parasiteicell infection ratio, was performed to analyse the 
relationship between parasite growth and ^H-uracil uptake. At several time intervals 
after the infection of Vero cells: (i) extracellular tachyzoites were removed from the 
flask and counted; (ii) the cell monolayer was disrupted and the numbers of intracellular 
tachyzoites counted. Data collected for each strain indicated that there was a good 
correlation between ^H-uracil incorporation (CPM) and numbers of intracellular 
tachyzoites. Data for pRH tachyzoites are shown in Figure 3.4. Therefore, in all 
subsequent experiments an increase or decrease in CPM was assumed to be a reflection
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of the growth or inliibition of growth of T. gondii tachyzoites, respectively. The total 
numbers of tachyzoites for each strain are shown in Figure 3.3b. It was noticeable that 
RH-HX and S48 tachyzoites grew at a faster rate than pRH, ARP^ or ANO^. For 
instance, at 144 h there were 25-fold more RH-HX tachyzoites and 17-fold more S48 
tachyzoites than pRH, ARP^ or ANO^.
3.4.3 Efficacy of arprinocid, arprinocid-l-N-oxide, adenosine-N-oxide and 
monensin on growth of T. gondii
Having investigated the reproducibility of the ^H-uracil incorporation assay and 
established the correlation between CPM and parasite growth, the assay was used to 
quantify the efficacy of arprinocid, arprinocid-1 -N-oxide, adenosine-N-oxide and 
monensin against T. gondii tachyzoites.
^H-Uracil uptake by pRH T. gondii tachyzoites grown within Vero cells was diminished 
significantly (P < 0.005) by treatment with arprinocid (Figure 3.5). Specifically, when 
drug was added to the culture 1 h before infection and ^H-uracil uptake measured during 
a 4 h period 48 h later, arprinocid (50 pM) inhibited the growth of T. gondii by 82.8 ±
7.3 % (n = 3). Arprinocid ( 0 - 5 0  pM) exhibited similar toxicity against pRH, ARP^ (P
< 0.005) and ANO^ (P < 0.001), with I C 5 0  values of 22.4 ± 5.0 pM (n = 3), 18.7 ± 2.9 
pM (n = 3) and 17.7 ± 2.2 pM (n = 3), respectively. There was no significant change (P
< 0.05) in the efficacy of arprinocid when ^H-uracil incorporation was measured during 
a 4 h period 24 h post infection (data not shown).
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Figure 3.3. Measurement o f the growth of pRH. ARP* ,^ ANO* ,^ RH-HX and 
S48 T. gondii strains (a) ^H-uracil incorporation was measured during a 4 h 
period 0 h, 4 h, 24 h, 48 h and 72 h post-infection of Vero cells. Data points 
are the mean ± s.d. of 3 experiments (b) Measurement o f the growth 
characteristics of pRH, A R P \ ANO* ,^ RH-HX and S48 T. gondii strains 
using microscopic analysis. Parallel cultures to those in the ^H-uracil assay 
(Figure 3.3a) were monitored at 0, 4, 24, 48, 72, 96 and 144 h post-infection 
o f Vero cells and the total number o f parasites counted.
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Figure 3.4. Correlation between ^H-uracil incorporation and 
growth of intracellular tachyzoites (pRH). Parallel cultures to those 
used in the ^H-uracil assay (Figure 3.3 a) were monitored at each 
time interval and number o f intracellular parasites counted. Data 
points are the mean ± s.d. of 3 experiments. A direct correlation 
between ^H-uracil incorporation and parasite growth was observed 
for each strain.
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Sensitivity of T, gondii tachyzoites to arprinocid
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Figure 3.5. Sensitivity of pRH, ARP^ and ANO^ T. gondii lines to 
arprinocid ( 0 - 5 0  p,M). Drug treatment occurred 1 h before 
infection of Vero cells. ^H-uracil incorporation was measured 
during a 4 h period 48 h post-infection. IC50 values for arprinocid 
are shown in the table below graph. Data points are the mean of 3 
experiments. Error bars have been omitted for clarity.
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^H-Uracil uptake by pRH T. gondii tachyzoites grown within Vero cells was reduced 
significantly (P < 0.05) by treatment with arprinocid-1 -N-oxide at 350 times lower 
concentration than arprinocid (Figure 3.6). The I C 5 0  concentration of arprinocid-l-N- 
oxide on pRH T. gondii tachyzoites was calculated to be 61 ± 2 8  nM (n = 3). The T. 
gondii strains, ARP^ and ANO^, were found to be 14 fold less sensitive to arprinocid-l- 
N-oxide, having I C 5 0  values of 832 ±71 nM and 875 ± 74 nM, respectively.
Adenosine-N-oxide (0 - 20 pM) exhibited similar toxicity to arprinocid against pRH (P 
< 0.05), ARP^ (P < 0.001) and ANO^ (P < 0.05) strains of T. gondii with I C 5 0  values of
12.5 ± 1.39 pM, 11.8 ± 2.4 pM and 8.1 ± 2.4 pM, respectively (Figure 3.7). Further 
analysis of adenosine-N-oxide (0 - 50 pM) showed that parasite growth was reduced by
74.2 ± 5.0 % (P < 0.001) in the presence of 50 pM drug. The calculated I C 5 0  of 
adenosine-N-oxide using this wider dose range was 14.5 ±2.1  pM (n = 3; data not 
shown).
The ionophore, monensin, inhibited pRH growth by 96.9 ± 2.45 % at 5 nM with an I C 5 0  
value of 0.14 ± 0.02 nM (n = 3) (Figure 3.8).
3.4.4 Effect of arprinocid, arprinocid-l-N-oxide, adenosine-N-oxide and monensin 
on growth of Vero ceils
In order to determine whether the effect of arprinocid, arprinocid-l-N-oxide, adenosine- 
N-oxide and monensin on T. gondii was secondary to an effect on the host cells a ^H- 
thymidine assay was performed on drug-treated uninfected Vero cells (Figure 3.9). 
Monensin (5 nM) had no significant effect on ^H-thymidine incorporation (P > 0.05)
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and did not alter the growth of Vero cells (visual observations). Arprinocid-l-N-oxide 
(400 nM) had no significant effect ^H-thymidine incorporation (P > 0.05) but reduced 
uptake by 99.5 ±0.1 % at 1 pM (P < 0.005). At this concentration of arprinocid-l-N- 
oxide (1 pM), Vero cells became rounded and detached from the surface of the well. In 
contrast, neither arprinocid ( 0 - 5 0  pM) nor adenosine-N-oxide ( 0 - 5 0  pM) had any 
noticeable effect on the Vero cells, although both compounds resulted in a significant 
increase (P < 0.05) in ^H-thymidine incorporation (Figure 3.9).
3.4,5 Efficacy of arprinocid and arprinocid-l-N-oxide on growth of RH-HX' T. 
gondii
A  mutant T. gondii isolate lacking the gene encoding for HXGPRT was used to test the 
possibility that the effect of arprinocid and arprinocid-l-N-oxide was dependent on the 
HXGPRT-mediated salvage pathway. A ^H-uracil experiment was performed using S48 
T. gondii as a control because this strain has a similar growth rate to RH-HX , and 
therefore any difference in drug efficacy would not be masked by differences in growth 
rate. ^H-Uracil incorporation by RH-HX T. gondii tachyzoites was significantly 
reduced by treatment with arprinocid (P < 0.001) and by treatment with arprinocid-l-N- 
oxide (P < 0.005). Calculated I C 5 0  values for arprinocid on RH-HX , S48 and pRH were
18.3 ±1.6 pM, 20.3 ± 2.2 pM and 17.8 ±1.5 pM, respectively (Figure 3.10) correlating 
with values previously determined (Section 3.4.3). The I C 5 0  values for arprinocid-l-N- 
oxide on RH-HX, S48 and pRH were 28 ± 21 nM, 10 ± 12 nM and 47 ± 18 nM (Figure 
3.11) correlating with values previously determined (Section 3.4.3). Therefore, the 
mechanisms of action of arprinocid and arprinocid-l-N-oxide are unrelated to 
hypoxanthine transport.
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Figure 3.6. Sensitivity of pRH, ARP^ and ANO*  ^T. gondii lines to 
arprinocid-l-N-oxide ( 0 - 1 0  p.M). Drug treatment occurred 1 h 
before infection of Vero cells. ^H-uracil incorporation was 
measured during a 4 h period 48 h post-infection. IC50 values for 
arprinocid-l-N-oxide are shown in the table below graph. Data 
points are the mean of 3 experiments. Error bars have been omitted 
for clarity.
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Figure 3.7. Sensitivity of pRH, ARP^ and ANO^  ^ T. gondii strains 
to adenosine-N-oxide (0 - 20 pM). Dmg treatment occurred 1 h 
before infection of Vero cells. ^H-uracil incorporation was 
measured during a 4 h period 48 h post-infection. IC50 values for 
adenosine-N-oxide are shown in the table below graph. Data points 
are the mean of 3 experiments. Error bars have been omitted for 
clarity.
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Figure 3.8. Sensitivity of pRH T. gondii to monensin (0 
- 5 nM). Drug treatment occurred 1 h before infection of 
Vero cells. ^H-uracil incorporation was measured during 
a 4 h period 48 h post-infection. Data points are the 
mean of 3 experiments ± s.d.
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Figure 3.9. Sensitivity of host Vero cells to arprinocid ( 0 - 5 0  
pM), arprinocid-l-N-oxide (0 - 20 pM), adenosine-N-oxide (0 - 
50 pM) and monensin ( 0 - 5  nM). Drug treatment occurred at 
same time as seeding of vero cells. ^H-thymidine incorporation 
was measured during a 6 h period 48 h post-infection. Data points 
aie the mean ± s.d. of 3 experiments.
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Figure 3.10. Sensitivity of RH-HX" 71 gondii to arprinocid (0 - 50 
pM). pRH and S48 T. gondii strains were used as controls. Drug 
treatment occurred 1 h before infection of Vero cells. ^H-uracil 
incorporation was measured during a 4 h period 48 h post-infection. 
IC50 values of arprinocid against each strain are shown in the table 
below the graph. Data points are the mean of 3 experiments. Error 
bars have been omitted for clarity.
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Figure 3.11. Sensitivity of RH-HX' T. gondii to aiprinocid-l-N- 
oxide ( 0 - 1  laM). pRH and S48 T. gondii strains were used as 
controls. Drug treatment occurred 1 h before infection of Vero 
cells. ^H-uracil incorporation was measured during a 4 h period 48 
h post-infection. IC50 values of arprinocid-1-N-oxide against each 
strain are shown in the table below the graph. Data points are the 
mean of 3 experiments. Error bars have been omitted for clarity.
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3.4.6 Dose treatment strategies
Both arprinocid and arprinocid-l-N-oxide were shown to be effective 2tnX\-Toxoplasma 
compounds inhibiting tachyzoite replication 24 h and 48 h post-infection. Consequently, 
experiments were conducted to investigate the effects of the drug within shorter periods 
of time and the efficacy of the compounds using different treatment regimes.
The effects of arprinocid and arprinocid-l-N-oxide on extracellular tachyzoites were 
investigated. Tachyzoites were incubated at 37°C for 2 h in the presence of arprinocid 
(0 - 50 pM), arprinocid-l-N-oxide ( 0 - 1 0  pM), or monensin ( 0 - 5  nM). Thereafter, 
drug was removed from tachyzoites by washing three times in 5 ml IMDM and 
centrifugation at 1500 x g for 10 min at 4°C. Vero cells were infected with these drug- 
treated tachyzoites and ^H-uraeil incorporation measured 48 h later, as described 
previously. There was no significant difference in CPMs between the lowest and 
highest concentrations of arprinocid (P > 0.05) or arprinocd-1-N-oxide (P > 0.05) 
(Figure 3.12). However, when tachyzoites were treated with monensin ( 0 - 5  nM) 
growth was reduced by 37.4 ± 7.2 % (Figure 3.12).
A second experiment was performed to investigate the effects of treating tachyzoites 
(and host cells) with arprinocid or arprinocid-l-N-oxide for a limited period only. Vero 
cells were incubated for 1 h in the presence of either arprinocid (0 - 50 pM) or 
arprinocid-l-N-oxide (0 -10  pM) and then infected with T. gondii tachyzoites (pRH), as 
described previously. However, drug was removed 24 h post-infeetion by washing cell 
monolayers three times in 1 ml IMDM. Cells and parasites in fresh IMDM (no drug) 
were incubated for a further 24 h and ^H-uracil incorporation measured, as described
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previously. Arprinocid (50 pM) and arprinocid-l-N-oxide (1 pM) decreased ^H-uracil 
incorporation by 64.2 ±9.1 % (P < 0.05) and 99.4 ±9.1 % (P < 0.005), respectively 
(Figure 3.13). Calculated IC50 values for arprinocid and arprinocid-l-N-oxide were 13.2 
±3.1 and 24 ± 6  nM, respectively.
To investigate further how quickly arprinocid and arprinocid-l-N-oxide exerted their 
effects, an experiment was conducted in which the treatment of tachyzoites was delayed 
by up to 48 h post-infeetion. Results showed that both arprinocid (20 pM and 50 pM) 
and arprinocid-l-N-oxide (0.1 pM and 0.5 pM) were effective whether the tachyzoites 
were treated for 48 h prior to the measurement of ^ H-uracil incorporation or just during 
the 4 h period of ^H-uraeil incorporation (Figure 3.14). Arprinocid (50 pM) and 
arprinocid-l-N-oxide (0.5 pM), when added to culture medium 48 h after infection, 
reduced ^H-uracil uptake by 59.7 ± 0.8 % (P < 0.05) and by 91.1 ± 1.1 % (P < 0.005), 
respectively.
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Figure 3.12. T. gondii tachyzoites (pRH) were incubated at 37^C 
for 2 h with arprinocid ( 0 - 5 0  pM), arprinocid-l-N-oxide ( 0 - 1 0  
pM) or monensin ( 0 - 5  pM). Drug was removed from the 
parasites by washing them three times in 5 ml IMDM. The drug- 
pretreated tachyzoites were subsequently used to infect Vero cells. 
^H-uraeil incorporation was measured during a 4 h period 48 h 
post-infection. Control assays were in the absence of drug. Data 
points plotted are the mean ± s.d. of 3 experiments.
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Figure 3.13. Sensitivity of T. gondii (pRH) to arprinocid (0 - 50 
pM) and arprinocid-l-N-oxide ( 0 - 1 0  pM) after limited treatment. 
Drugs were added to culture medium 1 h before infection of Vero 
cells and removed 24 h after infection by washing cultures three 
times in IMDM . ^H-uracil incorporation was measured during a 4 
h period 48 h post-infection. IC50 values for arprinocid and 
arprinocid-l-N-oxide are shown in the table below graph. Data 
points are the mean of 3 experiments.
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Figure 3.14. Sensitivity of T. gondii tachyzoites to arprinocid 
and arprinocid-1-N-oxide at -1 h, +4 h, +24 h, and +48 h relative 
to time of infection of Vero cells. T. gondii tachyzoites (pRH) 
treated with (a) arprinocid (0 - 50 pM) or (b) arprinocid-l-N- 
oxide (0 - 0.5 pM). ^H-uracil incorporation was measured during 
a 4 h period 48 h post-infection. Data points are the mean ± s.d. 
of 3 experiments.
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3.5 Discussion
Both arprinocid and arprinocid-l-N-oxide inhibited the in vitro growth of T. gondii 
tachyzoites when measured at 24 h or 48 h post-infection; arprinocid-l-N-oxide 
displayed greater toxicity against T. gondii tachyzoites having an IC50 over 350 fold 
lower than that of arprinocid. The efficacies of both these compounds were in good 
agreement with previously published data for T. gondii (Pfefferkorn et a l, 1988; 
Ricketts and Pfefferkorn, 1993).
The activity of anticoccidial drugs can vary between different organisms and thus 
activity against T. gondii does not necessary translate into similar toxicity against other 
coccidia. For example, ten-fold higher concentrations of both aiprinocid and arprinocid-
l-N-oxide were needed for a 50 % growth inhibition of E. tenella sporozoites (Wang 
and Simashkevich, 1980), whilst arprinocid had approximately a 1.5-fold higher I C 5 0  
digmmt Neospora caninum (Lindsay et a l, 1994). The relatively small difference in I C 5 0  
of arprinocid against N. caninum compared with T. gondii is unlikely to be significant 
since the 1-N-oxide metabolite is the most active compound. In addition to drug 
efficacy differences between species, drugs can show markedly different efficacies 
between two different in vitro screens used on the same organism. Results are largely 
dependent on the type of cells used and the type of medium. For example, arprinocid is 
more active in chick liver cells than chick kidney cells due to metabolism to the more 
potent arprinocid-l-N-oxide (Latter and Wilson, 1979). It is unlikely that Vero cells can 
metabolise arprinocid. Using chick kidney cells, the activity of lasalocid, but not 
monensin, has been shown to vary over 1000 fold between two types of medium. Since 
lasalocid and monensin are both ionophores, and ionophores exert their action by
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altering the ionic balance across membranes, it is conceivable that this activity would be 
affected by the ion composition of media (Latter and Wilson, 1979).
It is possible that arprinocid and arprinocid-l-N-oxide act via distinct mechanisms. 
Although structurally similar to arprinocid, the nitrogen-bound oxygen group present in 
arprinocid-l-N-oxide significantly increased the potency of this compound. It would 
appear that this substitution is responsible for the acquisition of drug-resistance since 
Pfefferkorn and co-workers (1988) made several attempts using chemical mutagenesis 
to create an arprinocid-resistant strain of T. gondii and failed on each occasion. By 
contrast, two successive attempts to create a diclazuril-resistant T, gondii mutant by 
chemical mutagenesis failed and was only achieved by growing parasites in 
progressively increasing concentrations of drug (Lindsay et a l, 1995). There has been 
no report on whether growing wild-type T. gondii under drug pressure could produce an 
arprinocid-resistant mutant. Further work using analogues of arprinocid-l-N-oxide 
would be valuable. Perhaps these analogues could include different substitutions of the 
oxygen group. Most importantly these structure-activity studies would provide vital 
information regarding the structure-activity relationships and inhibitory effects of purine 
analogues against T. gondii. Similarly, a structure-activity study using a 
hypoxanthine incorporation assay (Chulay et a l, 1983) has recently been performed to 
assess the ability of purine derivatives to inliibit the in vitro growth of P. falciparum 
(Harmse et a l, 2001). Other studies have assayed activities of structurally similar 
quinolones and fluoroquinolones against T. gondii (Gozalbes et a l, 2000; Khan et a l, 
1999b). Similarly structure-activity assays were performed to assess binding of 
nucleosides to T. gondii adenosine kinase (Iltzsch et a l, 1995) and binding to T. gondii 
uridine phosphorylase (el Kouni et a l, 1996).
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The two mutant strains (ARP^ and ANO^), compared with pRH, were less sensitive to 
arprinocid-l-N-oxide but equally sensitive to arprinocid. If the presence of an oxygen 
group at N9 contributes to increased toxicity against T. gondii then it might have been 
expected that adenosine-N-oxide would be more potent. Adenosine-N-oxide, which also 
has the oxygen group in the same position, was only slightly more toxic to T. gondii 
(there was no difference in efficacy between sensitive and resistant strains) than 
arprinocid, but not of the magnitude of toxicity of arprinocid-l-N-oxide. Although 
adenosine-N-oxide has some structural similarity to adenosine-N-oxide, it is possible 
that the presence of a pentose group could dramatically change its binding capabilities 
or membrane transport and thus alter its efficacy.
The anti-Toxoplasma activities of arprinocid (0 - 50 fxM), adenosine-N-oxide (0 - 20 
pM) and monensin ( 0 - 5  nM) are not likely to be secondary effects dependent on 
adverse effects on host cells. Although arprinocid and adenosine-1-N-oxid resulted in an 
increase in ^H-thymidine incorporation, the cells showed no signs of stress. This 
increase in ^H-thymidine incorporation may be related to a prolonged S-phase of the 
cell cycle, such that more thymidine is incorporated during the period of analysis 
(Pfefferkorn et a l, 1988). Electron microscopy might reveal more information about the 
effects of the compounds, particularly arprinocid-l-N-oxide, on the structure of 
intracellular organelles. Arprinocid-l-N-oxide at concentrations above 0.4 pM resulted 
in a significant reduction in ^H-thymidine incorporation and at concentrations above 1 
pM arprinocid-l-N-oxide, host cells became rounded and detached from the surface of 
the culture flask. Over 80 % of tachyzoites were killed at 0.1 pM arprinocid-l-N-oxide, 
which is below the concentration at which thymidine incorporation was affected and 
thus below the concentration which is toxic to Vero cells. It is certain that any effect of
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arprinocid-l-N-oxide at concentrations greater than 1 pM is related to an adverse effect 
on the host cells. This implies that, although arprinocid-l-N-oxide is a potent (and 
potential) mvXi-Toxoplasma drug, it may have a low therapeutic range that could be used 
safely and without side effects. Whether this in vitro host cell toxicity translates to in 
vivo toxicity remains to be elucidated. Many unknown factors not applicable in in vitro 
screens influence drug activity in vivo, such as absorption, distribution and 
bioavailability of the compounds.
It has been suggested that arprinocid inhibits hypoxanthine transmembrane transport in 
HeLa cells (Wang et al., 1979a) and in E. tenella schizonts grown in chick kidney 
epithelial cells (Wang and Simashkevich, 1980). Interpretation of how this translates to 
activity on extracellular T. gondii tachyzoites is difficult since any effect on host cells 
does not necessarily indicate a similar effect on T. gondii. Arprinocid ( 0 -5 0  pM) and 
arprinocid-l-N-oxide ( 0 - 1  pM) were tested against a null mutant of HXGPRT (RH- 
HX'; Donald et al., 1996). Although, the 1-N-oxide appeared to be slightly more toxic 
against RH-HX" it was concluded that there was no change in efficacy. Hence, the 
HXGPRT-mediated salvage pathway is not involved in the mechanism of action of 
either arprinocid or arprinocid-l-N-oxide. This is in agreement with Pfefferkorn et al., 
(1988) who also concluded that hypoxanthine transport was not involved in their 
mechanisms of action, since concentrations of hypoxanthine that inhibit parasite growth 
did not alter the efficacy of either arprinocid or arprinocid-l-N-oxide. Studies on the 
membrane transport of purines and inhibition by arprinocid and arprinocid-l-N-oxide 
are discussed in Chapter 6.
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Neither arprinocid nor arprinocid-l-N-oxide inhibited the invasion of host cells, since 
intracellular tachyzoites were present even at the highest concentrations of either 
compound. Moreover, neither compound was toxic to extracellular tachyzoites since 
normal invasion and replication occurred following incubation of parasites in the 
presence of drug for 2 h prior to them being used for infection of Vero cells (Figure 
3.12). In contrast, monensin reduced the ability of parasites to invade cells and replicate. 
This observation is not surprising since monensin, being an ionophore, alters the ionic 
balance across the parasite membrane thereby reducing the ability of extracellular 
parasites to invade cells. A similar observation was made by (Melton and Sheffield, 
1975) contrasting the activity of monensin against lasalocid, a poly ether antibiotic.
Parasiticidal compounds are ideal for short-term therapies since they act to completely 
inhibit parasite growth even after withdrawal of drug, whereas parasitistatic compounds 
inhibit parasite growth in the presence of drug but allow continued replication once the 
drug is removed. The 2int\-Toxoplasma effect of arprinocid and arprinocid-l-N-oxide 
appears to be parasiticidal, since the removal of drug after 24 h did not significantly 
alter their efficacies (based on IC50 values). However, it may be argued that the 
compounds are parasitistatic and not parasiticidal. Even though arprinocid and 
arprinocid-l-N-oxide were washed from the culture medium it is possible that (i) the 
compounds had already been internalised into the host cell and could still exert an effect 
on the parasite (ii) the compounds were bound to host cell/parasite proteins and were 
not completely removed by washing or (iii) the compounds coated the surface of the 
host cell and, despite washing, damaged the parasite during invasion thereby inhibiting 
normal replication. This type of observation has been reported previously for other anti- 
Toxoplasma drugs, for example paclitaxel (Estes et a l, 1998). It would be interesting to
106
Chapter 3: In vitro dmg assays
repeat this work using much shorter incubation times to obtain more information on 
how early during infection, arprinocid and arprinocid-l-N-oxide, exert their effects.
Treatment of tachyzoites with arprinocid-l-N-oxide (0.5 p,M) as late as 48 h after 
infection was just as effective as when treatment occurred before infection of host cells. 
In contrast, arprinocid (50 p,M) was slightly less effective 48 h post-infection compared 
with 1 h prior to infection. Since, it is the IN-oxide metabolite that is active in vivo this 
data is consistent with the findings of Luff (1986) who demonstrated that treatment of T. 
gondii infected mice with arprinocid 72 h after infection resulted in complete protection 
of mice. Wang and co-workers (1979a) noted that radiolabelled arprinocid was 
incorporated into HeLa cells and reached equilibrium within the first minute of 
incubation. Such a rapid uptake by mammalian cells would explain the expeditious 
efficacy against intracellular T. gondii tachyzoites.
Efficacy against bradyzoites/tissue cysts is central to the development of novel anti- 
Toxoplasma drugs. Published data indicate that arprinocid-l-N-oxide is active in vitro 
against intact tissue cysts and bradyzoites (Huskinson-Mark et a l, 1991), although 
whether this activity translates into in vivo efficacy remains to be elucidated. Arprinocid 
has been shown to be effective in murine models of Toxoplasma  and although 
Toxoplasma was noted in the brains of treated mice, the author does not make clear 
whether this refers to tissue cysts. Formation of cysts seams unlikely since the mice 
were infected with the non-cyst forming RH strain of T. gondii. Whilst it was part of the 
original objectives of this project, time limitations have prevented the further 
investigation of the efficacy of arprinocid and arprinocid-l-N-oxide against a cyst- 
forming strain using a mouse model. This information would be invaluable for future
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testing of these compounds against toxoplasmosis. There has been no published data on 
the pharmacokinetic profile of arprinocid or arprinocid-l-N-oxide.
In conclusion both arprinocid and arprinocid-l-N-oxide are toxic to intracellular 
parasites, although the metabolite is significantly more potent. Both compounds act 
apparently irreversibly and within a short period of time, and are specific to T. gondii at 
therapeutic concentrations. This data provide the groundwork for the continued 
investigation of the mode of action of arprinocid and arprinocid-l-N-oxide, and the 
mechanism of acquisition of drug-resistance. Specifically, this comprised of an 
investigation into the protein expression differences between arprinocid-1 -N-oxide- 
sensitive and -resistant parasites (Chapters 4 and 5) and an investigation of the mode of 
entry of these compounds into T. gondii tachyzoites (Chapter 6).
108
Chapter 4: Proteomics 1
CHAPTER 4
Proteom ics 1 : Tw o-dim ensional electrophoresis of T. gondii proteins
4.1 Introduction
4.1.1 Proteomics
Complete genome sequence or extensive expressed sequence tag (EST) databases are 
now available for many important medical and veterinary parasitic protozoa and are 
poised to revolutionise the study of gene expression in these organisms. In the past, 
analysing the expression of more than a handful of genes at any one time presented 
considerable practical difficulties. Much effort was previously concentrated on 
identifying parasite genes of interest by conventional cloning and sequencing as a first 
step to elucidating function. Technological breakthroughs such as the development of 
reverse transcription-polymerase chain reaction (RT-PCR) allowed analysis of mRNA 
expression between biological samples, but only for a few genes per assay. Now, many 
thousands of genes can be monitored in parallel to characterise the molecular events that 
occur during key biological processes such as parasite growth or differentiation. 
Genomics presents us with a new challenge: obtaining gene sequence is now less of a 
limiting step; rather, developing and employing methods for identifying which of the 
many thousands of genes expressed by an organism are relevant to a particular 
biological question has become a priority. The compelling desire for answers to
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fundamental biological questions, a better understanding of disease processes and 
ultimately the need for more specific, less toxic therapeutic agents has led to the more 
recent development of "post-genomic technologies". The use of gene microarrays 
allows the quantitative measurement of global gene expression and how this varies 
between two samples. Such microarray technologies provide detailed information on 
gene expression in biological systems but, because there is not always a direct 
correlation of mRNA abundance with protein levels (Gygi et a l, 1999), microarrays do 
not allow definitive predictions about protein abundance. Furthermore, the ‘one gene 
one protein’ hypothesis is not supportable because of extensive alternative splicing, 
RNA editing and post-translational modification of proteins (Graveley, 2001). Although 
little information currently exists for T. gondii on such mechanisms and what they 
might mean for protein expression, it seems likely that they will also be important 
features in the control of protein function in this organism. Moreover, for very many 
genes the reliable attribution of function based on DNA sequence alone is simply not 
possible at present. Thus for T. gondii, as for most organisms, global analysis of mRNA, 
although extremely powerful, has limitations. Direct studies at the level of the 
functional proteins themselves are required to support mRNA analyses.
Analysis of the 'PROTEin complement expressed by a genOME', termed proteomics 
(Wasinger et a l, 1995), has become a key technology (or collection of technologies) 
and a method of choice for the investigation of expressed gene products. For example, it 
has applications in the analysis of protein expression changes during cellular processes 
such as cell differentiation, the detection of disease markers perhaps in cancer studies, 
the validation and characterisation of novel therapeutic targets with the investigation of 
the mode-of-action of drugs (Araki et a l, 2000; Jungblut et a l, 1999; Page et a l, 1999). 
Proteomic methods have evolved from established protein separation techniques such as
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2-dimensional electrophoresis (2-DE) to encompass both the rapid identification of 
polypeptides by mass spectrometry (MS) and the development of bioinformatic 
methods developed to correlate enzymatic digest mass fingerprints and peptide 
fragmentation data with genome sequence (Parker, Garrels, et a l, 1998 153 /id; Parker, 
Garrels, et a l, 1998 153 /id; Patterson et a i, 2001). A schematic representation of these 
three areas is illustrated in Figure 4.1. The combination of physical protein data from 
mass spectrometry with genome data enables unambiguous identification of proteins 
from 2-DE gels, and characterisation of post-translational protein modifications, much 
faster and many times more economically than conventional peptide sequencing, such 
as Edman degradation.
4.1.2 History of two dimensional electrophoresis
Two-dimensional electrophoresis (2-DE) is a powerful technique for the analysis of 
complex mixtures of proteins from tissues, cells or other biological samples. Proteins 
are separated in two discrete steps. Smithies and Poulik (1956) performed the first 2-DE 
separation using paper electrophoresis and starch gel electrophoresis in succession to 
analyse serum proteins. The subsequent development of isoelectric focussing (lEF) for 
separation of proteins in the first dimension based on their charge properties and the 
introduction of polyacrylamide gel electrophoresis (PAGE) together with the 
discontinuous SDS gel system (Laemmli, 1970) resulted in an enhanced 2-DE 
technique. This method development eventuated nearly two decades later in the 
electrophoretic separation, with increased resolution and reproducibility, of exocrine 
pancreatic proteins (Scheele, 1975), mouse tissue and serum proteins (Klose, 1975) and 
notably over 1100 proteins of & coli (OTarrell, 1975). Although this type of 2-DE was 
first used in 1975, further improvements in the solubilisation of proteins and the
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Figure 4.1. Schematic representation of the key areas of proteomics. Proteomics 
consists of three distinct areas: (a) separation of proteins by 2-dimensional 
electrophoresis in terms of their isoelectric points and molecular masses; (b) mass 
spectrometry, for example MALDI-TOF to obtain a peptide mass fingerprint (PMF) 
profile and MALDI-PSD to obtain peptide fragmentation data; (c) PMF and peptide 
fragmentation data may be used to search protein/EST databases for matching 
theoretical digest patterns (bioinformatics).
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reproducibility and resolving power of the electrophoretic steps have together enabled 
CO- and post-translational modifications to be detected.
There is a tremendous wealth of information 'locked' into a 2-DE gel and the 'key' is to 
access, understand and store these data. Information on individual proteins such as pi 
and molecular mass, the numbers of expressed proteins and their level of expression 
may be obtained from a relatively simple analysis of gels. Further analysis, often with 
the aid of specialised computer software, allows more detailed examination of the 
protein complement.
These enhanced methods, coupled with mass spectrometric analysis of in-gel digested 
proteins, can now be used to characterise the complete proteome of some organisms 
including Saccharomyces cerevisiae (Shevchenko et a i, 1996) and Haemophilus 
influenzae (Fountoulakis et a l, 1998a; Fountoulakis et a l, 1998b). The application of 
proteomics to parasitological problems is now a real possibility (Barrett et a l, 2000; 
Ashton et a l, 2001). Although far less advanced, proteome analysis in some parasitic 
organisms has been already performed, e.g. Trypanosoma brucei and Plasmodium 
fa lciparum  (Huang et a l ,  2001; Rabilloud et a l,  1999; http://www.ebi.ac.uk 
/parasites/proteomes.html).
2-DE now normally comprises, in the first dimension, isoelectric focussing (lEF) using 
the recently developed immobilised pH gradient (IPG) strips to separate proteins 
according to their isoelectric points (pi) and, in the second dimension, SDS-PAGE to 
separate proteins according to their molecular weights (refer to Sections 4.1.3 and 4.1.4, 
respectively).
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4.1.3 The first dimension: Immobilised pH Gradients
Proteins are amphoteric molecules having positive, negative or zero charge depending 
on the pH of their surroundings. The net charge of a protein, i.e. the sum of all the 
charges of their constituent amino acids, is zero when at the isoelectric point (pi). 
Isoelectric focussing (lEF) relies on the presence of a pH gradient to separate proteins. 
Under the influence of an electric field, a positively charged protein will move to where 
its net charge is zero, in this case towards the cathode. The opposite is true, a negatively 
charged protein will move towards the anode until its net charge is zero. Once proteins 
have migrated to their pi value they will stay there until the electric field is removed. 
The degree of resolution of protein separation depends on two aspects: (i) the pH 
gradient in the separation medium; (ii) the size of the electric field. Throughout the late 
1970's and early 1980's carrier ampholytes were used to generate pH gradients in rod 
gels. Carrier ampholytes are small, soluble amphoteric molecules that move towards 
their pi value in the same fashion as described for proteins. However, carrier 
ampholytes were not well characterised and suffered from batch-to-batch variations 
during synthesis. Since the molecules were not fixed within the lEF gel, prolonged 
focussing resulted in the migration of water (electroendosmotic flow) and a shift in the 
pH gradient and, therefore, a shift in proteins' positions. In addition, the difficulty in 
handling rod gels without breakage or stretching meant that 2-DE using this technology 
was neither reproducible nor practical for separation of thousands of proteins (Dunn and 
Gorg, 2001). These difficulties were overcome by the introduction of fixed 
(immobilised) pH gradient (Bjellqvist et al., 1982) based on acrylimido buffers 
(Amersham Pharmacia Biotech Immobine™ chemistry). In contrast to carrier
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ampholytes, Immobine™ buffers are well-characterised molecules, each having an 
acidic or basic group bound to an acrylamide monomer (Figure 4.2).
CH2 -  CH-C-NH-R
II
O
Figure 4.2. Structure of acrylamido buffer (Immobine™ buffer). Each 
molecule has a defined acidic or basic group (R) attached to an acrylamide 
monomer.
Mixtures of these buffers are combined during the polymerisation of the immobilised 
pH gradient (IPG) gels. The advantages of IPG strips are: (i) gels are polymerised onto 
a plastic backing thereby preventing stretching of the gel; (ii) the gel gradient is fixed 
and thus not susceptible to the effects of electroendosmosis; and (iii) different pH 
ranges may be cast. IPG strips, supplied as dehydrated gels to allow long-term storage, 
are rehydrated, usually in the presence of a protein sample, and the proteins focussed 
using a flatbed electrophoresis unit under large voltages, typically 5000 V or more. A 
potential difference of this magnitude is required to obtain sharply focused bands. The 
number of volt-hours (Vh, a standardised method to describe the length of time of lEF) 
used for lEF depends on the type of IPG strip used, typically 32,500 Vh for pH 4 -7 and 
longer for narrow and basic pH ranges. The advantage of using a flatbed apparatus is 
that strips may be kept at a constant temperature (usually 20°C, since urea starts to 
crystallise at lower temperatures) using Peltier cooling chips. A good review of 2-DE
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using IPG strips (Gorg et a l, 2000) describes in more detail the advantages of this new 
technology.
4.1.4 The second dimension: SDS-PAGE
Following lEF, the IPG strips and proteins are equilibrated in SDS buffer containing 
DTT. Proteins must be bound to SDS to negate the effect of protein charge during 
protein separation in the second dimension. DTT is a charged molecule and is ionised 
during lEF causing migration of DTT to the anode. Thus, DTT disperses from the 
proteins during lEF. Replacement of this DTT ensures disulphide bonds remain broken 
and improves transfer to the second dimension (Herbert et a l, 1998). However, DTT 
causes point streaking that is often observed subsequent to silver staining. Thus a 
second equilibration is performed in the presence of SDS and iodoacetamide. 
lodoacetamide alkylates excess DTT reducing the transfer of DTT into the gel (Gorg et 
a l,  1987), Proteins are separated in the second dimension according to molecular 
weight by SDS-PAGE using either flatbed or vertical formats. Vertical systems are 
more convenient for running multiple gels simultaneously. In addition vertical units 
allow casting (or ready-made) gels of reduced thickness, typically 0 .5 -1  mm. Higher 
voltages may be applied resulting in increased resolving power of spots due to less 
diffusion.
4.1.5 Visualisation of proteins
Subsequent to separation on the 2"  ^ dimension, proteins are visualised by traditional 
methods such as Coomassie- or silver-staining or alternatively by the recently 
introduced fluorescent stains such as Sypro Ruby® (Molecular Probes). The advantages
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and disadvantages of these staining techniques will be discussed in this Chapter, in 
relation to the sensitivity of detection of proteins, and in Chapter 5, in relation to mass 
specti'ometry.
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4.2 Aims
Many parameters affect the resolution, separation and reproducibility of 2D-gels. The 
most critical are the choice of equipment, sample solubilisation procedures, running 
conditions (e.g. duration of lEF, pH separation range) and method of protein staining. 
The main objectives of this chapter were to optimise the 2-DE separation of proteins 
from T. gondii tachyzoites and to answer the following questions:
(i) How suitable is 2-DE for determining protein expression differences that are 
potentially associated with parasite virulence. For example, can it be used to 
characterise an attenuated vaccine line, such as S48 T. gondii?
(ii) The function of a gene can be investigated by creating gene knockout strains. 
For example, analysis of the gene encoding for HXGPRT was demonstrated to be non- 
essential for r. gondii survival by creating a null mutant (RH-HX ). However, there are 
consequences at the protein level of gene manipulation. Can 2-DE provide useful 
information on changes in protein expression as a result of gene manipulation?
(iii) The mechanism(s) of acquisition of drug resistance in ARP*  ^T. gondii is not 
known; it is possible resistance may be mediated by the up-regulation of a 
detoxification pathway or a modified drug transporter or changes in the drug target 
itself. The latter introduce a new question; a point mutation resulting in an amino acid 
change may cause the dysfunction of a drug transporter or lack of binding to the drug 
target. Can 2-DE detect protein modifications that relate to drug resistance?
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Bio informatics is a major aspect of this work since the ability to identify proteins of 
interest is paramount to exploiting the full potential of proteomics. This work, in 
conjunction with the development of strategies for the identification of T. gondii 
tachyzoite proteins by mass spectrometry (see Chapter 5), was intended for the 
production of a preliminary 2D-map of the T. gondii proteome.
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4.3 Methods
Two methods for 2-DE were used. The first method used the Investigator™ 2D gel 
system from Genomic Solutions (GS) and the second method used the IPGhor lEF unit 
and Hoefer DALT tank system purchased from Amersham Pharmacia Biotech (APB).
4.3.1 2D gel electrophoresis using the Investigator™ system (GS)
4.3.1.1 Preparation o f tachyzoites fo r  2-DE
Frozen tachyzoite pellets were disrupted in 40 \x\ of sample buffer I (0.3 % SDS, 200 
mM DTT, 50 mM Tris-HCl, pH 8.8). Proteins were denatured at 95°C for 5 min and 
incubated on ice for 10 min after the addition of 4 p,l sample buffer II (500 mM Tris- 
HCl, 50 mM MgCb, 2000 units/ml DNAse I and 750 units/ml RNAse A). Where 
indicated, proteins were sonicated and/or subjected to three cycles of freezing in liquid 
nitrogen and thawing in a gloved clenched fist. Solubilisation was enhanced further by 
the addition of 160 pi loading buffer (8 M urea, 4 % CHAPS, 40 mM Tris base, 6.5 mM 
DTT and 0.01 % bromophenol blue) to each sample. Rehydration buffer (8 M urea, 2 % 
CHAPS, 10 mM DTT, 2 % ampholytes and 0.01 % bromophenol blue) was then 
combined with sample to a total volume of 400 pi. Samples were vortexed vigorously 
for 1-2 min at each step. Finally, insoluble proteins were removed by centrifugation at 
16,000 X g at 4°C for 3 min.
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4.3.1.2 Isoelectric focussing and SDS-PAGE
Proteins were separated in the first dimension using the pHaser™ Isoelectric Focusing 
System (Genomic Solutions, USA). Solubilised proteins (400 pi) were pipetted into 
each groove of the pHaser tray and an 18 cm IPG strip (Amersham Pharmacia Biotech) 
placed gel-slide down over the sample. IPG strips were rehydrated for 24 h and the 
proteins focussed to their isoelectric points using the following parameters: max 
voltage, 5000 V; duration, 24 h 30 min; holding voltage, 124 V; and 80 pA/gel. 
Following isoelectric focusing, gels were equilibrated for 15 min in 10 ml equilibration 
buffer I (GS) and for 15 min in 10 ml equilibration buffer II (GS). Proteins were 
separated in the second dimension using the 2-DE Running System (GS). The lower 
tank (anode) was filled with 11 L of buffer containing 25 mM tris/acetate pH 8.3 and 
the upper tank was filled with 3 L of buffer containing 0.2 M tris, 0.2 M tricine and 0.4 
% SDS. During electrophoresis, the tank buffers were maintained at 10°C by peltier 
cooling. Focussed IPG strips were loaded on the top surface of precast 10 % 
homogeneous gels (GS), of dimensions 22 cm width x 22 cm length x 1 mm gap 
thickness. Proteins were separated according to molecular weight at 500 V (20 W 
maximum per gel) for 4.5 h.
4.3.2 2D gel electrophoresis using the IPGphor™ & Hoefer™ DALT (APB)
4.3.2.1 Preparation o f tachyzoites for 2-DE
Two methods (i and ii) of solubilisation were utilised.
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(i) Protein from 1x10^ tachyzoites was initially solubilised in 40 pi of 0.1 % SDS in 40 
mM Tris and subjected to 3 cycles of rapid freezing using liquid nitrogen and thawing 
in a gloved clenched fist followed by a denaturing step at 95°C for 5 min. Solubilisation 
was further improved by the addition of 40 pi lysis buffer containing 8 M urea, 4 % 
CHAPS and 40 mM Tris. Solubilisation was aided by sonication at room temperature 
for 5 min in a water bath sonicator (Ultrasonics Ltd, UK) and the addition of 
rehydration buffer, to a final sample volume of 350 pi, containing 8 M urea, 2 % w/v 
CHAPS, 22 mM DTT (added fresh), 0.5 % v/v IPG buffer (Amersham Pharmacia 
Biotech) and bromophenol blue. At the end of the procedure, insoluble material was 
removed by centrifugation at 16,000 x g for 3 min at 4"’C.
(ii) Frozen tachyzoite pellets (1 x 10^) were disrupted by the addition of 40 pi lysis 
buffer (described above) and subjected to 3 cycles of rapid freezing using liquid 
nitrogen and thawing in a gloved clenched fist, followed by sonication at room 
temperature for 5 min in a water bath sonicator (Ultrasonics Ltd). Solubilisation was 
aided by the addition of 310 pi rehydration buffer (described above). Insoluble material 
was removed by centrifugation at 16,000 x g for 3 min at 4°C, as described.
Since the total amount of protein that can be rehydrated into an IPG strip depends upon 
the pH range to be analysed and also the method of visualising, protein loading was first 
optimised. For pH 4-7, pH 6-11 and narrow range pH 5.5-6.7 linear IPG strips, 5x10^ 
tachyzoites (approximately 100 pg protein) were used for each gel stained with silver 
and 1 x 1 0 ^  tachyzoites for each Coomassie Blue-stained gel. Preparative Coomassie 
Blue-stained gels for mass spectrometry were loaded with 2x10^ tachyzoites.
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4.3.2.2 Multiple casting o f  large-format gels
Gels (23 cm width x 19 cm length x 1 mm gap thickness) were cast using the Hoefer™ 
DALT Multiple Gel Caster (Amersham Pharmacia Biotech). All apparatus and gel 
cassettes were thoroughly cleaned using 18 MQ water before gel casting was begun. 
The gel caster was assembled as described in the manufacturer's manual inserting the 
recommended number of filler blocks and separator sheets to enable 12 gels to be cast 
simultaneously. A feed tube and funnel were connected to the bottom of the balance 
chamber, which was filled with 150 ml of displacing solution (see below for recipe). 
The gel solution was prepared as outlined in Table 4.3.1 (without APS and TEMED) 
and degassed using a vacuum pump for 15 minutes whilst being stirred slowly. The 
appropriate volumes of TEMED and APS were added to the gel solution to begin 
polymerisation and gel mix slowly poured into the funnel (taking care to minimise air 
bubbles) and thus into the gel casting unit. Once pouring was complete, the feed tube 
was removed and the displacing solution allowed to 'push' the remaining gel solution 
into the casting block. If necessary, more displacing solution (up to 50 ml) was added to 
the balance chamber in order to raise the level of the gel solution in the gel cassettes to 
the appropriate height. Immediately after pouring, the surface of each gel was overlaid 
with 0.75 ml of water-saturated «-butanol resulting in a level gel surface. The gel 
casting block was covered with damp towels and the gels left to polymerise overnight 
(tests using small amounts of gel solution indicated polymerisation was complete in 
approximately 1 hour). After polymerisation, the surface of each gel was washed with 
dddHiO to remove «-butanol and unpolymerised acrylamide. The gel cassettes were 
also cleaned in dddHiO and stored in a polystyrene box at 4°C. Gels, covered with
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damp towels to prevent drying out and cracking, were stored for no longer than 14 days 
before use.
Table 4.3.1. Recipe for casting 12 large format gels. Gels have 
dimensions 23 cm width x 19 cm length x 1mm thickness and are cast using 
Hoefer™ DALT Multiple Gel Caster (Amersham Pharmacia Biotech).
Solution Volume (ml)
Acrylamide 40 % 192.8
N-N'-methylenebisacrylamide 2% 102.9
1.5 M Tris-HCL pH 8 . 8 190.2
I 8 MÊ2 H2 O 265.9
10 % SDS 7.71
10% APS* 7.71
10 % TEMED* 1.35
added im m ediately before gel pouring 
Displacing Solution: 0.375 M Tris-HCl, 50 % glycerol, trace bromophenol blue.
Overlay solution: 50 ml «-butanol, 5 ml dddHiO.
4.3.2.3 Isoelectric focussing and SDS-PAGE
Except where stated, all electrophoretic equipment, gel analysis equipment and reagents 
for 2-DE were supplied by Amersham Pharmacia Biotech Ltd, UK. Proteins were 
separated in the first dimension using the IPGhor™ Isoelectric Focusing (lEF) system 
employing immobilised pH gradient (IPG) strips. T. gondii proteins were focused to 
their isoelectric points using 18 cm Immobiline DryStrips™ according to the conditions 
in Table 4.3.2. Rehydration and lEF were performed at 20°C. Following lEF, the 
proteins were reduced and bound to SDS by equilibrating each strip for 15 min in 10 ml 
of SDS Equilibration Buffer (50 mM Tris-HCl pH 8 .8 , 6  M urea, 30 % v/v glycerol, 2
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% w/v SDS) containing 100 mg DTT (added fresh before use). A second equilibration 
step in SDS Equilibration Buffer containing 250 mg iodoacetamide (added fresh before 
use) instead of DTT was performed in order to prevent protein re-oxidation and to 
minimise reactions of cysteine residues. After equilibration, the IPG strips were loaded 
onto 10 % homogeneous acrylamide gels (1 mm thickness x 24 cm width x 19 cm 
length), sealed with 0.5 % agarose (SeaKem) and proteins electrophoresed for 20 h at 
100 Vand i r C .
Table 4.3.2. Isoelectric focusing steps used to focus 4-7 linear (50 p.A/strip) 
and 6-11 linear (30 pA/strip) IPG strips.
IPG Step Voltage Duration
(h)
Gradient
type
Rehydration - 12
1 500 1 Stepped
4-7 linear 2 1000 1 Stepped
3 8000 4* Stepped
Rehydration 30 12 Stepped
1 500 1 Stepped
6-11 linear 2 1000 1 Stepped
3 8000 0.5 Linear
4 8000 6* Stepped
*These steps were extended as n ecessa iy  until the final volt-hours reached for the
4-7 linear and 6-11 linear IPG strips w ere a minim um  o f  32500 Vh and 55000 Vh, respectively.
4.3.3 Visualisation of proteins
4.3.3.1 Coomassie-Blue staining
Gels were soaked in 350 ml Coomassie stain overnight and destained using several 
washes of Coomassie destain (350 ml) until the background was clear.
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Coomassie stain (1 L): 0.5 g Coomassie Brilliant Blue R250, 100 ml glacial
acetic acid, 125 ml isopropanol.
Coomassie destain: 10 % glacial acetic acid, 12.5 % methanol, 77.5 %
dddHsO.
43.3.2 Silver stain Idt (APB, Heukeshoven and Dernick, 1985)
Gels were stained using the Plusone™ Protein Silver Staining Kit (Amersham 
Pharmacia Biotech) and Hoefer™ Automated Gel Stainer (Amersham Pharmacia 
Biotech). Proteins were first fixed for 30 min in Fixative Solution and then sensitised 
for 30 min in Sensitiser Solution. Gels, washed 3 x 5  min in 18 MQ water, were soaked 
in Silver Solution for 20 minutes and then washed 2 x 1  min in 18 MQ water. Gels spots 
were visualised by soaking the gel in Developer Solution for between 4 and 5 min 
depending on the quantity of protein present and presence/absence of glutaraldehyde. 
When developing was finished, gels were soaked in Stop Solution for 10 min and 
washed 3 x 1 5  min in 18 MQ water. All solutions (325 ml per gel) were made using 18 
MQ water. This protocol is tabulated in more detail, for comparison with other stains 
used, in Table 4.4.3.
For mass spectrometry of silver-stained protein spots, gels were washed twice in 
fixative and glutaraldehyde was omitted from Sensitiser Solution. Gels, which were to 
be subsequently analysed by mass spectrometry, were stored in 1 % acetic acid until 
protein extraction was performed. Other analytical gels for long-term storage were 
soaked in preserving solution, heat-sealed in plastic wrap and stored at 4°C.
126
Chapter 4: Proteomics 1
4.33.3 Silver stain Idt (Genomic Solutions, (Rabilloud, 1992)
Proteins were fixed, for 1 h, in Fixative Solution and then sensitised for 60 min or 
overnight in Sensitiser Solution. Gels, washed 4 x 1 5  min in 18 MQ water, were placed 
in 500 ml Silver Solution for 30 min and excess silver removed by washing 1 x 1  min in 
18 MQ water. Development of gels typically took between 5 and 10 min and was 
stopped by placing each gel into Stop Solution for 10 min. All solutions (500 ml per 
gel) were made using 18 MQ water. Gels were placed into 20 % glycerol preservative 
for 10 min and stored as described in section 4.3.3.2. This protocol is tabulated in more 
detail in Table 4.4.3.
4.3.3.4 Morrisey silver stain (Morrisey, 1981)
Proteins were fixed in Fixative Solution for 1 h, washed 3 x 1 5  min in 18 MQ water to 
remove SDS and fixative, and then soaked in DTT Solution for 20 minutes. Gels were 
placed in Silver Solution for 20 min and rinsed in 18 MQ water for 5 min. Subsequently 
gels were washed in 300 ml of Developing Solution for 30 s and then immersed in fresh 
Developer Solution. Development of gels typically took between 5 and 10 min and was 
stopped by placing each gel into Stop Solution for 5 min and then rinsing the gels in 18 
MQ water for 10 min. All solutions (500 ml per gel) were made using 18 MQ water. 
Gels were preserved and stored as described in section 4.3.3.2. This protocol is 
tabulated in more detail in Table 4.3.3.
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Table 4.3.3. Silver-staining protocols for visualisation of proteins.
PlusOne™ silver stain Kit^ Genomic Solutions Kit‘ Morrisey stain'
Fixative
Solution
40  % ethanol
10 % glacial acetic acid
40  % ethanol
10 % glacial acetic acid
50 % methanol
10 % glacial acetic acid
30 min 60 min 60 min
Sensitiser
Solution
30 % ethanol,
5 m l 25 % glutaraldehyde 
40 m l 5% sodium  thiosulpliate 
68 g sodium  acetate
30 min
10 m l 50 % glutaraldehyde 
30 % ethanol
2.5 g potassium  tetrathionate 
68 g  sodium acetate
60 min. or overnight
Wash,
18 MQ HzO 3 x 5  min 4 x 1 5  min 3 x 1 5  min
DTT
Solution
5 m g DTT  
20 min
Silver
Solution
10 m l 2.5 % silver nitrate 
0.4 ml 37 % formaldehyde
2 g  silver nitrate 
0.25 m l formaldehyde
2.04  g silver nitrate
20 min 30 min 20 min
Wash, 
18MQ HzO 2 x 1  rain 1 x 1  min 1 X 5 min
Developer
Solution
25 g  sodium carbonate 
0.2 m l 37 % formaldehyde
30 g  potassium carbonate 
0.15 m l foim aldehyde 
7.5 m g sodium thiosulpliate
34.7 g sodium  earbonate 
0.5 ml fonnaldehyde
300 m l for 30 s and then  
replace with fresh 500 ml
approx. 4 - 5  min approx. 5 - 10 min approx 5 - 10 min
Stop
Solution
14.6 g EDTA-Na2-2H20 50 g Tris base
20 ml glacial acetic acid
30 m l glacial acetic acid
10 min 10 min 5 min
Wash, 
18MQ HzO 3 x 1 5  min 1 X 10 min
Reagents required for 1 L.
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4.3.4 Image analysis
Images of gels were acquired at 300 dpi using a Labscan v3.0 software (Amersham 
Pharmacia Biotech) on a Umax flatbed scanner (OD max 3.4) with integrated 
transparency adapter. Images were analysed using ImageMaster® 2D v3.01 software 
(Amersham Pharmacia Biotech).
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4.4 Results
4.4.1 Sample preparation and resolution of 2-DE separations (GS)
In retrospect of the quality of the gels run using the Amersham Pharmacia Biotech 
(APB) system and regardless of the staining technique, gels run using the Genomic 
Solutions (GS) system contained fewer protein spots. Moreover, the resolution, in terms 
of how rounded spots were, was comparatively inferior.
Sample preparation is critical to the outcome of 2D-gels and was therefore investigated 
by comparing the manufacturers' (GS) recommended sample preparation protocol with 
the non-chemical lysis methods, such as sonication and/or freezing in liquid nitrogen 
and thawing (Figure 4.3 a-c). The GS sample preparation protocol (and silver staining 
using the GS silver stain kit) resulted in the detection of just 161 protein spots on a pH 3 
- 10 non-linear gel (Figure 4.3a). Automatic and manual detection of spots using 
ImageMaster® 2D was made more difficult because of the overall poor quality of the 
gel. Several well-resolved proteins may be seen in the acidic region of the gel, although 
there were increased numbers of low molecular weight proteins and better resolution of 
spots between pH 7 and 10. With the intention of further improving protein 
solubilisation and thus enhancing separation, the sample preparation protocol was 
modified to include three cycles of rapid freezing in liquid nitrogen and thawing (Figure 
4.3b). Although the quality of the gel appears to have improved because the proteins 
were more strongly stained, the total number of protein spots (165 spots) was similar to 
the previous gel (Figure 4.3a). Accurate and consistent developing of gels using an 
automatic gel stainer was not available at the time of this analysis. As with the
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pH 3
(a)
pH 3
(b)
10 Non-linear
Genomic Solutions 
protocol
I
10 Non-linear
 ^ + 3 X freeze/thaw 
cycles in liquid N;
pH 3
(c)
10 Non-linear
+ 3 X freeze/thaw 
cycles in liquid N] + 
sonication 5 min
Figure 4.3. 2-DE separation of S48 T. gondii tachyzoites (1.2 x 10*^ ) 
using three different solubilisation protocols (Genomic Solutions 
equipment), (a) Standard procedure (refer to Section 4.3.1.1). (b) 
Samples were subjected to 3 cycles of freezing in liquid nitrogen and 
thawing subsequent to the addition of lysis buffer, (c) Samples were 
sonicated in a water bath at 22°C for 5 min in addition to the method 
in (b).
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GS sample solubilisation method (Figure 4.3a), spots using this modified method were 
poorly resolved, particularly in the high molecular weight and acidic regions of the gel. 
The procedure for sample preparation was subsequently modified to include sonication 
of the protein sample in addition to three cycles of freezing in liquid nitrogen and 
thawing (Figure 4.3c). In this experiment, a larger number of resolved proteins (194 
spots) were visualised, including several in the high molecular weight area of the gel. 
The overall quality of the gel was improved. Other variations of sample solubilisation 
methods were tested, including osmosis of cells using dddH2Ü and omission of SDS 
from the lysis buffer (data not shown). These gels were not significantly improved 
compared with the gel shown in Figure 4.3c.
4.4.2 Assessment of three silver-staining protocols and the reproducibility of 2-DE 
gels (GS)
It was considered that the limited number of proteins detected might be as a 
consequence of lack of sensitivity of the silver stain. Therefore, three staining methods 
were compared: (i) The Genomic Solutions Silver-Stain Kit (used above) resulted in 
low background gels with a good intensity of proteins staining (Figure 4.4a); (ii) As a 
cost-saving initiative, the Genomic Solutions Silver-Stain Kit, based on Rabilloud's 
stain (1992), was attempted using ‘home-made' chemical solutions. There was no 
increase in the number of proteins detected compared to the GS Kit (Figure 4.4b). The 
developing stage lasted 45 minutes whereas the GS Kit takes approximately 5 min; (iii) 
The Morrissey stain (1981) afforded no increase in sensitivity of detection of proteins 
(Figure 4.4c).
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Figure 4.4. Comparison of three different silver stain methods for 
visualisation of proteins separated by 2-DE (Genomic Solutions 
equipment), (a) Genomic Solution Kit (b) ‘Home-made’ preparation of 
chemicals used in ‘a ’ (c) Morrisey stain. The reproducibility of the Silver- 
Stain Kit was tested using a different preparation of cells (d). The dotted 
box represents an area which was found to be reproducible between the 
gels shown in a, b, c and d.
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The reprodueibility of gel separation and silver-staining using the GS Silver Stain Kit 
was assessed by analysing a second batch of T. gondii proteins prepared from a 
subsequent passage. Although the quality of the gel photograph and scanned image is 
less good, in silico analysis of the gels highlighted some areas of high reproducibility 
between gels (Figure 4.4d, boxed area).
The inability to separate and visualise large numbers of T. gondii proteins together with 
the apparently low resolving power of the GS system was of concern. Therefore, the 
equipment was changed to that supplied by Amersham Pharmacia Biotech (APB).
4.4,3 Sample preparation, resolution and sensitivity of 2-DE separations (APB)
Two methods of sample preparation (described in Section 4.3.2.1) were compared using 
the APB equipment (Figure 4.5). Analysis of proteins solubilised by the first method (i) 
and separated using pH 3-10 non-linear IPG strips detected 436 proteins whilst method
(ii) detected 592 proteins. Protein spots separated using each method (i and ii) were 
highly resolved and significantly better than the 2-DE separations performed using the 
GS equipment. For all subsequent analyses, method ii was chosen since the greater 
numbers of spots were obtained using this solubilisation protocol.
The sensitivity of 2-DE analysis of T. gondii tachyzoites was investigated by 
determining the number of resolved protein spots detected on Coomassie- and silver- 
stained gels over a range of pH separations (Table 4.4.1). Figure 4.6(a) shows typical 
gels of tachyzoite proteins separated over pH ranges 4-7 linear (panel i) and 6-11 linear
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(panel ii) and stained using the APB Silver-Stain Kit. Gels were analysed by a 
combination of automatic spot detection using digital images processed by 
ImageMaster® 2D software and manual detection. As expected, silver-staining proved 
more sensitive than Coomassie staining (Figure 4.7 a and b); but these differences could 
in part be lessened by increasing the number of tachyzoites loaded onto Coomassie- 
stained pH 4 - 7  linear gels. For instance, an average of 514 polypeptide spots were 
resolved on Coomassie gels loaded with 2x10^  tachyzoites (416 pg protein) compared 
with an average of 630 spots on equivalent silver-stained gels which had been loaded 
with 0.5 X 10  ^ parasites (104 pg protein) (Table 4.4.1). Although silver-stained gels 
were generally significantly more sensitive than Coomassie-stained gels, in a small 
number of instances Coomassie staining detected proteins not seen with silver staining. 
With both silver- and Coomassie-stained gels, further increases in the number of 
tachyzoites added to each gel resulted in some loss of resolution of the more abundantly 
expressed proteins, although weaker protein spots were detected more readily. The most 
striking increase in sensitivity and resolution was achieved when proteins were 
separated on narrow range IPG strips. For example, over 500 protein spots were 
resolved on a silver-stained gel over just a single pH unit using the pH 5.5-6.7 IPG strip 
(Figure 4.8).
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(a) pH 3 10 Non linear
(b) pH 3 10 Non linear
Figure 4.5. Comparison of two sample solubilisation 
pro toco ls  (A m ersham  Pharm acia  Biotech 
equipment), (a) M anufacturer’s recommended 
protocol (refer Section 4.3.2. li). (b) Same method, 
except solubilisation was enhanced by freezing in 
liquid nitrogen and thawing, and sonication in a 
water bath (refer Section 4.3.2.1 ii).
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Figure 4.6. (a) 2-DE gel separations of proteins from 5 x 10^  T. gondii RH strain 
tachyzoites. Proteins were focused to their isoelectric points using 18 cm 
Immobiline pH Gradient strips. Panels (i) and (ii) show typical pH 4-7 linear and 
pH 6-11 linear gels, respectively. Proteins were separated in the second dimension 
according to molecular mass using a 10 % (w/v) homogeneous SDS-PAGE gel (24 
cm X 19 cm). The proteins were visualised by silver staining, (b) Reproducibility of 
the sample preparation, gel electrophoresis and staining. Each panel (i-iii) 
represents the same enlarged region (dotted box) of replicate silver-stained gels. 
Each of the 3 gels were run independently on different days using different batches 
of prepared tachyzoites and using different batches of poured gels. A digital 
composite image of all three gels created using ImageMaster® 2D software is 
shown in panel (iv) using only spots present in all three replicate gels to produce an 
"averaged gel".
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Figure 4.7. Spot detection using ImageMastef" 2D. (a) 
Coomassie blue stained gel loaded with 1 x 1 0 ^  pRH 
tachyzoites and (b) silver-stained gel loaded with 0.5 x 10*^  
pRH tachyzoites. Spots detected by ImageMaster ® 2D are 
highlighted in blue and red, respectively, (c) Gel stained 
with silver was overlaid on Coomassie-stained gel, clearly 
showing those spot detected by both staining choices and 
the enhanced sensitivity of silver staining.
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Table 4.4.1. The sensitivity of 2-DE analysis of T. gondii tachyzoites. The number of 
resolved protein spots for Coomassie- and silver-stained gels using a range of pH 
separations. Gels were analysed by a combination of automatic spot detection using 
digital images processed by ImageMaster® 2D software and manual detection.
IPG pH range No.
tachyzoites
Protein (pg) Stain No. resolved protein spots
Average Range Sample
size
4 - 7  linear 0.5 X 10*^ 104 Silver 630 591 - 685 3
4 - 7  linear 1 X 1 0“ 208 Coom assie 193 1 7 6 - 2 1 7 3
4 - 7  linear 2 x  1 0 “ 416 Coom assie 514 452  - 576 2
6 - 1 1  linear 1 X 10^ 208 Silver 373 3 4 0 - 4 1 4 4
6 - 1 1  linear 2 x  1 0“ 416 C oom assie 123 - 1
5.5 - 6.7 linear 1 X 10*^ 208 Silver 513 - 1
4.4.4 Reproducibility of 2-DE separations (APB)
The reproducibility of sample preparation, gel electrophoresis and gel staining was 
investigated by running sequential replicate gels with protein prepared from different 
batches of parasites on different days. Most variability between replicate gels occurred 
at the very periphery of the gel i.e. at very high or low molecular weights and at the 
extremes of the pH gradient. When these data were excluded from the analysis, the 
majority of protein spots could be resolved with a very high degree of reproducibility. 
The outcome of a typical experiment is shown in Figure 4.6(b). Each panel (i-iii) 
represents a magnified inset of replicate silver-stained gels from three different batches 
of parasites run on different days, thus introducing the maximum number of potential 
variables. A digital composite image of all three gels created using ImageMaster® 2D
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software is shown in Figure 4.6(h) panel (iv) using only spots present in all three 
replicate gels to produce an 'averaged gel'.
With the aid of computer software, high abundance proteins visualised using Coomassie 
Blue were also reproducibly detected on replicate gels stained using silver. For example, 
protein from 1 x 10  ^ T. gondii tachyzoites visualised using Coomassie Blue were 
outlined by ImageMaster® 2D in blue and similarly protein from 0.5 x 10  ^ T. gondii 
tachyzoites visualised using silver-staining were highlighted in red (Figure 4.7a and b, 
respectively). Using ImageMaster® 2D, proteins were matched and overlaid, clearly 
indicating those proteins visualised in both staining techniques (Figure 4.7c).
4.4.5 Standardisation of sample preparation (APB)
Since T. gondii tachyzoites are obligate intracellular parasites, great care was taken to 
minimise any host cell contamination in the tachyzoite protein preparations. Filtration 
through 3 pm polycarbonate membranes and differential eentrifugation resulted in the 
removal of most contaminating host cell material. This was initially confirmed 
microscopically by examining tachyzoite preparations before protein solubilisation. 
Moreover, none of the polypeptide spots subsequently excised from the 2-DE gels and 
analysed by mass spectrometry were shown to be of host cell origin (Chapter 5).
To determine whether the length of time the parasites had been grown in host cells and 
whether the ratio of intracellular:extracellular tachyzoites had any influence on the 
protein expression profiles, parasites were harvested at 2, 3, 4 and 5 days after invasion 
of the parasites into cells. In general, the protein expression profiles between different
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pH 5.5 pH 6.7
Figure 4.8. 2-DE separation of proteins from pRH T. gondii 
tachyzoites (1 x 10 )^ using a narrow range IPG strip. Proteins 
spots (513) were visualised using silver staining.
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days were comparable with areas of the gels showing good reproducibility. However, 
some protein expression differences were observed between each time point (Figure 
4.9). Further analysis of these gels, together with additional repeat experiments would 
be required to detect subtle changes, such as gradual increases/decreases in protein 
expression over the period of 5 days. This is a large undertaking and not within the 
scope of this study. Therefore to remove this variable, all parasite harvests were 
standardised at 72 h after infection of host cells.
4.4.6 2-DE analysis of S48 J. gondii vaccine line
The power of 2-DE as a technique for determining protein expression differences 
between vaccine and non-vaccine lines of T. gondii, and thus for identification (in 
combination with mass spectrometry) of proteins that are potentially associated with 
virulence factors was investigated. Proteins from pRH and S48 tachyzoites (0.5 x 10 )^ 
were separated by 2-DE in the pH range 4 - 7  and stained using silver. Image analysis, 
performed using ImageMaster® 2D, identified several areas where protein expression 
was identical between these two lines. One such area, magnified, is shown in Figure 
4.10. After performing detailed spot detection (automatic and manual) and overlaying 
images of each gel, several proteins were detected that were potentially differentially 
expressed (Figure 4.11a). However, visual analysis of replicate gels indicated that the 
majority of these protein differences were not real (refer to Discussion). Interestingly, 
five proteins were detected as present in pRH tachyzoites but absent from the vaccine 
line, and two proteins were found in the S48 line but not in pRH tachyzoites (Figure 
4.11a). These proteins expression differences were reproduced in one other replicate 
gel. Of these differences, two proteins present in pRH and absent in S48 (Figure 4.1 la,
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Figure 4.9. Selected region of a 2-DE gel of T. gondii tachyzoites 
harvested at varying times during the in vitro cycle of infection and lysis 
of host cells. The white arrow indicates a protein that is differentially 
expressed during the 4-day period. Tachyzoites were harvested at 48 h, 72 
h, 96 h and 120 h after infection of host cells (panels a - d). Protein from 5 
X 10^  tachyzoites was separated on each gel and visualised by silver 
staining.
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Figure 4.10. Conservation of protein expression between pRH and S48. 
Each panel represents the same enlarged region of a 2-DE gel of pRH 
and S48. Gels were stained with silver.
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Figure 4.11. Comparison of RH and S48 T. gondii lines, (a) S48 T. gondii 
proteins (5 x 10  ^ tachyzoites) separated by 2-DE and visualised using silver. S48 
proteins detected by ImageMaster® 2D Elite and manual detection are outlined in 
blue. A 2-DE separation of RH T. gondii proteins (5 x 10^  tachyzoites) visualised 
using silver was also analysed using ImageMaster® 2D Elite. RH protein spots, 
outlined in red, are shown overlaid on the S48 2D gel. Two proteins present in 
RH and absent in S48 are indicated by white arrows. The dotted box region has 
been enlarged clearly demonstrating differential protein expression between RH 
and S48 T. gondii (b(i) and (ii), respectively). Other proteins that may be 
differentially expressed between these lines are indicated by black arrows (a). 
The vast majority of unmatched S48 proteins (blue) are expressed in low 
quantities and careful analysis of gels suggests that these are not ‘real’ 
differences.
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white arrows) were reproducible differences detected in three replicate experiments. 
The same region of the S48 and pRH gels containing these protein expression 
differences is shown, enlarged, demonstrating the presence of two proteins found in 
pRH and their absence in S48 (Figure 4.11b).
4.4.7 2-DE analysis of HXGPRT knockout line
Protein expression changes as a result of genetic manipulation of T. gondii were 
investigated using 2-DE. Similar analyses to that described for S48 and pRH (Section 
4.4.6) was performed for analysis of protein expression (pH range 4 - 7 )  differences 
between a mutant T. gondii line, RH-HX, lacking the gene encoding for HXGPRT and 
the parental line, SRH. As with S48 and pRH, areas of high protein similarity between 
SRH and RH-HX" were demonstrated. Digital images of each gel were processed using 
ImageMaster® 2D, overlaid and proteins in each line matched (Figure 4.12a). Several 
proteins appeared to be differentially expressed, although detailed visual analysis of 
replicate gels indicated that many were not reproducible. However, one protein present 
in 3 of 4 gels of SRH line but present in only 1 of 4 gels of RH-HX was discovered 
(Figure 4.12a, b).
It was expected that the protein HXGPRT would be present in SRH but absent from 
RH-HX r. gondii tachyzoites. Two sequences encoding for HXGPRT were found in 
GenBank (accession numbers AAD44365 and AAB60214) and using MS-Product 
(http://prospector.ucsf.edU/ucsfhtml3.4/msdigest.htm) estimated isoelectric points and 
molecular weights were obtained (pi = 5.89, MW = 26.4; and pi = 6.10, MW = 31.5,
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Figure 4.12. Comparison of SRH and RH-HX T. gondii lines, (a) RH-HX T. 
gondii proteins (0.5 x 10  ^ tachyzoites) separated by 2-DE and visualised using 
silver. RH-HX proteins detected by ImageMaster® 2D and manual detection are 
shown outlined in blue. A 2-DE separation of parental SRH T. gondii proteins 
(0.5 x 10*^  tachyzoites) was also visualised using silver and analysed using 
ImageMaster® 2D. SRH protein spots, outlined in red, are shown overlaid on the 
RH-HX 2D gel. A protein present in SRH and absent in RH-HX is indicated by 
the white arrow. The dotted box region has been enlarged to indicate more 
clearly this differentially expressed protein (b(i),(ii)).
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respectively). Analysis of the 2D-gels in these regions failed to identify any protein 
expression differences.
4.4.8 2-DE analysis of an arprinocid-l-N-oxide -resistant T. gondii mutant
The application of 2-DE for the detection of proteins that may be related to the 
acquisition of drug-resistance was investigated. Protein expression between arprinocid-
1-N-oxide-resistant (ARP^) and -sensitive (pRH) lines was compared using 2-DE and 
the linear pH ranges 4 - 7, 6 - 11 and 5.5 - 6.7. No protein expression differences 
between these lines could be identified using pH 4 - 7  linear and pH 6 - 1 1  linear IPG 
strips and Coomassie Blue staining (data not shown). Consequently, in all subsequent 
experiments proteins were visualised by sensitive silver staining.
Replicate 2D gels of protein from pRH and ARP^ T. gondii tachyzoites using the pH 
range 4 - 7  (0.5 x 10  ^tachyzoites) and 6 - 1 1  (0.5 x 10  ^ tachyzoites), and 5.5 -  6.7 (1 x 
10  ^ tachyzoites) and stained with silver were analysed using both visual analysis and 
ImageMaster® 2D software. Image analysis using ImageMaster® 2D consisted of 
automatic spot detection followed by extensive manual editing of spots to remove those 
not considered to be real (such as background noise from silver-staining) and 
incorporate spots not detected by the software. Four replicate gels of pRH and three 
replicates of ARP^ in the pH range 4 -7 were processed and an average gel of pRH 
created, whereby a protein spot must be present in at least three of the four replicate gels 
(Figure 4.13a). Similarly an average gel of ARP^ was created, whereby a protein must 
be present in all three replicate gels (Figure 4,13b). A protein present in only 2 out of 3 
gels was not considered reproducible so the stringency for the ARP^ average gel was
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Figure 4.13. Composite protein gels of pRH and ARP*^  T. 
gondii, (a) pRH T. gondii proteins present in a minimum of 3 of 
4 replicate silver-stained 2-DE gels, (b) ARP"  ^ T. gondii proteins 
present in 3 of 4 replicate silver-stained 2-DE gels. The arrow 
indicates a protein present in ARP*^  and absent from pRH.
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increased. Analysis of the two average gels for pRH and ARP^ indicated that 
approximately 20 - 25 proteins differed in their expression between the drug-resistant 
and -sensitive lines. However, visual analysis of each individual gel showed that only 
one of these protein spots was a reproducible difference (Figure 4.13, arrow). This 
protein was reproducibly expressed in 3 replicate gels of ARP^ and was consistently 
absent from 4 replicate gels of pRH (each gel was run on a different day using a 
different batch of parasites, as discussed in Section 4.4.4). The same enlarged region 
from representative pRH and ARP^ gels highlighting this protein expression difference 
is shown in Figure 4.14.
Proteins in the pH range 6 - 1 1  were analysed by the same process as for 4 - 7 gels, 
described above. Average gels were created for both pRH and ARP^ using the criterion 
that a protein must be present in at least 2 of the 3 replicate gels for each line (Figure 
4.15a and b, respectively). As was demonstrated with the analysis of the pH 4 -  7 linear
2-DE gels, the creation of pH 6 - 1 1  linear average gels resulted in many false positive 
protein expression differences between the drug-sensitive and -resistant lines. None of 
these differences were confirmed as reproducible by visual analysis of the gels.
The single reproducible protein expression difference that was detected between pRH 
and ARP^ using the pH 4 - 7  linear range was investigated further by zooming into that 
region of the gel. The estimated pi of this differentially expressed protein was 6.3 and 
therefore pH 5.5 -  6.7 IPG strips were used. Duplicate 2-DE gels each loaded with 1 x 
10  ^ tachyzoites were run for the drug-sensitive (Figure 4.16) and -resistant lines, and 
analysed using ImageMaster® 2D. Although, overlaid images of each gel indicated the 
presence of many differentially expressed proteins, no reproducible changes were
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Figure 4.14. Differentially expressed protein reproducibly 
expressed in ARP^ T. gondii tachyzoites and not in pRH T. 
gondii tachyzoites. Enlarged region of gel shown as boxed 
area in Figure 4.13.
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Figure 4.15. Composite protein gels o f pRH and ARP*  ^ T. 
gondii, (a) pRH T. gondii present in a minimum of 3 o f 4 
replicate 2-DE gels, (b) ARP*  ^ T. gondii proteins present in 3 of 
3 replicate 2-DE gels.
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pH 5.5 pH 6.7
Figure 4.16. Comparison of pRH and ARP T. gondii 
lines using pH 5.5 - 6.7 linear IPG strips. T. gondii 
proteins (1 x 10  ^ tachyzoites) were separated by 2-DE 
and visualised using silver. pRH proteins detected by 
ImageMaster® 2D and manual detection are shown 
outlined in blue. ARP^ protein spots, outlined in red, are 
shown overlaid on the pRH 2D gel.
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detected. In addition, more gels are needed to confirm any protein expression 
differences. The protein difference found using pH 4 -  7 linear IPG strips could not be 
found using the pH 5.5 - 6.7 linear IPG strip. Indeed, because of the large numbers of 
proteins (> 500) that were separated in approximately 1 pH unit, it was difficult to 
correlate these proteins with those protein separated on a pH 4- 7 gel.
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4.5 Discussion
Two-dimensional electrophoresis is one of the most widely accepted methods for the 
separation and comparison of complex protein mixtures and has become the main 
platform from which to base proteomic studies. 2-DE offers greater protein resolution 
potential than any other current separation technique and has recently been used to map 
large numbers of proteins from different organisms and tissues and also to identify 
changes in protein expression (reviewed by (Jensen and Pennington, 2001). The 
considerable progress that has been made in the speed and accuracy of protein 
identification from individual spots by mass spectrometry means that the mapping of 
the entire proteome is now an achievable and economically viable prospect for some 
organisms. In this study it was demonstrated that 2-DE gel analysis is capable of 
resolving over a thousand individual polypeptide spots from as few as 1 x 10^  T. gondii 
tachyzoites using a combination of 4-7 linear and 6-11 linear IPG strips with silver 
staining. Moreover, a narrow pH range gel (one pH unit, 5.5-6.7) resolved almost as 
many spots (>500) as a pH 4-7 linear gel, suggesting that the full resolving potential of 
2-DE analysis for tachyzoite proteins would be even greater if multiple single pH unit 
analyses were conducted. The data presented suggest that the total number of tachyzoite 
polypeptides resolvable by single pH unit 2-DE and silver-staining is 3000-4000, 
assuming 500 spots per pH unit over the range pH 4-8, but fewer at the high and low 
extremes of pH. Despite the considerable resolution of these 2-DE analyses, it is 
important to note that the data will not represent all tachyzoite proteins; there are some 
well-established technical limitations with 2-DE such as solubilisation of basic proteins 
and detection of low copy number proteins (Celis and Gromov, 1999).
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In the early phase of this study many difficulties were encountered in setting up the 
techniques to achieve great resolution, sensitivity and reproducibility. Clearly sample 
preparation and staining choice are important and are discussed below, but also equally 
significant, and perhaps less often considered, is the choice of equipment. Several 
manufacturers produce different machines and different formats, for example horizontal 
2"  ^dimension systems versus vertical 2"  ^dimension systems. The critical consideration 
is the transfer of proteins from the first dimension IPG strip to the second dimension 
gel. In the 1980's flatbed SDS-PAGE systems suffered due to troublesome 'edge-to- 
edge' contacts that resulted in gel shrinkage and swelling leading to incomplete 
migration of proteins from the to the 2"  ^dimension (Gorg et al., 1985). Since both 
the GS and APB systems used in this work were vertical, these factors would not 
influence the numbers or resolution of protein spots. The markedly different gels 
obtained by each system (GS and APB) is perhaps related to the lEF system used and 
the numerous technical differences in the equipment from each supplier. For example, 
the GS and APB systems have maximum voltages for isoelectric focussing (lEF) of 
5000 V and 8000 V, respectively. In order to achieve the same volt-hours with both sets 
of equipment, longer focussing times were required using the GS system and thus 
electroendosmotic effects or increased protein precipitation may have occurred. In 
addition, higher voltages enable sharper focussing of proteins. It seems unlikely that 
voltage differences alone contributed to the gel differences between the two systems. 
The type of IPG strip holder and the cooling system employed in both these systems, 
together with the increased user manipulation of IPG strips during lEF in the GS system 
compared to the APB system, all may contribute towards the overall quality of 
separation of proteins. A recent publication compared three different commercially 
available lEF units (the Multiphor, IPGphor and the Protean lEF cell) and found that the
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number of spots generated, reproducibility and staining intensity all varied between 
machines independent of sample preparation (Choe and Lee, 2000). Generally the 
IPGphor performed least well. However, as stated in the article, optimisation of 
protocols for specific machines would have yielded better results. Since the resolution 
and sensitivity of the 2-DE was higher using the APB system, this was the equipment 
chosen for the remainder of the study.
The issue of reproducibility needed to be carefully addressed since the ability to run 
consistent gels is paramount when comparing samples. Good reproducibility could be 
achieved for the T. gondii tachyzoite protein separations even with samples prepared 
from different batches of parasites on different days. In addition, 2D-gels were not 
bought precast from the manufacturer but were manually cast in batches of 12. This 
added another variable to the ability to run reproducible gels, but was not found to be a 
major issue. Newer systems now available, such as the DALT II (Amersham Pharmacia 
Biotech), have precast gels on fixed plastic supports available. This should enhance 
reproducibility between gels further, stop gel shrinkage/expansion during staining 
processes, and most importantly enable the high-throughput analysis of gels in 
combination with automatic spot pickers and digesters.
In order to obtain reproducible results, it was important to standardise both sample 
preparation and the source of material. The proteome of an organism is not a stable 
entity and will change rapidly as the functional requirements of the organism change, 
for example during differentiation. Comparison of the proteome of tachyzoites 
harvested at different times after cell infection (Figure 4.8) demonstrated that 
differential protein expression occurred in tachyzoites during the in vitro cycle of 
invasion and lysis of cells. This highlighted the need to standardise the time of harvest
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of tachyzoites for 2-DE analysis. Studies involving the comparison of different T. 
gondii isolates would need to address this issue carefully when comparing protein 
expression profiles between different T. gondii strains that may grow at different rates 
in tissue culture.
A further consideration with 2-DE is the sensitivity, linearity and dynamic range of the 
stains used to visualise the proteins. Although silver staining proved more sensitive than 
Coomassie-Blue staining, quadrupling the amount of protein loaded onto a Coomassie 
gel enabled over 500 spots to be visualised in the pH 4-7 range (compared to an average 
of 630 with silver staining). Further increases in protein loading, however, resulted in 
the loss of resolving power, particularly with high abundance proteins. Whilst silver 
staining proved more sensitive than Coomassie staining, it has two important 
disadvantages. Firstly, the non-linearity of silver staining and limited dynamic range can 
make assessment of the level of protein expression difficult. Secondly, low detection 
limits often occur in MS because the stain modifies cysteine residues and the 
glutaraldehyde and formaldehyde used in the procedure alkylate protein amino groups 
(Patton, 2000). Whilst glutaraldehyde may be omitted from the staining, formaldehyde 
may not as it is required to reduce silver nitrate to silver. In this project, a modified 
silver stain, omitting the use of glutaraldehyde, was used on some gels and a limited 
number of high abundance proteins stained by this method were identified by MS 
(Chapter 5).
The molecular weight and pi range of proteins that can be analysed on a single gel is 
limited and a complete proteome analysis for an organism is thus unlikely to be possible 
using a single gel. One of the aims of this study was to identify protein changes between 
a drug-resistant and -sensitive strain of T. gondii. Only one reproducible difference was
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detected and given the overall reproducibility of the gels it is tempting to suggest that 
this protein may be related to or even responsible for acquisition of resistance. It would 
be interesting to investigate whether or not this same protein is expressed in the other 
arprinocid-l-N-oxide strain, ANO^ and also whether this protein is expressed in the 
drug-resistant Eimeria spp identified by Chapman (1983). It is possible that other 
proteins varying between the drug-sensitive and -resistant T. gondii lines, despite 
extensive visual and software analysis of the gels, were not noticed. For example, a 
subtle change in protein position or a small increase/decrease in expression of a protein 
are not easy to detect (limitations in software analysis is discussed below). The 
advantage of newer stains such as the Sypro Ruby is that this stain has the same 
sensitivity of detection as silver but, in contrast to silver staining, is linear, thus allowing 
more accurate measurements of protein expression (Patton, 2000). It must also be 
considered that drug-resistance may occur due to a modified drug transporter and that 
this protein, being membrane bound, may not have been solubilised. Membrane proteins 
are notoriously difficult to solubilise for 2-DE due to their hydrophobicity and 
visualisation of membrane transporters requires more emphasis to be placed on the 
method of solubilisation. Recently a number of methods have been developed that have 
dramatically improved the solubility for 2-DE analysis for this important group of 
proteins (Rabilloud et al., 1999). Other techniques are also available for improving 
protein solubilisation, such as the use of non-ionic reducing agents like tributyl 
phosphine (Herbert et a/., 1998), the addition of chaotropes including thiourea and the 
use of amidosulfobetaine detergents such as ASB-14 and C8(j) (Phadke et a l, 2001). The 
relatively simple extraction methods used in this study by Phadke et a l appeared to give 
good solubility for many inner and outer cell membrane proteins (for instance, transport 
and receptor proteins). However, the issue of T .gondii membrane proteins will need to
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be addressed more fully in further work. Alternative methods to 2-DE for protein 
separation for proteomic analysis could be considered in the future, including the 
development of "arrays" or "chips" for rapid, high-throughput analysis similar to that in 
use for mRNA microarrays (Jensen and Pennington, 2001), or the use of liquid-phase 
chromatographic separations coupled to MS (LC-MS) (Keough et ah, 2000). However, 
these technologies are as yet some way from being generally applicable. Moreover, the 
results of this work demonstrate that high-resolution 2-DE separations of parasite 
protein populations can be achieved with consistent reproducibility and these should be 
sufficient for many analyses.
The problem of eliminating gel-to-gel variation was aided by the production of 
composite gels derived from averaging computer-generated images. This made 
comparisons between different protein populations easier. For example, proteins 
differentially expressed in tachyzoites harvested from tissue culture at different times 
after cell invasion were identifiable by comparison with the standardised gels. Of 
particular advantage, is the ability to open two linked windows, each containing a 2D 
gel, so that by scrolling through the same (linked) areas of two gels, the 'human eye' can 
easily detect protein differences between the two gels. Automatic spot detection is an 
important facility central to the function of the software. However, there are limitations 
and further improvements in the encoding algorithms are needed for the software to be 
completely beneficial. Currently, the extremes of spot sizes are not readily detected and 
detection of background noise can be problematic. Extensive manual editing and 
matching of spots is required, thus reducing the efficiency of the software (Voss and 
Haberl, 2000). Because of the failure of the software to detect all spots and the inability 
to detect manually all remaining proteins accurately, the average gels that are created
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contain errors. For example, a protein manually incorporated into one gel may have 
inadvertently been missed on a replicate gel. Consequently, many proteins appear to be 
differentially expressed between lines but are in fact false positives. Confirmation of 
these potential differences is essential. The software can work though, in that the 
reproducible protein difference between pRH and ARP^ was also found using average 
gels.
The criteria applied in the creation of average gels were strict. In general, for a protein 
to be included in the analysis it must be present in at least all but one of the gels. 
Reducing this parameter to allow for more errors reduced the frequency of false positive 
protein expression differences. One danger with gel averaging, however, may be that 
more subtle protein changes could be missed due to elimination from the composite 
images. For gel-to-gel comparisons, a more attractive approach may be to include spots 
from all gels and apply multivariate statistical analysis to the data (Vohradsky, 1997). 
This would enable not only subtle statistically significant protein changes to be 
detected, but also help identify groups of polypeptides whose expression is altered in a 
linlced manner. For example, the up- or down-regulation of components in a metabolic 
pathway as a result of gene-manipulation could be identified in this way.
Further improvements in software are needed for the full potential of 2-DE analysis to 
be realised. The task at hand is very difficult and ultimately 'intelligent' software is 
needed. The new release version of ImageMaster® claims to have improved spot 
detection and matching algorithms (http://www.nonlinear.com/ news__press_releases/10- 
8-2001.htm) and a similar program, Progenesis, claims to be automated ‘hands free’ 
analysis software for batch processing large numbers of gels (http://www.nonlinear.com 
/news_press_releases/23-3-2001.htm). The most exciting prospect is the recently
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developed CyDye™ technology and fluorescence detection software (Amersham 
Pharmacia Biotech). Fluorescence 2-D difference gel electrophoresis (DIGE) allows 
samples (A and B), labelled with different fluorescent dyes, to be co-separated on the 
same gel, thereby eliminating gel-to-gel variation (Beaumont, et ah, 2001). Proteins 
from sample A are visualised by excitation at wavelength 1, and proteins from sample B 
are visualised by excitation at wavelength 2. Dedicated DeCyder 2D analysis software 
(Amersham Pharmacia Biotech) accurately detects and matches proteins from the two 
samples with minimal user input (20 images may be analysed in 15 min) and allows 
differences to be easily visualised by simultaneous excitation at both wavelengths 
(Beaumont, et al., 2001). Moreover, spot intensities may be viewed in 3-D and 
specialised algorithms enable statistical analysis to be performed. The technology is 
also compatible with existing staining technologies, for example Sypro Ruby, and is 
designed to function with automatic spot pickers and digesters. Whilst this technology is 
affordable to limited research groups, its predicted ease of use and high-throughput 
facilities will make proteomics an essential tool for the investigation of many biological 
questions. As was demonstrated in this study, 2-DE has the capabilities to detect protein 
changes associated with virulence, genetic modifications and for investigation of 
acquisition of drug resistance.
It is not known how many proteins are to be expected in the proteome of T. gondii 
tachyzoites. Based on gene densities from Plasmodium falciparum (Bowman et a l, 
1999), there may be as many as 17,000 genes present in T. gondii (Ivens, 2000). 
However, only a proportion of these will be expressed in tachyzoites and not all will 
encode proteins. Nevertheless, this number of genes seems high for a relatively simple 
organism, given a recent estimate for the human genome of just 30,000 genes (Claverie,
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2001). The latest release of the T. gondii EST database contains just over 5,000 
consensus sequences, but EST databases almost certainly exclude a sizeable number of 
low, or transiently expressed, genes. Moreover, the "one gene one protein" hypothesis is 
unlikely to hold for T. gondii. Our 2-DE analysis showed that several clearly resolved 
protein spots appeared to be encoded by the same gene, for example actin and HSP70. 
These proteins presumably result from different isoforms of the same protein or from 
post-translational modifications of that protein. Complex patterns are seen for structural 
molecules such as actin in Drosophila, where two isoforms of actin and precursor 
molecules are clearly resolved by 2-DE (An and Mogami, 1996), Further 
characterisation of the T. gondii proteome is likely to reveal many other such examples. 
Recent work suggests that alternative splicing in T. gondii may account for two 
isoenzymes of the purine salvage enzyme, hypoxanthine-guanine phosphoribosyl- 
transferase (W hite et al., 2000). These observations imply that the functional 
complexity of T. gondii will be significantly greater than would appear from its primary 
gene sequence and highlights the need for further proteomic studies.
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CHAPTER 5
Proteom ics 2: Identification of T. gondii proteins 
using m a ss  spectrom etry
5.1 Introduction
5.1.1 Genome and protein databases
The output of DNA sequencing projects, including the human genome map 
(McPherson et al., 2001), during the last few years has resulted in a massive increase in 
the size of protein, nucleotide and expressed sequence tag (EST) databases. Notably the 
DNA databases have expanded not just for higher eukaryotes, but also for lower 
eukaryotes and prokaryotes including those for important pathogenic micro-organisms. 
These advanced databases have been used for analysing proteomes. For instance, 
proteome studies on Helicobacter pylori (Jungblut et al., 2000), ?tnd Mycobacterium 
bovis (Jungblut et a l, 1999) have resulted in the identification of proteins from 2-DE 
gels which include virulence factors and novel antigens. Currently over 5 million EST 
sequences exist within Genbank, which can be utilised to correlate protein data with 
genomic information. For example, a recent proteome study of the human spliceosome 
complex identified protein spots not just from full gene sequences, but also from 
expressed sequence tags. This confirmed that where there is limited genomic sequence
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information, EST sequence databases are sufficient to identify samples (Neubauer et 
a l, 1998).
The recent completion of the Caenorhabditis elegans genome-sequencing project 
(ftp://ftp.sanger.ac.Uk/pub/databases/C.elegans_sequences) has been a major stimulus 
for studies on nematodes. The genomes of several protozoan parasites, including 
Plasmodium falciparum (Anonymous, 2001), Cryptosporidium parvum (Piper et a l, 
1998; Liu et a l ,  1999; Strong and Nelson, 2000) and Trypanosoma brucei 
(ftp:/ftp.ebi.ac,uk/pub/database/parasites/brucei) are in the final stages of genome 
sequencing. For others such as the coccidia Toxoplasma gondii, Neospora caninum and 
Eimeria species genome information is more limited. However, expressed sequence tag 
(EST) databases exist, some of them being highly developed containing several 
thousand sequences (http://www.ebi.ac.uk/parasites/paratable.html). The analysis of 
gene expression in both the tachyzoites and bradyzoites of T. gondii has been 
significantly advanced by the creation of EST libraries for these stages (Ajioka et a l, 
1998; Ajioka, 1998). Currently there are about 16,000 ESTs available for T. gondii 
tachyzoites including 3,000 for bradyzoites (http://ParaDB.cis.upenn.edu/toxo/ 
index.html). Construction of a non-redundant consensus EST database (approximately 
5200 sequences) has helped to characterise tachyzoites and bradyzoites genes (Wan et 
a l, 1997).
5.1.2 Mass spectrometry
Proteomics is very much a technology driven science. Advances in 2-DE and staining 
chemistries have driven the ability to separate and visualise thousands of proteins. 
Similarly, improvements in the resolution of mass spectrometers together with vastly
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expanding genome and protein databases have enabled the identification of these 
proteins. In the 1980's, the introduction of automated sequencers (Hewick et al., 1981) 
allowed Edman degradation to become the major technology for sequencing 
proteins/peptides. This approach employed a step-wise chemical degradation of 
peptides from the V-terminus, separation by reverse phase HPLC and identification of 
derivatised amino acids based on their retention times. Edman degradation suffers from 
many drawbacks that limit its use for sequencing of small quantities of gel-separated 
proteins. For example, the presence of gaps in the sequence due to low abundance 
amino acids or modified residues and blockage of the TV-terminus due to acétylation or 
reactions of amino acid groups with chemical buffers, acrylamide or stains used to 
visualise the proteins. The recent developments in mass spectrometry (MS) have 
surpassed V-terminal degradation techniques and have since become the mainstay of 
protein/peptide sequencing, especially as MS approaches are readily automatable 
(Gevaert and Vandekerckhove, 2000).
Mass spectrometry relies on the ability to create charged gas-phase ions in a vacuum 
and has advanced significantly since the introduction of two 'soft' ionisation processes 
in the 1980s - (1) electro spray ionisation (ESI) (Fenn et al., 1989) and (2) matrix 
assisted laser desorption/ionisation (MALDI, Karas and Hillenkamp, 1988). They are 
referred to as 'soft' ionisation methods since during the ionisation process the molecules 
are not degraded. The three commercially available types of mass spectrometer are 
MALDI-time-of-flight (TOF) with/without post source decay (PSD), ESI triple 
quadrupole and the ESI ion trap. Reviews of these mass spectrometers and 
protein/peptide identification have been published extensively (Patterson et al., 2001; 
(Borchers et a l,  2000; Chaurand a/., 1999; M sixm etal, 2001; Pappin, 1997;
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Shevchenko et a l, 2000; Spengler, 1997; Yates, III, 2000). A brief description of 
MALDI-TOF/PSD is given here, since it is most relevant to the work presented.
MALDI-TOF/PSD mass spectrometers consist of three major components - (i) a 
MALDI ionisation source (ii) a mass analyser and (iii) a detector. Peptides are co­
crystallised with a matrix onto a stainless-steel target plate, which is inserted into the 
vacuum chamber (10"  ^ - 10"^  Torr) of the mass spectrometer. The matrix, a small 
weakly acidic molecule, absorbs energy from a laser (337 nm) and emits this energy as 
heat which results in desorption of the sample. Gas-phase ions are generated which are 
subsequently accelerated at a fixed voltage (usually > 20,000 V) and, through a series 
of lenses, are directed into the field-free drift region of the mass spectrometer. Since all 
ions are accelerated with the same potential from a fixed point they will drift according 
to their mass : charge ratio. Lighter ions travel more quickly and appear at the detector 
sooner - hence time-of-flight (TOF) analysis.
During the ionisation process a spread of kinetic energies is imparted across the ion 
cloud (generated from the laser pulse) resulting in a small variation in the kinetic 
energy of each ion and thus a loss of resolving power. In terms of the peptide mass 
fingerprint spectra, mass peaks become broader, especially for larger ion masses, and 
the ability to resolve carbon isotopes of peptides is reduced. Two improvements have 
been made to this technology to increase the mass resolution of peaks - (i) the 
introduction of an ion mirror (refiectron) and (ii) delayed extraction. The reflectron, 
placed at the end of the flight tube, has a potential difference applied to it that is 
slightly higher than the accelerating voltage. Consequently, ions reaching the reflectron 
are decelerated to a dead stop and then re-accelerated back to a second detector. Since 
ions with a higher kinetic energy peneti'ate the reflectron further than ions with a lower
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kinetic energy, slower ions 'catch up' with quicker ions. Hence, reducing the initial 
spread of energy and increasing the mass resolution. The second improvement was the 
introduction of delayed extraction by Vestal et al, (1995) and Brown and Lennon 
(1995) based on a technique pioneered by Wiley and McLaren (1953). In this process, 
ions are allowed to spread out before the voltage is applied (a second lens placed nearer 
the sample focuses ions before they are accelerated into the flight tube) significantly 
decreasing the spread of kinetic energies and limits peak broadening.
In MALDI-PSD mass spectrometry, as the ions pass through the flight tube they 
acquire sufficient energy to fragment (energy arises mainly from laser irradiation and 
gas-phase collisions), i.e. they undergo post source decay (PSD). The daughter ions that 
are produced have the same velocity as the parent ion but, since they have different 
masses, they have different kinetic energies. A specific parent ion and related daughter 
ions are selected by electrostatic beam blanking (an ion gate consisting of a plate and 
three wires which have a voltage across them that serve as a high voltage switch to 
deflect all ions except those of a specific mass range). The reflectron used in MALDI- 
TOF mode is now used as an energy analyser to discriminate between ions of different 
kinetic energy. Ions with increased kinetic energy penetrate further into the reflectron 
and arrive later at the second detector thus enabling the measurement of the masses of 
the daughter ions. The reflectron focuses ions over a limited magnitude of kinetic 
energies and so in order to focus fragment ions of a wider range, the voltage across the 
reflectron must be successively dropped, usually over several steps. Computer software 
is used to generate a complete ion fragmentation pattern by overlapping each individual 
fragment spectra. The fragmentation of peptides predominantly occurs along the carbon 
backbone resulting in characteristic ion masses that are sequence-specific (Chaurand et
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a l ,  1999). Peptide fragment ions are designated on the basis of the type of bond 
dissociation and by the type of charge retention. The most common types of ions 
observed in a post source decay spectra are a, b, y, immonium and internal fragment 
ions (Figure 5.1a and b). The number of amino acids in a fragment is written in 
subscript, e.g. b] contains the three amino acids from the V-terminus. Differences in the 
masses of consecutive ions of a specific series, for example 'b2 ' and 'b f  are 
characteristic of the mass of an amino and therefore may be used to determine the 
amino acid sequence of a peptide. Immonium ions are low mass ions which indicate the 
presence of an amino acid but give no sequence information. Internal fragment ions 
resulting from the partial fragmentation of a peptide may be used to confirm the peptide 
sequence, but only once the sequence has been interpreted. Other fragment ions that 
occur in PSD may be due to the loss of ammonia (minus 17 mass units) or the loss of 
water (minus 18 mass units). As a consequence of the complexity of the spectra, 
manual inteipretation can be a complex process and is often not possible.
5.1.3 Identification of proteins
The identification of proteins using mass spectrometry data is simplified by the use of 
specialised software algorithms that compare actual peptide mass fingerprinting data 
(MALDI-TOF) or peptide fragmentation data (MALDI-PSD) with theoretical patterns 
generated from databases (Gevaert and Vandekerckhove, 2000). For example the MS- 
FIT and MS-TAG programs (ProteinProspector tools, refer to section 5.3.3 for more 
detail). Protein identifications may be obtained by searching protein/DNA databases. 
The specificity of the protein information generated by mass spectrometry correlates 
with the specificity of the search and ultimately the confidence level of a match. This is 
an important factor to be considered when identifying proteins from EST databases.
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(a )
Y3
C-terminus ions
Y2 y i
NH
biai
7V-teiminus ions
(b)
H 2 N = C — H
Figure 5,1. Examples of sequence ions that result from the 
cleavage of bonds along the backbone of a protonated 
peptide, (a) a-type and b-type ions arise from the breakage 
of a C-C and C-N bonds, respectively, with the charge 
remaining on the iV-terminus fragment. 'Y'-type ions arise 
from the breakage of C-N bonds with the C-terminus 
fragment retaining the charge, (b) Immonium ion, which 
indicates the presence of a specific amino acid but gives 
no sequence information.
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5.2 Aims
The optimisation and construction of a partial proteome map of the tachyzoite stage of 
T. gondii by 2-DE analysis was described in chapter 4. To gain the full potential of 
proteomics, proteins of interest need to be identified. The objectives of this chapter 
were:
(i) To create a skeleton 2-DE gel map of T. gondii tachyzoite proteins and in doing 
so evaluate the value of the T. gondii DNA sequence data currently available for direct 
protein identification using matrix-assisted laser-desorption/ionisation time-of-flight 
(MALDI-TOF) mass spectrometry. In common with many other microbial pathogens, 
complete genome sequence for T. gondii is not yet available. Accordingly, the value of 
the substantial T. gondii EST database for protein identification by post source decay 
analysis (MALDI-PSD) was also investigated.
(ii) To identify a protein expressed in the arprinocid-1 -N-oxide-resistant T. gondii 
strain (ARP^) but not in the parental drug-sensitive strain (pRH). The differentially 
expressed spot was visualised using silver staining and so the compatibility of a 
modified silver stain to MS was also investigated, together with the applicability of 
fluorescent staining techniques.
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5.3 Methods
5.3.1 Processing of proteins for mass spectrometry.
Protein digestion was performed according to the method of Heilman et al,  ^ (1995). 
Briefly, protein spots were excised from the gel and sliced into small pieces using a 
clean scalpel blade. Gel pieces were washed for 1 h with 500 pi 100 mM ammonium 
bicarbonate, for 1 h with 500 pi 100 mM ammonium bicarbonate/50% (v/v) acetonitrile 
and for 10 min in 50 pi 100% acetonitrile. Remaining solvent was removed by drying 
the gel pieces for 1-2 min in a vacuum centrifuge (DNA speed Vac, Savant Ltd, UK). 
Proteins were incubated for 15 min at room temperature in 10 pi 25 mM ammonium 
bicarbonate containing 0.2 pg sequence-grade modified trypsin (Promega Ltd, UK). 
Gel pieces were covered with 20 pi buffer and digestion allowed to continue overnight 
at 37°C on a flatbed shaker at 200 rpm (shaking was found to improve the trypsin 
autolysis peaks that were subsequently used for internal calibration of peptide mass 
fingerprint data). Tryptic digests were stored frozen at -20°C until analysis.
5.3.2 Mass spectrometry.
The peptide mixtures from the tryptic digests were desalted and concentrated using 10 
pi C l8 ZipTips™ (Millipore) according to the manufacturer's instructions. Typically, 
samples were eluted in 1 pi of 50 % v/v acetonitrile/0.1 % trifluoroacetic acid (TFA). 
Two methods for application of sample to the MALDI target plate were employed. For 
the dried droplet method (Karas and Hillenkamp, 1988), eluted sample was mixed 1:1 
with a saturated solution of a -cyano-4-hydroxycinnamic acid (HCCA, Sigma Aldrich
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Ltd, UK) in 50 % (v/v) acetonitrile/0.3 % TFA. Samples (0.5 pi) were applied to a 
stainless steel target MALDI plate and air-dried before analysis in the mass 
spectrometer. For the solution phase nitrocellulose method (Landry et a l, 2000), 
HCCA matrix was prepared in acetone (40 mg/ml) and, separately, nitrocellulose was 
dissolved in acetone (20 mg/ml). Matrix, nitrocellulose and 2-propanol were combined 
in a ratio of 2:1:1. Eluted sample was combined 1:1 with this matrix solution and 0.5 pi 
spotted onto the target plate and air-dried. After drying, samples were washed for 10 s 
with 3 pi of 5 % (v/v) formic acid, followed by a wash for 10 s with 3 pi 18 MQ water. 
Samples were again air-dried before acquisition of spectra. Unless stated otherwise, the 
dried droplet method of matrix/sample preparation was used.
All mass spectrometry was performed using a PerSeptive Biosystems Voyager DE- 
STR equipped with a nitrogen laser (337 nm, 3 ns pulse width, 3 Hz repetition rate). 
Peptide mass fingerprint spectra were acquired in the reflectron positive mode with 
delayed extraction (150 ns) using approximately 200 laser shots and calibrated using 
trypsin autolysis peaks as internal standards (842.5100, 2211.1046 Da). All post source 
decay (PSD) spectra were acquired in segments, with each segment representing a 
reduction in the reflectron voltage of 15 %. Depending on the size of the peptide being 
analysed, 10-14 segments were used. Each segment was the result of averaging up to 6 
acquisitions, with each acquisition being the result of accumulating 50 laser shots. P.E. 
Biosystems Voyager Data Explorer software (version 5.01) was used to generate a 
single contiguous PSD spectrum from the segments, which was then calibrated using 
angiotensin I ion fragments as a standard curve. In both reflectron and PSD mode, ions 
were accelerated at 20 kV.
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5.3.3 Database searching.
Peptide mass fingerprint (PMF) data from MALDI-TOF and peptide fragmentation 
data from MALDI-PSD were used to search genomic and protein databases including 
Genpept translated nucleotide database (http://www.ncbi.nlm.nih.gov/Entrez), 
Swissprot protein database (http://www.expasy.ch/sprot/sprot-top.html) and pdbEST 
expressed sequence tag database (http://www.ncbi.nlm.nih.gov/dbEST/index.html). All 
searches were performed using the MS-FIT or MS-TAG algorithm available from the 
ProteinProspector search tools developed by P. R. Baker & K. R. Clauser at the 
University of California, San Francisco (http://prospector.ucsf.edu). Searches were run 
on the World Wide Web (WWW) or locally on databases (or database subsets) that 
were either downloaded from the WWW or from the Pfizer Central Research Intranet. 
Search criteria used were molecular mass between 1-100 kDa (except when searching 
ESTs) and all isoelectric points. Cysteines were carbamidomethylated and allowed 
modifications considered were oxidation of methionine and acrylamide-modified 
cysteine. A maximum of 1 missed cleavage site was allowed and a mass tolerance of ± 
50 ppm. For peptide fragmentation data, mass tolerance of ± 50 ppm was allowed for 
the precursor mass and ± 1500 ppm for fragment ions. Matches to T. gondii proteins 
using PMF data were considered unambiguous when there was a minimum of 5 
peptides and 15 % sequence coverage (Mann et al., 2001). Matches to ESTs using PMF 
data were considered significant with a minimum of 2 peptides. Searches of protein and 
EST databases using peptide fragmentation data were considered unambiguous when 
(i) more than 70 % of fragment ions matched to the peptide sequence, and (ii) the 
majority of these matches corresponded to ‘a’, ’b’ and 'y', or related ions (Chaurand et 
a l, 1999).
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5.4 Results
5.4.1 Preparation of samples for mass spectrometry
Twenty protein spots from a 2-DE gel (6-11 linear IPG) of T. gondii tachyzoites were 
digested with trypsin and analysed by matrix-assisted-laser-desorption/ionisation time- 
of-flight mass spectrometry (MALDI-TOF MS) using both the dried-droplet (DD) and 
solution phase nitrocellulose (SPN) methods of preparing samples. The SPN and DD 
methods resulted in very similar spectra with peptide masses in good agreement. The 
number of peptide peaks seen in each method differed only for those of relatively low 
intensity, with neither method being obviously better at enhancing sensitivity. The 
intensities of the highest peaks in each spectrum were similar with both methods, 
however there were differences in relative intensities of some peaks (Figure 5.2). For 
example, a peptide of mass 974.5259 was approximately twice the intensity of a 
peptide having a mass of 2893.5282 using the DD method whereas the intensity of the 
equivalent peaks using the SPN method differed by 9 fold. Four samples were 
identified as T. gondii proteins (catalase, lactate dehydrogenase, 20 kDa cyclophillin 
and cytochrome b) by searching Genpept using both DD and SPN methods (Table 
5.4.1). PMF data for the remaining unidentified samples was used to search pdbEST. 
More matches to T. gondii ESTs were obtained using the SPN method compared with 
the DD method. However, despite more than 4 peptides matching in each result, only 
one sample (Ctoxqual2_2078) gave the same EST match using both techniques. Since 
the DD method requires less sample manipulation and is quicker, this method was 
chosen for subsequent MS analysis.
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Figure 5.2. Comparison of (a) dried-droplet (Karas and 
Hillenkamp, 1988) and (b) solution phase nitrocellulose 
(Landry et a i,  2000) methods for preparation of mass 
spectrometry samples. T. gondii proteins were separated by 
2-DE and visualised using Coomassie Blue, before being 
tryptically digested and analysed by MALDI-TOF MS. 
Neither method was found to be significantly better than the 
other, although some peaks were found to vary in their 
intensities.
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Table 5.4.1. Comparison of two methods for preparing sample and matrix for mass 
spectrometry. Twenty T. gondii tachyzoite protein samples from a 2-DE gel were 
analysed by MALDI-TOF MS and the resulting PMF data used to search Genpept and 
pdbEST. Samples for MS were prepared using the dried droplet (Karas and 
Elillenkamp, 1988) and the solution phase nitrocellulose methods (Landry et aL, 2000).
Sample No. Dried droplet Solution phase nitrocellulose
1 N o match C toxqual2_l 17
2 Ctoxqual2_144 C toxqual2_1032
3 N o match EST488511
4 Catalase Catalase
5 Ctoxqual2_468 Ctoxqual2 2078
6 N o match C toxqual2_60
7 Lactate dehydrogenase Lactate dehydrogenase
8 EST467670 EST 116842
9 N o  match N o match
10 N o match N o match
11 20 kDa cyclophillin 20 kDa cyclophillin
12 N o match Ctoxqual2_1762
13 EST 7586419 E S T l 17640
14 N o match CtoxquaI2 665
15 Ctoxqual2 2078 CtoxquaI2_2078
16 Ctoxqnal2 312 Ctoxqual2_25
17 E ST623360 Ctoxqual2_573
18 E ST623404 C toxqual2_2184
19 EST622793 N o match
20 Cytochrome b Cytochrome b
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5.4.2 Construction of a skeleton 2-DE proteome map for T. gondii tachyzoites
Having established a standardised and reproducible method for the preparation and 
separation of T. gondii proteins, a skeleton 2-DE map was created for tachyzoite 
proteins (Figure 5.3). Tachyzoite proteins were separated by using 4-7 linear and 6-11 
linear IPG strips and the second dimension gels stained with Coomassie Blue. 
Polypeptide spots covering a wide range of molecular weights, isoelectric points and 
relative intensities were excised from the gels and characterised by mass spectrometry. 
Protein spots (71 in total) were digested overnight with trypsin and analysed by both 
MALDI-TOF and MALDI-post-source decay (MALDI-PSD) mass spectrometry. The 
protein identities of over half of the samples (61 %) were readily determined by using 
the resulting mass spectrometry data to search genomic and protein databases. The 
results of database searches demonstrated that the T. gondii proteins could be identified 
in one of three ways: (1) from complete gene sequences of T, gondii in databases 
(Table 5.4.2); (2) from single or consensus ESTs of T. gondii (Table 5.4.3); (3) based 
on the homology between the T. gondii peptides and peptides of known proteins of 
other organisms (Table 5.4.4).
5.4.3 IdentiOcation of T, gondii proteins using peptide mass fingerprint data from 
MALDI-TOF MS to search protein databases
Searching the Genpept and Swissprot protein databases with peptide mass 
fingerprinting (PMF) obtained by MALDI-TOF analysis data enabled 28 % of the total 
number of samples (46 % of the identified samples) to be identified from their full gene 
sequences. For example, three dense granule protein precursors GRAl (Accession
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Table 5.4.2. Identification of T. gondii tachyzoite proteins using peptide mass 
fingerprint data from MALDI-TOF mass spectrometry to search full gene sequence 
databases. Matches were confirmed by searching protein and EST databases with 
peptide fragmentation data from MALDI-PSD analysis.
Result of database search with 
peptide mass fingerprint data
Identification confirmed by peptide 
fragmentation data
Genpept / 
Swissprot
Theoretk 
moleculai 
mass 
(kDa); piGenpept match Genpept match” EST match
Accession
No.
D ense granule protein precursor, G R A l ++ C toxqual2_2619 A 07518 28.2; 4.7
D ense granule protein precursor, GRA2 44- Ctoxqual2_1721 J04018 28.0; 9.8
D ense granule protein precursor, GRA7 4- C toxqual2_31 U 79158 25.9; 5.1
Lactate dehydrogenase'’ 4-4- Ctoxqual_3845 U 35118 35.5; 6.0
Lactate dehydrogenase'’ 4-4- C toxqual_3845 U 35118 35.5; 6.0
R lioptiy protein precursor, R O PIA 4- C toxqual2_1897 M 71274 42.7; 5.8
Actin'^ 4- C toxqual2_931 U 10429 41.9; 5.1
A ctiif 4- C toxqual2_931 U 10429 41.9; 5.1
Tubulin beta chain N ot done N ot done P10878 50.1; 4 .7
A ntigen p28 N ot done N ot done M 99392 19.8; 9.0
Catalase N ot done N ot done A F161267 57.3; 6.7
18kDa C yclophilin 4- Ctoxqual2_223 U 04633 19.7; 6.1
20kD a Cyclophilin 4-4-4- Ctoxqual2_743 U 04634 38.1; 9.0
A ctin  depolym erising factor 4- Ctoxqual2 2834 U 62146 13.0; 8.4
Peroxiredoxin 4- Ctoxqual2_665 A F305718 19.9; 7.0
Superoxide dismutase 4- Ctoxqual2_197 A F029915 22.6; 6.6
Heat shock protein, HSP70 4- Ctoxqual2_1265 U82281 72.3; 5.1
Heat shock protein, HSP70 4- _ d U82281 72.3; 5.1
Heat shock protein, HSP70 4- N ot done U82281 72.3; 5.1
Heat shock protein, HSP70 4- N ot done A F023616 70.6; 5.2
® +  con-esponds to the number o f  peptides analysed  
T w o sam ples analysed from pH overlap region on 4-7 linear and 6-11 linear gels 
Tw o sam ples analysed from different areas o f  4-7 linear gel 
'*No EST match was obtained
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Table 5.4.3. Identification of T. gondii tachyzoite proteins by using peptide mass 
fingerprint data (MALDI-TOF) and peptide fragmentation data (MALDI-PSD) to 
search pdbEST, Putative proteins were identified from TBLASTX search of ESTs to 
known proteins.
Result of database search 
with peptide mass 
fingerprint data
Result of database search with 
peptide fragmentation data
Putative protein
EST match EST match
Ctoxqual2_349 C toxqual2_349 Heat shock protein 30
C toxqual2_2078“ Ctoxqual2_2078 Fm ctose bisphosphate aldolase
C toxqual2_2078“ Ctoxqual2 2078 Fructose bisphosphate aldolase
N o  match C toxqual2_257 H om ology to Eimeria antigen
N o  match A W 703329 Triosephosphate isomerase
N o  match C toxqual2_1252 P33 protein (D ense granule GRA6)
N o match C toxqual2_3031 Enolase
N o match Ctoxqual2_247 GAPDH
N o match C toxqual2_1516 Elongation factor
N o  match Ctoxqual2_2195 N o hom ology
N o  match Ctoxqual2_195 Antioxidant protein 2
N o match T gE ST zya25f04.y l N o  hom ology
N o match T g E S T zya43el0 .yL N o hom ology
N o  match Ctoxqual2_349'’ Heat shock protein 30
N o  match Ctoxqual2_195'’ Antioxidant protein
N o  match C toxqual2_87L A denylyl cyclase associated protein
N o match
ToxqualS 12851(W 05902) 
T oxqual574387(W 66308)
Protein disulphide isomerase
N o  match
C toxqual2_1780
T oxqual623420 Guanine nucleotide binding protein
” Tw o sam ples analysed from different areas o f  4-7  linear gel 
EST/consensus sequences confirmed by  analysis o f  tw o peptides
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Table 5.4.4. Putative protein characterisation using peptide fragmentation data 
acquired by MALDI-PSD mass spectrometry to identify T. gondii proteins based on 
homology to peptides from proteins of different organisms.
Protein Homology Databasesearched Species
N o. ions  
111 «itching
Accession
number
Elongation factor-1-alpha Genpept C. parvum s 2 2 U 69697
Elongation factor-1-alpha Genpept
S. cerevisiae 
T. cruzi
^ 3 0 X 00779
L76077
H istone H4 Genpept
P. falciparum  
H. sapiens
s 3 0  
a  27
U 65675
X 60482
ATP synthetase (3 subunit Genpept
S. cerevisiae 
M. pneumoniae
^ 17 
S: 14
M 12082
U 43738
Protein phosphatase 2C pdbEST A. thaliana a 2 1 A B 028608
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number A07518), GRA2 (Accession number J04018) and GRA7 (Aceession number 
U79158), a rhoptry protein (ROPIA) (Accession number M71274) and lactate 
dehydrogenase (Accession number U35118) were readily identified, along with other 
proteins, from the Genpept database (Table 5.4.2). In the majority of cases, the 
theoretical molecular weights and isolectric points matched to the position of the 
proteins on the 2-DE gels. However, in one sample, rhoptry protein precursor ROPIA, 
the theoretical and observed values did not correspond. Although this protein did not 
focus to its theoretical position, time of flight and post source decay analyses of two 
separate tryptic digest preparations of the protein spot yielded identical results. The 
discrepancy between actual and theoretical isolectric point may indicate co- and/or 
post-translational modification of the polypeptide.
5.4.4 Using peptide mass fingerprint data (MALDI-TOF) to search EST databases
Peptide mass fingerprint (PMF) data can also be used to search the pdbEST database 
(or a subset of ESTs). Accession numbers from possible matches may then be used to 
search the T. gondii EST database (http://ParaDB.cis.upenn.edu/toxo/index.html) to 
identify a corresponding single, or consensus EST sequence. In one third of the samples 
identified in this survey, PMF data also matched to T. gondii EST entries. For example, 
PMF data identified T. gondii dense granule protein precursor (GRAl) from Genpept 
(A07518) and from a single EST (AW702218) from pdbEST. In some instances, PMF 
data matched to several ESTs which were subsequently found to belong to the same 
consensus sequence (Table 5.4.3). For example, PMF data matched to eight EST 
sequences which were found to belong to the same T. gondii consensus sequence, 
Ctoxqual2 2078. In such cases, matches were confirmed by post-source decay (PSD)
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analysis. However, some protein spots gave weak PMF matches to single ESTs and 
further analysis of the sample by peptide fragmentation using PSD analysis was 
required to give unambiguous protein identity.
5.4.5 Identification of proteins using peptide fragmentation data obtained by 
MALDI-post-source decay (PSD) analysis
All proteins that were identified by PMF data were subsequently confirmed by PSD 
analysis of 1 or more peptides and searching Genpept. In each case, the protein match 
obtained with peptide fragmentation data agreed with that from PMF (Table 5.4.2). 
Peptide fragmentation data obtained by MALDI-PSD was found to be the most reliable 
method of protein identification from EST sequences. To test this, all samples which 
had been unambiguously identified by PMF data were subsequently analysed by PSD 
and the peptide fragmentation data used to search pdbEST without reference to the 
protein database. Matching ESTs identified in this way were then used in a BLAST 
search and in each case found to match the protein identity obtained by PMF (Table
5.4.2). For example, peptide fragmentation data of 3 peptides from the same sample 
each confirmed the protein identity of a 20 kDa cyclophillin (searching Genpept) and in 
addition, data from all of the peptides confirmed the corresponding consensus EST 
sequence for this protein, Ctoxqual2_743 (searching pdbEST),
Of the total number of samples investigated, 25 % (42 % of the identified samples) 
were identified from searching six-frame translations of ESTs rather than from full 
gene sequences using peptide fragmentation data (Table 5.4.3). BLAST search 
homology allowed a putative protein to be assigned to each match. Several categories 
of results were distinguished: (a) protein spots could be linked to gene sequence using
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peptide fragmentation data from peptides that matched to a single EST; (b) protein 
spots could be identified from peptides that matched several ESTs belonging to the 
same consensus sequence; (c) protein spots could be identified from peptides that 
matched different ESTs but were later shown to belong to an contiguous open reading 
frame. For instance, PSD analysis of two peptides from a single sample matched to two 
different ESTs (W05902 and W66308) which, at the time of analysis, had not been 
previously linked in the EST consensus database. As our mass spectrometry suggested 
these peptides and their corresponding EST matches were from the same gene (since 
they were derived from the same protein spot), we sought to test this by amplifying by 
PCR the gene fragment linking the two ESTs (Figure 5.4). Primer sequences designed 
to EST W05902 and EST W66308 amplified a single band of 580 bp suggesting that 
the two EST sequences were indeed part of a single open reading frame. The resulting 
fragment was sequenced from both ends to reveal the linking DNA fragment. BLAST 
searching of this sequence showed homology to several protein disulphide isomerases 
(PDI) from different species, with the top match to C. elegans. Since this analysis was 
conducted, a new release of the Toxoplasma consensus EST database (version 3) has 
confirmed that the two ESTs do indeed belong to the same contig (Ctoxqual 695) with 
high homology to PDI (BLAST score = 2e-31) (Figure 5.5). PCR amplification of 
gene fragments using primers designed on the two ends of a consensus EST sequence, 
of which two peptides matched to either end of the contig, was also demonstrated. For 
example, primer sequences designed from peptides that matched to opposite ends of 
Ctoxqual2_1780 amplified a single band of 850 bp (Figure 5.4). BLAST searching of 
this fragment sequence showed high homology to a Chlamydomonas reinhardtii 
guanine nucleotide binding protein (BLAST score = le-24).
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1000 bp 
750 bp
500 bp
Figure 5.4. PCR amplification of gene fragments encoding putative T. gondii 
proteins identified by MALDI-PSD mass spectrometry. Putative protein 
identities were assigned by searching the pdbEST database with peptide 
fragmentation data (MALDI-PSD). Primers designed from two matching 
ESTs (W05902 and W66308), 5 -CGT CGA TGC CAC CAG CGA GA-3’ 
and 5 -CGG GTG TCA CGG AGT TCC TT-3% amplified a 580 bp fragment 
which was sequenced and subsequently shown to have homology to protein 
disulphide isomerase (lane 2). Primers designed from either end of a T. gondii 
consensus sequence (Ctoxqual2_1780), 5 -GCA AGC AGG ACG AT A ATC 
GA -3’ and 5 -GAG TTA GAG TCC AGA GAG TA -3’, amplified an 850 
bp fragment which was sequenced and subsequently shown to have homology 
to guanine nucleotide binding protein (lane 3). Lane 1, DNA ladder; Lane 4, 
control.
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i) Reading frame +3
Q u e r y :  15  QAVREYPTLTLFRKEKPEKYTGGRTAESNC*VXXXXXXXXXXXXXXXXXXXXXXXXHPIA 1 9 4  
Q VREYPTLTLFRKEKPEKYTGGRTAE+ PIA
S b j c t :  97 QGVREYPTLTLFRKEKPEKYTGGRTAEAIV-EWIEKMTGPAVTEVEGSAEDKVTKEAPIA 1 5 5
Q u e r y :  1 9 5  FVAELASKDSDMAKLFEEXANEVPPAGKGSWLSTGASXEKDXLPSLXGGHLKPSQAKTKD 3 7 4  
FVAELASKDSDMAKLFEE ANE G+ GAS EK G + KTKD
S b j c t :  1 5 6  FVAELASKDSDMAKLFEEVANESRQLGR-FLAKYGASDEKIYSLRYEEG-TEAFTGKTKD 2 1 3
Q u e r y :  3 7 5  ELKKFVDTESFPLXG 4 1 9  
ELKKFVDTESFPL G 
S b j c t :  2 1 4  ELKKFVDTESFPLLG 2 2  8
Figure 5.5. Sequence alignment of protein disulphide isomerase from Toxoplasma gondii. 
A gene fragment from a putative T gondii protein identified by MALDI-PSD mass 
spectrometry was amplified (Figure 5.4.3) and sequenced. The resulting T. gondii 
sequence (query) showed high BLASTX homology to protein disulphide isomerase 
from C. elegans (not shown). Since this study the new release of the T. gondii EST 
database has confirmed the protein identity (sbjct)(score = 2e-31. Sequence alignments 
for two different reading frames are shown (i and ii). Query sequence highlighted in bold 
letters indicates the sequence initially identified by mass spectrometiy.
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Furthermore MS data were found to help in mapping the EST database. For example 
Ctoxqual2_347 was identified from 2 peptides, the first matched to 2 EST sequences 
and the second peptide matched to 10 EST sequences. At the time of analysis, version 2 
of the T. gondii database listed a total of 7 EST sequences as part of the contig. The 
current version 3 of the database now lists a total of 13 EST sequences to be part of this 
contig (renamed as Ctoxqual_3057) including the sequences that were identified as part 
of the MS study.
5.4.6 Using peptide fragmentation data to identify proteins based on homology 
with proteins of other organisms
Of the total number of identified samples, 12 % were characterised by matching 
peptide fragmentation data of 1 or 2 peptides to peptides from proteins of organisms 
other than T. gondii (Table 5.4.4). For example, a sample whose PMF spectra from 
MALDI-TOF found no match in the Genpept and pdbEST databases was further 
analysed by PSD. Two peaks (1192.6847 kDa and 1325.7778 kDa) were selected for 
fragmentation by PSD. The resulting peptide fragmentation spectra were used to 
search the Genpept protein database for all organisms. Both peptides were found to 
have homology to peptide sequences from Histone H4, from Plasmodium falciparum 
and from Homo sapiens (Figure 5.6a-c). Retrospective analysis of proteins that had 
been previously identified as T. gondii proteins, but without reference to the T. gondii 
database, revealed that some of these could have been correctly characterised by 
homology to other organisms. These included actin {Plasmodium falciparum, 
Entamoeba histolytica, Caenorhahditis elegans), HSP70 (Theileria parva. 
Trypanosoma cruzi, Saccharomyces cerevisae), ATPase {S. cerevisiae, Mycoplasma
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genitalium) and phospolipase-2C (Neospora caninum). However, others such as 
GRAl, lactate dehydrogenase and ROPl could not be characterised by homology.
5.4.7 Identification of silver- and fluorescence-stained proteins
Having established a working method for the reliable identification of T. gondii 
proteins from protein and genome databases using peptide mass fingerprint and peptide 
fragmentation data, the sensitivity of detection of silver- and fluorescence-stained T. 
gondii proteins was investigated. A modified silver stain was used to visualise proteins. 
Several changes were made to the procedure, (i) gels were fixed twice in fixative (ii) 
glutaraldehyde was omitted from the sensitizer solution; and (iii) 100 pi formaldehyde 
was added to the developer solution (per 250 ml). Only a few samples were analysed 
and of these good spectra were obtained for the more abundant proteins, i.e. those that 
were previously identified on Coomassie blue stained gels. For example, actin 
(U10429) was readily identified from PMF data (Figure 5.7a) and confirmed by PSD 
analysis. A second sample could not be identified from PMF data alone but was 
subsequently assigned to a T. gondii consensus sequence, Ctoxqual2_349 by PSD 
analysis (Figure 5,7b).
Although silver staining detects proteins as low as 5 ng, incompatibility with MS poses 
problems, which may be overcome using the recently developed fluorescent dyes. 
Good MS spectra were obtained with Sypro red enabling the identification of several 
proteins. For example, actin (U 10429) was easily identified using PMF data from 
Sypro red stained protein (Figure 5.8a). Although the spectra contained fewer peptides 
than the spectra obtained for the equivalent protein stained with silver, the peak 
intensities were 5 times greater. A second sample stained with Sypro red resulted in no
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Figure 5.6. Identification of a putative T. gondii protein using MALDI-PSD. (a) 
Peptide mass fingerprint (PMF) of a protein spot excised from a 2-DE gel, digested 
with trypsin and analysed on a MALDI-TOF/PSD mass spectrometer. Searching 
protein and EST databases with PMF data alone resulted in no matches, (hi) Peptide 
1192.6847 and (bii) peptide 1325.7778 were fragmented by MALDI-PSD mass 
spectrometry. Both peptides were found to have homology to peptide sequences 
from Histone H4, from Plasmodium falciparum and from Homo sapiens (c).
190
Chapter 5: Proteomics 2
(a) Sample 1
1776.8855
100
90
80
70
w 60c
50
Ç
40
30
20
10
0
767.4476
1493.7672
1955.0684 
1517.7325
928.4761
ijt.. . iuLlj
1234.71 i s y  2232.0913
1090.570^^3^80, 5>708.7498
i U |
I* iUiiJ I hi iii
1994.9954  ^
JU.U— jkiuJiiL
1.8E+4
699
(b) Sample 2
100 
90 
80
I  80 
I  50
^ 40 
30 
20 
10 
0
1119 1539 1959
Mass (m/z)
1210.7105
1558.7994
2379 2799
2.2E+4
842.5100
871.4770
7461.4063
>11 O iJI» i lt)ii
si
1179.6317 
13087030 
^  1475.8007
1904.9538 2384.9246
1708.7367
699.0 1118.8 1538.6 1958.4 2378.2
Mass (m/z)
2798.0
Figure 5.7. Analysis of silver-stained proteins by MALDI- 
TOF mass spectrometry. T. gondii proteins, separated by 2-DE 
and visualised using a modified silver stain, were analysed by 
MALDI-TOF/PSD MS. Sample 1 (Figure a) was identified as 
actin (U10429) by searching Genpept and confirmed by PSD 
analysis (not shown). PMF data for Sample 2 (Figure b) was 
insufficient to identify the protein; post source decay analysis 
of two peptides from this sample identified the T. gondii 
consensus sequence Ctoxqual2_349.
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Figure 5.8. Analysis of Sypro Red-stained proteins 
by MALDI-TOF mass spectrometry. T. gondii 
proteins, separated by 2-DE and visualised using 
Sypro Red fluorescent stain, were analysed by 
MALDI-TOF/PSD MS. Sample 1 (Figure a) was 
identified as actin (U10429) by searching Genpept 
and confirmed by PSD analysis (not shown). PMF 
data for Sample 2 (Figure b) was insufficient to 
identify the protein; post source decay analysis 
identified the protein as having homology to enolase 
(X55981) from Zea mays.
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Figure 5.9. Analysis of a differentially expressed T. 
gondii protein by MALDI-TOF and MALDI-PSD mass 
spectrometry. The proteins of arprinocid-1 -N-oxide- 
sensitive and -resistant T. gondii tachyzoites were 
compared using 2-DE. A differentially expressed 
protein present in the resistant line, but not in the 
sensitive line, was analysed by MALDI-TOF/PSD mass 
spectrometry. The protein was visualised using the 
modified silver stain but proved to be present in 
insufficient quantities to identify by MS (a) even when 
4 spots were pooled together (b).
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matches from PMF data but was identified as enolase (X55981) from Zea mays by PSD 
analysis (Figure 5.8b).
5.4.8 Attempts to identify a protein specific to drug-resistant parasites
The protein expression profiles of isogenic arprinocid-l-N-oxide-sensitive and - 
resistant T. gondii strains were analysed by 2-DE and silver staining. Protein spot 
differences (see Chapter 4) were analysed by ImageMaster 2D and one such difference 
excised, tryptically digested and analysed by MALDI-TOF/PSD MS. The protein spot 
was weak in intensity and as expected only a weak PMF spectra could be obtained 
(Figure 5.9a) even when 4 spots were pooled together (Figure 5.9b). Post source decay 
analysis was attempted and weak speetra obtained with ion peaks indistinguishable 
from background noise. Database searches of Genpept and pdbEST using both the PMF 
and PSD data yielded no matches.
194
Chapter 5: Proteomics 2
5.5 Discussion
The introduction of delayed extraction techniques used in conjunction with MALDI- 
TOF MS has enabled the accuracy of peptide mass database searches to be as low as ± 
10 ppm (Clauser et a l,  1999). Together with the ability to gain de novo sequence 
information by PSD analysis, these methods have significantly increased the likelihood 
of correct protein identifications from the rapidly growing size of protein and EST 
databases. Analogous to sample preparation determining the outcome of a 2-DE gel, 
the isolation procedures used for extracting digested proteins from 2-DE polypeptide 
spots and the preparation of samples for MS can have a significant impact on the 
sensitivity of detection of peptides. When processes are optimised, protein 
identifications may be obtained from low picomole to high femtomole quantities 
(Gevaert and Vandekerckhove, 2000).
The original protocol for tryptic digestion (Heilman et a l, 1995) suggested that after 
removing the supernatant from the overnight incubation in trypsin, two further 
extractions should be performed. In agreement with a detailed study of the recovery of 
peptides (Speicher et a l, 2000), these two additional extracts provided minimal benefit 
to the overall quality of the PMF data. Speicher et al, (2000) demonstrated that over 75 
% of peptides were recovered in the first extract and that subsequent extractions 
contribute no more than 10 % of total peptide recovery. Additional extracts and the 
subsequent concentration of extracts by vacuum centrifugation increase peptide losses 
due to adsorption to plastic surfaces and increase salt contamination.
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The critical parameters in achieving optimal sample preparation for MS are; (i) 
achieving a high concentration of peptides relative to contaminants such as salt residue; 
and (ii) the formation of a homogeneous crystalline matrix. Desalting and concentration 
of peptide samples using ZipTips proved to be a fast (each sample was completed in 
approximately one minute) and reliable method of increasing the signal to noise ratio. 
The nitrocellulose solution phase method of preparing targets has been reported to be 
far more effective than the dried droplet method and a much-improved version of a 'fast 
evaporation' method which suffers technical difficulties due to the speed at which 
acetone evaporates (Landry et ah, 2000). In contrast, data presented in this thesis 
indicate that there was no significant difference between the dried droplet and solution 
phase nitrocellulose methods (the fast evaporation method was attempted 
unsuccessfully). The difference in findings may be a reflection of proteins analysed in 
this report being separated by 2-DE and that contaminating substances often present in 
2-DE and not in simple SDS-PAGE techniques, e.g. CHAPS, may have reduced the 
effectiveness of the solution phase nitrocellulose method. Since neither method offered 
any overwhelming advantage over the other, the dried-droplet method of preparing 
samples was adopted because it involved less sample manipulation.
MALDI-TOF mass spectrometry is a fast and reliable method of protein identification 
which relies on comparing peptide mass fingerprints from analysis of enzymatically 
digested protein samples to computer generated theoretical fingerprint profiles from 
protein/EST databases. Protein matches are ranked according to algorithms that take 
into account protein properties, such as species of origin and expected mass range, in 
addition to the percentage sequence coverage and mass accuracy, to calculate the 
probability (and confidence level) of a correct identification. One example is the
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modified MOWSE scoring algorithm, developed by Pappin et al, (1993), and utilised 
by MS-FIT (ProteinProspector tools). Whilst strict rules can be applied to govern the 
likelihood of a correct identification, such as a minimum of 5 peptide matches, results 
are often open to user interpretation. For example, a large MW protein identified by 5 
peptides may score lower than a small MW protein identified with a similar number of 
peptides because the percentage coverage has decreased. Recently a new search engine, 
Profound (http://prowl.rockefeller.edu/cgi-bin/ProFound), employing a new type of 
scoring algorithm based on Bayesian probability theory, has been developed and is 
claimed to be superior to the ProteinProspector algorithms (Zhang and Chait, 2000). 
Indeed, identification of proteins from mass spectrometry data is relatively simple with 
these newer algorithms, but ultimately the protein must initially be present in the 
database. Designing algorithms that minimise user interpretation when searching EST 
databases is more difficult. For instance, an expected protein mass range cannot be 
applied to an EST sequence database search.
Proteome studies of fiilly sequenced organisms such as yeast have been able to identify 
the vast majority of proteins using mainly genome sequence information (Parker et a l, 
1998; Shevchenko et a l, 1996a). In our study, 28 % of the samples analysed were 
identified by correlating the peptide mass fingerprint data with complete gene 
sequences, but as samples were analysed mainly from Coomassie blue stained gels 
there would have been an unavoidable bias towards more highly expressed proteins. 
For example, dense granule, rhoptry and structural proteins were readily identified in 
the analysis. Interestingly, these proteins which appeared to be highly expressed on the 
protein gel also show high representation in non-normalised EST databases suggesting 
that there is a good correlation between mRNA and protein expression for these
197
Chapter 5: Proteomics 2
molecules. The relationship between the transcriptome and the proteome of T. gondii 
awaits future analysis, but it is perhaps unlikely that there will be a simple 
stoichiometry between the two. Further work on integrating transcriptome and 
proteome data will be essential for more meaningful interpretation of the emerging 
microaiTay data for T. gondii and other protozoa.
In order to increase the success of protein identification, PMF data were used to search 
the pdbEST database. PMF data obtained by MALDI-TOF are often unsuitable for EST 
database searches, since EST sequences are usually too short (approx. 200-400 bp) for 
reliable identification and there is the uncertainty of the correct reading frame 
(Boguski, 1995; Shevchenko et a l,  2000). However, since a highly developed 
consensus EST database is available for T. gondii, its suitability for searches on six- 
frame translations of these longer consensus sequences was tested. Matches to ESTs 
were found in a large number of samples, but only in a small number of samples were 
matehes with PMF data considered reliable; these corresponded to large consensus EST 
sequences such as those for fructose bisphosphate aldolase (Ctoxqual2_2078, Table
5.4.3). Thus, whilst PMF data alone may be used to search EST databases, these 
matches must be treated with caution because EST sequences are not long enough to 
ensure confident matches. Perhaps this may be remedied by using multiple digestions 
of protein samples, each with enzymes of differing specificity (James, 1997). For 
example, PMF data from two separate digests of a sample using two different enzymes 
may be used to search Genpept (all organisms)/pdbEST. The top 50 hits on each results 
page from each digest may then be compared and cross checked for proteins that 
appear on both lists. In this event further analysis would still be required for increased 
confidence of a correct identification.
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In contrast to PMF data, peptide fragmentation data obtained by MALDI-PSD gives 
information that can be used to search protein databases and six-frame translations of 
ESTs to yield primary sequence. This was demonstrated to be a highly successful 
strategy for assigning ESTs to polypeptide spots excised from the 2-DE gels based on 
matches to one or more peptides. However, although many matches to ESTs with PSD 
data were unambiguous (especially those with matches to two or more peptides), the 
exact nature and function of the proteins coded by the matching EST remains to be 
elucidated.
In some instances MS analysis of T. gondii proteins provides information that can help 
interpret the EST database. For instance, where two or more ESTs were demonstrated 
to be linked to the same gene by virtue of the fact that they were both identified from a 
single protein spot. Significantly, peptide fragmentation data could also be used to 
identify T. gondii proteins based on homology of peptides to known proteins from other 
organisms. This was found to work well with highly conserved proteins such as histone 
H4 or ATP synthetase (3 subunit, molecules which are likely to share peptide homology 
with r. gondii, but not as well for more species-specific proteins, such as dense granule 
proteins or rhoptry proteins. Although homology searching was demonstrated for T. 
gondii tachyzoites, this method also should be applicable more generally, thus allowing 
proteome analysis of other organisms whose genome is currently unsequenced, for 
example, Neospora caninum or Eimeria species. As protein/EST databases increase for 
other apicomplexan parasites the success of homology searching with peptide 
fragmentation data obtained either by post source decay analysis or tandem mass 
spectrometry will become an increasingly valuable approach for those apicomplexan 
parasites still lacking genomic analysis.
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The initial aim of this work was to identify the differentially expressed protein found 
between the arprinocid-1-N-oxide-sensitive and -resistant T. gondii lines (pRH and 
ARP^). Although an extensive Toxoplasma EST database permitted the putative 
identification of many proteins by MALDI-TOF/PSD MS, this differentially expressed 
protein remains unidentified. The relative incompatibility of silver-staining with mass 
spectrometry analyses was significant in the inability to obtain sequence information 
for this protein. However, recent advances in fluorescent staining, such as Sypro 
Ruby® (discussed below), and the introduction of automatic spot pickers, both of which 
were not available during this study, now enable mass spectrometry analysis of low 
abundance proteins. Further advances in the genome sequencing of T. gondii should 
increase the possibility of identification of proteins. The following strategies ( 1 - 5 )  
offer conceivable solutions for the identification of the differentially expressed protein.
(1) The advantage of silver staining over Coomassie blue staining is the sensitivity 
of detection, between 1 and 10 ng of protein (Rabilloud, 1992). Although silver 
staining methods require several steps that are time consuming, some protocols can be 
completed in less than 2 h and, in conjunction with automatic gel stainers, with 
minimal manual input. However, the lack of linearity of staining and protein 
modifications induced by strong oxidising and sensitising agents, e.g. Ag"^ , sodium 
thiosulphate and glutaraldehyde, often make mass spectrometry more difficult. This is 
in contrast to some published work that have identified low nanogram concentrations of 
known proteins stained by silver and observed no chemical modifications (Shevchenko 
et al., 1996b). The modified silver stain used in this report worked well allowing the 
identification of abundant proteins. However, although the removal of glutaraldehyde 
and the reduction of formaldehyde served to reduce crosslinking effects that are
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problematic for MS, the sensitivity of detection of proteins within the 2-DE gel was 
reduced. This simply may be overcome by increasing the amount of protein loaded 
onto the gel. Alternatively, the removal of silver ions prior to digestion using chemical 
reducers such as potassium ferricyanide and sodium thiosulphate has been 
demonstrated to enhance peptide detection from silver-stained spots (Gharahdaghi et 
a l, 1999). This technique used in conjunction with MALDI-TOF allowed the detection 
of 10 ng of protein.
(2) Alternative fluorescent stains such as Sypro Ruby® (Gorg et a l, 2000) are best 
placed to overcome the problem of silver-staining since they rival the sensitivity of 
silver and are more compatible with MS. Analysis of a small number of protein spots 
from this study that had been stained with Sypro red showed that good MS spectra 
could be obtained; Sypro Ruby® is the stain of choice for highest sensitivity in 2-DE 
analysis. This or other fluorescent dyes may therefore become the stain of choice in 
future proteomic studies where high sensitivity and compatibility with MS is required. 
Recently a new fluorescent metal chelate, ruthenium II tris was shown to have similar 
sensitivity to Sypro Ruby® and have even better sensitivity in mass spectrometry 
analysis (Rabilloud et a l, 2001).
(3) Manual interpretation of PSD spectra is often challenging due to the large 
numbers of peaks obtained representing sequence specific and internal fragment ions. 
Recent advances in chemistry have now produced methodologies for charge 
derivatisation of tryptic digests. One such protocol involves the attachment of a charged 
tag to the N-terminus of peptides which, when analysed by PSD, fragments along the 
CHR-C(O) backbone of the peptide, yielding predominantly a-type sequence ions
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(Shen et a l, 1999). The resulting spectrum is easier to interpret manually, since the 
mass differences between consecutive pairs of a-type ions correspond to sequential 
amino acid residues.
(4) By increasing the sequence coverage of the parent protein, a higher level of 
confidence in identification of the protein is obtained. Despite the many advantages of 
MALDI-TOF MS, such as rapid detection of picomolar amounts of protein, it suffers 
the disadvantage of being biased towards the detection of ions that contain an arginine 
residue over those that contain lysine residues (Krause et a l, 1999). However, this may 
be overcome by increasing the basicity of lysine by chemically converting lysine to 
homoarginine with O-methylisourea (Hale et a l, 2000).
(5) Work involved in this chapter has centred on the use of a MALDI ionisation 
source, however, another common source is electrospray ionisation (ESI). In ESI the 
analyte is in solution and enters the mass spectrometer either by infusion or 
nanoelectro spray, or increasingly in combination with reversed phase liquid 
chromatography (LC-MS). The advantages of nanoelectrospray ionisation techniques 
are that very low flow rates, a few nano litres per minute, may be achieved thus 
allowing complex mixtures to be analysed. LC-MS allows sample cleanup, separation 
and concentration all in one step reducing sample loss due to manipulation (Mann et 
a l ,  2001). It also has the added advantage of allowing automated high-throughput 
screening. The most common ESI mass spectrometer is the triple-quadrupole that 
consists of three sections or quadmpoles (Q1 - Q3). Typically, quadrupole mass 
spectrometers are operated in MS-MS mode, whereby an ion having a specific 
mass:charge ratio is selected in Q1 and subjected to collision induced dissociation 
(CID) in Q2 with the resulting fragment ions detennined in Q3. Recently, the Q3
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quadrupole has been replaced with a TOP analyser (Q-TOF) resulting in higher 
accuracy and resolution (Borchers et al., 2000). In addition, the ESI source may also be 
replaced with a MALDI source (MALDI-Q-TOF) enabling proteins from complex 
mixtures to be identified by searching protein and EST databases with increased 
accuracy (Shevchenko et at., 2000). These improvements in mass spectrometric 
technologies will allow increased sample handling, analysis of low copy number 
proteins and, together with the development of more powerful database search 
algorithms, should allow the identification of previously unsequenced proteins by 
homology searching (Shevchenko et at., 2001).
In conclusion, T. gondii tachyzoite proteins separated by 2-DE may be identified, 
despite limited genome information, by using a combination of MALDI-TOF and -PSD 
mass spectrometry data to search both protein and EST databases. Not all of proteins 
analysed were subsequently identified but other approaches exist to improve MS 
sensitivity and aid manual interpretation of spectra. Although proteomics will not tell 
us about protein function directly, it will prove to be an essential tool in pinpointing the 
proteins and genes for which future detailed functional analysis is required. For 
example, the identification and characterisation of proteins thought to be involved in 
acquisition of drug resistance. Proteomics will be a key technology in helping to 
interpret the complexity of the genome and will provide a better understanding of 
disease.
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CHAPTER 6
Characterisation of Purine Transporters in T. gondii:
Effects of Arprinocid and Arprinocid-1 -N-oxide on Purine S a lvage
6.1 Introduction
6.1.1 Purine transport in T. gondii
Toxoplasma gondii is incapable of purine de novo synthesis and must salvage essential 
purines from its host environment (Perrotto et a l, 1971). Consequently, purine 
transporters and salvage enzymes provide potential conduits and attractive targets, 
respectively, for the development of improved ânti-Toxoplasma drugs. Although the 
purine salvage pathways in T. gondii are fairly well understood, little is known about 
the transporters in T. gondii and much controversy surrounds the theory that adenosine 
is the preferred salvage substrate.
Using mutant Chinese hamster ovary (CHO) cells with a defect in purine synthesis as 
host cells for T. gondii, neither radiolabelled formate nor glycine were incorporated into 
T. gondii purines and thus it was concluded that T. gondii is an auxotroph for purines 
(Schwartzman and Pfefferkom, 1982). Similarly many other protozoa, such as Eimeria 
spp and Plasmodium spp, are incapable of de novo purine synthesis (Hassan and
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Coombs, 1988). The purine salvage pathways present in T. gondii are shown in Figure 
6 . 1 .
With the exception of adenosine, T. gondii nucleosides are first hydrolysed to the free 
base before being incorporated. All four purine bases (hypoxanthine, xanthine, guanine 
and adenine) are incorporated into their respective nucleotides via 
phosphoribosyltransferase (PRTase) enzymes (Krug et a l, 1989). The enzyme 
responsible for phosphoribosylisation of 6-oxypurines, hypoxanthine-xanthine-guanine- 
phosphoribosyl-transferase (HXGPRT), has been cloned (Donald e? a/., 1996). A 
separate enzyme, adenine phosphoribosyltransferase, for the incorporation of adenine, 
exhibits nearly 3-fold lower activity compared with HXGPRT (Krug et a l, 1989). 
Using adenosine deaminase deficient host cells, deaminase activity was detected for 
adenosine, adenine and guanine. The low specific activity of adenosine deaminase 
conflicts with data suggesting that intracellular T. gondii tachyzoites convert 15 % of 
adenosine to inosine (Krug et a l, 1989). The exact role of adenosine deaminase is 
unclear. Adenosine is incorporated directly via adenosine kinase and since this enzyme 
exhibits a ten-fold higher activity than the HXGPRT-mediated salvage of 6-oxypurine 
bases (Krug et a l, 1989), it is possible that adenosine is the preferred substrate for 
purine salvage. Consistent with this theory, an adenosine transporter (TgATl) has been 
identified in the plasma membrane of T. gondii tachyzoites (Schwab et at., 1995). 
However, the sub-micromolar concentration of free adenosine in the host cell cytoplasm 
is inconsistent with the low affinity of this transporter (Km = 120 fiM). (Schwartzman 
and Pfefferkom, 1982) showed that tachyzoites are capable of using adenine nucleotides 
as a purine source, after degradation to adenosine. However, tachyzoites lack an uptake 
system for adenine nucleotides (Ngo et a l, 2000). An NTPase capable of hydrolysing 
ATP to AMP has been identified in the parasitophorous vacuole
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(Asai et a l, 1983; Asai et a i, 1995), but the parasite appears to lack the ecto 5'- 
nucleotidase (5'NT) required for the final hydrolysis to adenosine (Ngo et a l, 2000). 
Consistent with the notion that T. gondii has multiple purine salvage pathways, 
hypoxanthine and guanine are rapidly incorporated into extracellular tachyzoites 
(Schwartzman and Pfefferkom, 1982). Moreover, separate T. gondii mutants containing 
gene deletions of HXGPRT (Donald et a l, 1996), TgATl transporter (Chiang et a l, 
1999) or adenosine kinase (Darling et a l, 1999) have been shown to be viable.
6.1.2 Mammalian nucleoside/nucleobase transport
In mammalian cells, nucleotides are synthesised either de novo or from exogenous 
nucleosides and bases via a salvage pathway. Purine salvage first requires transport 
across the plasma membrane. Nucleoside/base transporters are of particular interest for 
designing therapeutic agents since these transport routes are potential conduits for the 
entry of dmg molecules into the host cell cytoplasm. Consequently, these transporters 
are possible entry routes for drugs against intracellular pathogens, for example T. 
gondii. Nucleoside transporters expressed by mammalian erythrocytes and the majority 
of cultured cell lines are non-concentrative equilibrative transporters with a broad 
specificity (Plagemann and Woffendin, 1988). Two forms are identifiable based on 
their inhibition by niti*obenzylthioinosine (NBTI), either to nanomolar amounts (NBTI- 
sensitive) or micromolar amounts (NBTI-resistant). Human erythrocytes express only 
the equilibrative NBTI-sensitive (e.ç) transporter (Plagemann and Woffendin, 1988). 
Two distinct nucleobase transporters have been characterised, (i) sodium dependent 
nucleobase transport in epithelial cells, and (ii) facilitated diffusion in non-epithelial
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cells. The latter has been characterised in human red blood cells and found to transport, 
with a high affinity, adenine and guanine (Domin et a l, 1988).
6.2 Aims
Since arprinocid and arprinocid-1-N-oxide are both purine analogues, it is feasible that 
they may penetrate T. gondii via a purine transporter and/or exert their effects by 
interfering with purine salvage pathways. Indeed, previous work has demonstrated that 
arprinocid and arprinocid-1-N-oxide may affect hypoxanthine transport (Chapter 1). 
Hence, the main objectives of this work were to
(i) Characterise purine nucleoside (adenosine and inosine) and nucleobase transport 
(adenine and hypoxanthine) in extracellular T. gondii tachyzoites and investigate 
whether any of these transporters are involved in the uptake of arprinocid or arprinocid- 
1-N-oxide.
(ii) Investigate whether arprinocid-1-N-oxide resistance in T. gondii is the result of 
altered purine transport kinetics. Resistance to chemotherapeutic agents is often 
associated with mutations in the transporter responsible for their selective accumulation. 
Examples include resistance to tubercidin (7-deazaadenosine) in Leishmania donovani 
(Vasudevan et a l, 2001) and to arsenicals in Trypanosoma brucei (Maser et a l, 1999).
(iii) Investigate whether arprinocid and arprinocid-1-N-oxide inhibit mammalian 
nucleoside/nucleobase transporters, specifically adenosine and adenine transport. These 
transporters have been characterised extensively in red blood cells and, although human 
erythrocytes do not provide a model of T. gondii infection, transport analysis in these 
cells will give further information on the activity of arprinocid and arprinocid-1-N- 
oxide against mammalian cells.
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6.3 Methods
6.3.1 Preparation of T. gondii tachyzoites
Tachyzoites were separated from host cells by filtration as described (section 2.2.2) and 
washed twice in assay buffer (33 mM HEPES, 98 mM NaCl, 4.6 mM KCl, 0.55 mM 
CaCb, 0.07 mM MgS0 4 , 5.8 mM NaH2? 0 4 , 0.3 mM MgCE, 23 mM NaHCOs and 14 
mM glucose, pH 7.3) by centrifugation at 1500 x g for 15 min at 4°C. Tachyzoites were 
counted and re-suspended in assay buffer at a density of between 1.5 - 2.5 x 10^/ml.
6.3.2 Transport studies using 71 gondii
The analysis of transport of purine nucleosides (adenosine or inosine) and purine 
nucleobases (adenine or hypoxanthine) into extracellular T. gondii tachyzoites was 
performed using a modified oil-stop technique previously described for transport 
measurements in Trypanosoma brucei brucei (de Koning, 2001). Assay buffer (100 p.1) 
containing radiolabelled nucleoside or radiolabelled nucleobase (permeant) and, where 
appropriate, various concentrations of test compound, was layered over 200 {il of a 7:1 
mixture of di-M-butyIphthalate (BDH, Poole, U.K.) and light mineral oil (Sigma). 
Arprinocid and arprinocid-1-N-oxide were diluted from stock concentrations of 50 mM 
and 3 mM, respectively, in 100 % DMSO. Final concentrations of DMSO were 1 % 
throughout, which had no noticeable effect on cells. Transport assays, performed at 
room temperature, were initiated by rapid pipetting of tachyzoites ( 1 0 0  pi) to the 
permeant. Assays were stopped by the addition of 1 ml ice-cold 4 mM (hypoxanthine or 
adenine) or 10 mM (inosine or adenosine) ice-cold unlabelled permeant. Parasites were 
centrifuged through the oil layer at 16,000 x g for 1 min using a Heraeus Biofuge
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centrifuge (Jencons PLS, Bedfordshire, UK). Subsequently, each tube was flash-frozen 
in liquid nitrogen and the bottom of the tube, containing the cell pellet, cut into 6  ml 
scintillation vials. Tachyzoite pellets were lysed in 250 pi 5 % (w/v) TCA for 90 min 
before being mixed with 3 ml Ecoscint A scintillation fluid (National Diagnostics, 
Atlanta, GA). Radioactivity was determined by using a 1219 RackBeta Spectral 
scintillation counter (LKB Wallac, Finland). All assay data points were performed in 
triplicate.
6.3.3 T. gondii growth measurements
The in vitro growth of T. gondii tachyzoites was measured by quantification of the 
incorporation of ^ H-uracil, as described in Chapter 3.
6.3.4 Transport studies using human red blood cells (hRBCs)
Human blood cells from healthy volunteers were obtained from the Glasgow and West 
of Scotland Blood Transfusion Service. The blood was preserved in citrate-phosphate- 
dextrose adenine (16 mmol/1 citric acid, 89 mmol/1 sodium citrate, 16 mmol/1 sodium 
dihydrogen phosphate, 161 mmol/1 glucose and 2  mmol/1 adenine) and stored for less 
than 1 week. Blood cells, in a total volume of approximately 10 ml, were washed three 
times by centrifugation at 1800 x g for 10 min at 4°C in 50 ml erythrocyte medium 
(EM, 140 mM NaCl, 5 mM KCl, 20 mM Tris/HCl pH 7.4, 2 mM MgCh and 0.1 mM 
EDTA). After each wash, white blood cells were removed using a pasteur pipette. 
Washed hRBCs were resuspended in three times their volume of EM (25 % 
haematocrit) at a density of 2 - 2.5 x 10  ^cells/ml. Transport assays were performed as 
described above except that radiolabelled permeant and inhibitor was layered over 250
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pi di-/7-butyIphthalate (BDH). Assays were initiated by rapid pipetting of the cell 
suspension ( 1 0 0  pi) into permeant and were stopped by the addition of 1 ml ice-cold 
stop medium containing 19 mM papaverine in 165 mM NaCl for adenine uptake assays 
or 20 pM dilazep in EM for adenosine uptake assays. Cells were then pelleted by 
centrifugation at 16,000 x g for 1 min, as described above. The aqueous and oil layers 
were removed using a suction pump and remaining radioactivity above the pellet wiped 
away using cotton buds. RBC protein was solubilised in 0.25 ml 1 % triton X-100 for 
20 min, precipitated by the addition of 0.25 ml 5 % (w/v) TCA and centrifuged at 
16,000 X g for 10 min. Supernatant was transferred to scintillation vials and radio­
activity measured, as described, after the addition of 3.5 ml scintillation fluid. All assay 
data points were performed in triplicate.
6.3.5 Calculation of transport kinetics
Kinetic parameters were calculated using the FigP graphical package (Biosoft, 
Ferguson, MO) and are presented as a mean ± S.E. of three independent experiments. K; 
values were calculated using the equation, K; = ICso/[l + (L/Km)] (Cheng and Prusoff, 
1973). Consistent with monophasic competitive inhibition, Hill coefficients were found 
to be consistently close to -1. Experimental data and kinetic values from separate 
experiments are shown in the text as averages ± standard errors (n = 3); representative 
data from an experiment is presented in figures and corresponding legends. Transport of 
permeant refers to mediated transport minus radioactivity associated with the cells due 
to diffusion or binding. Counts per minute resulting from diffusion and binding were 
taken to be those associated with the cell pellet in parallel incubations but in the 
presence of saturating concentrations of unlabelled permeant.
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6.4 Results
6.4.1 Purine nucleoside transport
Uptake of [^H]adenosine at 1.25 pM and 2.5 mM by pRH T. gondii tachyzoites was 
linear for at least 90 s (Figure 6.2a). Uptake of adenosine was saturable, with 2.5 
mM unlabelled adenosine greatly reducing uptake rates (Figure 6.2a). The remainder of 
uptake is assumed to be as a result of diffusion since 1 mM adenosine saturated uptake 
(Figure 6.2b inset). Therefore, in subsequent experiments uptake at 2.5 mM adenosine 
was subtracted from every datapoint to yield mediated uptake. [^H] Adenosine transport 
(1.25 pM), in the presence of unlabelled substrate (0 - 1000 pM) confonned to simple 
Michaelis-Menten kinetics (Figure 6.2b inset) having Km and Vmax values of 108 ± 20 
pM (n = 3) and 0.066 ± 0.002 pmol/10^ parasites/s (n = 3), respectively. Adenosine 
transport was found to be inhibited by both arprinocid (Ki = 3.3 ± 1.1 pM, n = 3) and 
arprinocid-1-N-oxide (Ki = 10.4 ± 3.4 pM, n = 3) with Hill slopes of approximately -1, 
consistent with competitive inhibition (Figure 6.2b). At the highest concentrations 
tested, arprinocid (50 pM) and arprinocid-1-N-oxide (60 pM) greatly inhibited 
adenosine transport, compared with similar assays in the absence of drug, by 82.9 ± 4.4 
% (n = 3) and 98.9 ± 4.1 % (n = 3), respectively (P < 0.001). These results are in 
agreement with arprinocid and arprinocid-1-N-oxide being taken up by the T. gondii 
adenosine transporter.
The kinetic constants, Km and Vmax, for [^H]adenosine (1.25 pM) transport in an 
arprinocid-1-N-oxide-resistant strain of T. gondii (ARP^) were not significantly 
different (P > 0.05) from those for adenosine transport in the isogenic parental line
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Figure 6.2. Adenosine transport in T. gondii tachyzoites. (a) 
Uptake of 1.25 pM pH]adenosine (7.21 ± 1.04 x 10'"^  pmol/10^ 
parasites/s) and 2.5 mM pH]adenosine (1.07 ± 0.56 x 10"^  
pmol/1 0  ^pai'asites/s) was measured over various intervals between 
0 and 90 s. (b) Uptake of [^H]adenosine (1.25 pM) over 45 s by 
RH T. gondii in the presence of unlabelled adenosine (IC50 = 63.5 
± 17.0 pM), arprinocid (IC50 = 3.5 ± 1.4 pM) and arprinocid-1-N- 
oxide (IC50 = 9.3 ± 4.7 pM). Micbaelis-Menten graph, inset, shows 
calculated K,„ and values, for this experiment, for adenosine 
transport of 63.5 ± 17.0 pM and 0.069 ± 0.004 pmol/10^ 
parasites/s, respectively. 1 0 0  % control rate was 1 . 1  ± 0 . 2  x 1 0 "^  
pmol/1 0  ^parasites/s.
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(pRH), and similarly conformed to Michaelis-Menten kinetics (Figure 6.3 inset). The 
kinetic constants, Km and Vmax, were determined to be 70 ± 31 pM (n = 3) and 0.050 ± 
0.027 pmol/10^ parasites/s (n = 3), respectively. The adenosine transporter in the 
resistant strain was equally sensitive to arprinocid-1-N-oxide (Ki = 11.3 ± 2.8, n = 3) as 
the parental strain (Figure 6.3).
Transport of pH]inosine at 0.1 pM, 1 pM and 10 pM was linear for up to 180 s (Figure 
6.4a). Uptake of inosine (1 pM), measured at 120 s, was saturable by unlabelled inosine 
over the range 0 - 1 0  mM and exhibited Michaelis-Menten kinetics (Figure 6.4b and 
inset). Km and Vmax values for this transporter were calculated as 656 ± 259 pM (n = 3) 
and 0.28 ± 0.09 pmol/10^ parasites/s (n = 3). In three independent experiments, 
arprinocid (50 pM) and arprinocid-1-N-oxide (50 pM) had no significant effect on the 
transport of pH]inosine.
6.4.2 Inhibition of TgATl with dipyridamole
Data obtained so far were consistent with arprinocid and arprinocid-1-N-oxide being 
transported by TgATl and therefore, to ascertain whether either compound was 
transported via TgATl, a ^H-uracil assay to measure parasite growth (Section 3.3.1) 
was conducted using dipyridamole to block adenosine transport. Dipyridamole (10 pM) 
has been shown to block adenosine transport (Schwab et a l, 1995). Therefore a change 
in the efficacy of arprinocid or ai*prinocid-l-N-oxide, measured in the presence of 
dipyridamole, would verify whether or not the T. gondii adenosine transporter (TgATl) 
was involved in the mechanism of action of arprinocid or arprinocid-1-N-oxide. Control 
experiments in the presence of only dipyridamole died, indicating that dipyridamole.
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Figure 6.3. Adenosine transport In arprinocid-1-N-oxide-resistant 
T. gondii tachyzoites (ARP* )^. Uptake of adenosine (1.25 pM) 
over 45 s by ARPr T. gondii in the presence of unlabelled adenosine 
(IC50 -  54.0 ± 18.5 pM) and arprinocid-1-N-oxide (IC50 ^4 .5  ± 1.1 
pM). Michaelis-Menten graph, inset, shows calculated K,„ and 
values, for this experiment, for adenosine transport of 59.5 ± 7.4 
pM and 0.031 ± 0.001 pmol/10^ parasites/s, respectively. 100 % 
control rate was 1 . 1  ± 0 . 2  x 1 0 '  ^pmol/1 0  ^parasites/s.
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Figure 6.4. Inosine transport in pRH T. gondii tachyzoites. 
(a) Uptake of 0.1 pM inosine (1.60 ± 0.21 x 10'^
pmol/10^ parasites/s), 1 pM [% ]inosine (1.08 ± 0.076 x lO '^  
pmol/10^ parasites/s) and 10 pM pH]inosine (5.67 ±0.31 x 
lO"'^  pmol/1 0  ^ parasite s/s) measured over various intervals 
between 0 and 180 s. (b) Uptake of 1 pM inosine by RH 
T. gondii in the presence of unlabelled permeant (IC50 = 1074 
+ 313 pM). Michaelis-Menten graph, inset, shows calculated 
K,„ and values for this experiment of 473 + 39 pM and 
0.208 ± 0.005 pmoI/10^ parasites/s, respectively. 100 % con­
trol rate was 2.5 + 0.18 x lO"'^  pmol/10^ parasites/s.
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itself, had mti-Toxoplasma activity. Further investigations revealed that dipyridamole 
could indeed inhibit T. gondii growth with an IC50 = 3.5 ± 0.75 pM (Figure 6.5a). 
Manual counting of concurrent dipyridamole-treated-infected cultures also indicated 
that dipyridamole inhibited the growth of T. gondii (Figure 6.5b). Consequently, 
measurement of arprinocid- and arprinocid-1-N-oxide-uptake by the adenosine 
transporter could not be achieved.
6.4.3 Effect of arprinocid and arprinocid-l-N-oxide on adenosine and adenine 
transport in human erythrocytes
To investigate the effect of arprinocid and arprinocid-1-N-oxide on facilitated transport 
in human erythrocytes, a modified oil-stop technique was performed. Papaverine and 
dilazep have been shown to be efficient inhibitors of nucleobase and nucleoside 
transport, respectively, and therefore act as effective stop solutions for the reliable 
measurement of initial rates of transport (Domin et a l, 1988; Plagemann and 
Woffendin, 1988). Transport of 1 pM pH]adenine measured using seven datapoints was 
linear up to 15 s with a rate of 0.059 ± 0.005 pmol/10^ cells/s (r  ^= 0.96) (unpublished 
observation, H. de Koning, 2001) and similarly uptake of 1 pM pH]adenosine was 
linear using 10 datapoints over 20 s with a rate of 0.035 ± 0.001 pmol/10^ cells/s 
(Figure 6.6). All transport assays were performed at 5 s, well within the linear phase. 
Neither arprinocid (1 - 50 pM) nor arprinocid-1-N-oxide (1 - 60 pM) had any 
significant effect on the transport of adenine or adenosine in red blood cells (P > 0.05) 
compared with equivalent assays in the absence of drug. Controls with 1 mM unlabelled 
permeant completely inhibited uptake (n = 3; data not shown).
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Figure 6.5. Inhibition of T. gondii growth by dipyridamole, 
(a) Growth of T. gondii tachyzoites was quantified by 
uracil incorporation, as described in Chapter 3, in the 
presence of dipyridamole (0 - 10 pM). The IC 5 0  of 
dipyridamole was calculated as 3.5 ± 0.75 pM. Data points 
are the mean ± SE (n = 3). (b) Parasites grown using 
exactly the same parasitexell ration in concurrent infected 
culture flasks were counted at 48, 72 and 96 h post­
infection. Uninfected drug-treated Vero cells showed no 
obvious signs of distress compared to untreated uninfected 
control cells.
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6.4.4 Purine nucleobase transport
Uptake of ^[H]-adenine at 0.1 pM, 1 pM and 10 pM by extracellular T. gondii 
tachyzoites (pRH) was comparatively slow and linear for up to 180 s, with rates of 8.2 
± 2.0 X 10'  ^pmol/10^ parasites/s, 6.8 ± 0.89 x 10'  ^pmol/10^ parasites/s and 3.9 ± 0.7 x 
10’"^ pmol/10^ parasites/s, respectively (Figure 6.7a). At 1 pM, pH]-adenine uptake was 
not saturable by unlabelled adenine concentrations up to 1 mM (Figure 6.7b).
Uptake of [^H]-hypoxanthine at 0.1 pM, 1 pM and 10 pM by T. gondii tachyzoites was 
rapid and linear for up to 180 s (Figure 6.8a). pH]-Hypoxanthine transport (0.3 pM) 
measured at 120 s over a range 0 - 1000 pM unlabelled permeant was saturable and 
complied with simple Michaelis-Menten kinetics, with a Km value of 0.91 ±0.19 pM 
and a Vmax value of 0.0045 ± 0.0014 pmol/10^ parasites/s (n = 3) (Figure 6.8b and 
inset). The inhibitory effects of potential substrates for this hypoxanthine transporter, 
designated TgHTl, were tested by measuring initial uptake rates at 0.3 pM pH]- 
hypoxanthine, in the presence of varying concentrations of test compounds (Figure 6.9). 
The 6-keto nucleobases, guanine (6.9 pM) and xanthine (134 pM) inhibited 
hypoxanthine transport by 50.2 ± 2.9 % (P < 0.005) and 61.4 ±2. 1 % (P < 0.005), 
respectively, whereas the aminopurine adenine and the nucleosides, adenosine and 
inosine, were less potent inhibitors (21 ± 3.8 %, 50.5 ± 2.0 % and 47.6 ± 5 . 7  %, 
respectively, at 1 mM). The hypoxanthine analogue allopurinol also weakly inhibited 
hypoxanthine transport, by 29.7 ± 8.4 % at 1 mM (P < 0.05). Arprinocid (50 pM) had 
no significant effect on the transport of hypoxanthine whilst, arprinocid-1-N-oxide (30 
pM) reduced uptake by 24.2 ± 8.7 % (P < 0.05).
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Figure 6.7. Uptake of adenine by extracellular 
pRH T. gondii tachyzoites. (a) Uptake of ^[H]- 
adenine at 0.1 pM, 1 pM and 10 pM by T. gondii 
tachyzoites was linear for up to 180 s (rates are 
shown in text), (b) Uptake of adenine (1 pM) 
by T. gondii tachyzoites was determined at 120 s 
in the presence of unlabelled substrate (0 - 1000 
pM). No carrier-mediated transport of adenine 
was observed as indicated by the non-saturable 
linear uptake of adenine (5.31 ± 0.12 x 10""^  
pmol/10^ parasites/s).
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Figure 6.8. Hypoxanthine transport in RH T. gondii tachyzoites. (a) 
Uptake of 0.1 pM pH]hypoxanthine (1.04 ± 0.27 x 10'"^  pmoI/10^ 
parasites/s), 1 pM pHJhypoxanthine (4.26 ± 0.22 x 10'"* pmol/10^ 
parasites/s) and 10 pM pH]hypoxanthine (1.75 ± 0.092 x 10"^  
pmol/10^ parasites/s) measured over various intervals between 0 
and 180 s. (b) Uptake of [^H]hypoxanthine (0.3 pM) over 120 s by 
T. gondii in the presence of unlabelled hypoxanthine (ICg  ^= 0.59 ± 
0.12 pM). Michaelis-Menten graph, inset, shows calculated and 
^max values for this experiment of 0.49 ±0.11 pM and 0.0045 ±3.3 
X 10"'^  pmol/10^ parasites/s, respectively. 100 % control rate was 
0.002 ± 2.2 X 10 pmol/10^ paiasites/s.
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Figure 6.9. Inhibition profile of the T. gondii hypoxanthine 
transporter, TgHTl. Uptake of pH]hypoxanthine (0.3 pM) was 
measured in the presence of various inhibitors. Guanine (6.9 pM; 
P < 0.005), xanthine (133.5 pM; P < 0.005), adenosine (1 mM; P 
< 0.005) and inosine (1 mM; P < 0.05) significantly reduced the 
transport of hypoxanthine. Data shown are the average of three 
independent experiments and S.E.
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Figure 6.10. Uracil transport by T. gondii. Uptake of 1 pM pH]- 
uracil (1.8 ± 0.2 x 10"^  pmol/10^ cells/s), and in the presence of 50 
pM arprinocid (8.0 ± 3.0 x 10'  ^pmol/10^ cells/s) or in the presence 
of 60 pM arprinocid-1-N-oxide (9.4 ± 0.7 x 10'  ^ pmol/10^ cells/s) 
over various time intervals between 0 and 180 s (n = 2).
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6.4.5 Effect of arprinocid and arprinocid-l-N-oxide on ^H-uracil transport In J. 
gondii
Uptake of 1 pM ^H-uracil by T. gondii tachyzoites was measured over various time 
points between 0 and 120 s (Figure 6.10). The rate of uptake of ^ H-uracil was reduced 
approximately two-fold by the presence of 50 pM arprinocid and by the presence of 30 
pM arprinocid-1-N-oxide (Figure 6.10).
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6.5 Discussion
Purine salvage by T. gondii from the host cell requires translocation of the purine across 
the parasitophorous vacuole membrane (PVM) and subsequently across the parasite cell 
membrane. Studies of the PVM, poses technical difficulties and consequently little is 
known about its exact function. However, the PVM is permeable to small solutes up to 
1300 - 1900 Da, allowing free exchange of small molecules between the host cell 
cytoplasm and vacuolar spaces and so is unlikely to provide any barrier to purine bases 
and nucleosides (Schwab et a l, 1994). In contrast, the tachyzoite cell membrane will 
form a barrier amenable to the study of transport across this membrane, after tachyzoites 
have been separated from the host cell.
Results from investigations of the purine transporters of T. gondii tachyzoites using the 
oil-stop technique provide evidence for the presence of facilitated transport routes for 
adenosine (TgATl), inosine (designated TglTl) and hypoxanthine (designated TgHTl). 
The calculated value of Km for TgATl (Km = 105 ± 22 pM) is in agreement with that 
from previously published work (Schwab et a l, 1995) and is also in agreement with the 
Km calculated for TgATl expressed in oocytes (Chiang et a l, 1999).
The published Km for inosine transport is 81 pM (Schwab et a l, 1995) whilst data 
presented in this report suggest a Km value 8-fold higher. The reason for this 
discrepancy is unclear. Furthermore, in this study no evidence of two inosine 
transporters (Schwab et a l, 1995) was found and careful evaluation of Schwab and co­
workers' data suggest that inosine was transported only by the dipyridamole-insensitive 
transporter (TglTl). Data obtained for the uptake of inosine by T. gondii tachyzoites
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exhibited a monophasic inhibition profile, consistent with a single transporter for 
inosine. Whilst TgATl has been reported to be inhibited by inosine (Chiang et a l, 
1999; Schwab et al, 1995) no evidence has been presented that prove inosine is actually 
transported by this transporter. Clearly more work needs to be done to establish the 
exact substrate specificities of these transporters, but it is certain that purine nucleosides 
are taken up with only low affinity. In contrast, TgHTl has a high affinity for 
hypoxanthine, and is likely to also transport guanine and perhaps xanthine into T. 
gondii,
Schwab et al, (1995) proposed that TgATl also transported hypoxanthine and adenine, 
on the basis of the ability of these nucleobases to inhibit adenosine uptake at 1.6 mM. 
Similarly, Chiang et al, (1999) showed that hypoxanthine and guanine, but not adenine 
and xanthine, inhibit approximately 35 % of adenosine uptake at 0.5 mM. However, 
results obtained in this study suggested uptake of adenine was due to diffusion. This is 
consistent with the observation that the incorporation of [^HJadenine is negligible in 
extracellular T. gondii tachyzoites (Schwartzman and Pfefferkom, 1982). While TgATl 
may have some very low affinity for hypoxanthine, it is unlikely to contribute 
significantly to the overall hypoxanthine flux.
The previously reported low affinity of TgATl for adenosine (Schwab et a l, 1995) 
seems to contradict the hypothesis that adenosine is the preferred substrate for purine 
salvage by T. gondii. Currently, the most convincing evidence for this theory is (i) the 
high activity of adenosine kinase (Krug et a l, 1989) and (ii) the presence of an 
adenosine transporter, TgATl. However, it is highly unlikely that adenosine is 
accumulated in the parasitophorous vacuole at a much higher concentration (closer to 
the Km of TgATl) than is present in the host cytoplasm because the PVM is effectively
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porous to small molecules such as adenosine. Therefore, adenosine will be in 
equilibrium between the parasitophorous vacuole and the host cell cytoplasm at a 
concentration far lower than the Km of TgATl.
Whilst the hypothesis of preferential uptake of adenosine by T, gondii cannot be 
discounted, all in all it is likely that the TgHTl transporter described here makes a very 
significant contribution to purine salvage. This is consistent with the observation that 
both TgATl and adenosine kinase null mutants are viable (Chiang et a l, 1999; Darling 
et a l, 1999). One theory could be that adenosine deaminase present within host cells 
may convert adenosine to inosine (Krug et a l, 1989) and subsequent metabolism of 
inosine to hypoxanthine by mammalian inosine phosphorylase would allow transport of 
hypoxanthine into T. gondii via TgHTl and the HXGPRT-salvage pathway.
In P. falciparum two nucleoside/nucleobase transporters PfNTl and PfENTl, differing 
only by one amino acid, have been identified by two independent research groups 
(Carter et a l, 2000; Parker et a l, 2000). PfENTl has a low affinity for adenosine (Km = 
320 ± 50 |llM) (Parker et a l, 2000) and similarly TgATl also has a low affinity for 
adenosine. In contrast, PfNTl has been reported to have a much higher affinity for 
adenosine (Km = 13.2 ± 4.3 p,M) (Carter et a l, 2000). Further work is necessary to 
address this discrepancy, to elucidate whether or not PfENTl and PfNTl are distinct 
transporter proteins, and whether or not P. falciparum has similar transport proteins to 
T. gondii. Interestingly, T. gondii has a high affinity hypoxanthine transporter (TgHTl) 
and P. falciparum PfENTl has a low affinity for hypoxanthine (Km = 420 ± 1 0  piM) 
(Parker et a l, 2000) suggesting that they both have distinct purine salvage requirements.
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Several protozoan purine transporters have been implicated in the uptake of and 
resistance to various chemotherapeutic agents. Examples include the T, cruzi adenosine 
transporter and tubercidin resistance (Finley et a l, 1988; Nozaki and Dvorak, 1993), the 
Leishmania donovani LdNT2 transporter and resistance to formycin B (Aronow et a l, 
1987), and the involvement of the T. b. brucei P2 transporter in uptake of diamidines 
and melaminophenylarsenicals (Maser a/., 1999). Data presented in this thesis 
indicate that resistance to arprinocid-1 -N-oxide is unlikely to be due to a modified 
adenosine transporter (TgATl) since inhibition of adenosine transport by aiprinocid-1- 
N-oxide in the drug-resistant line was similar to that observed in the drug-sensitive line. 
In this study, it was investigated whether arprinocid and its 1-N-oxide metabolite enter 
host cells by the broad-specificity equilibrative nucleobase and es nucleoside 
transporters present in human red blood cells and many other tissues (de Koning and 
Diallinas, 2000; Plagemann et a l,  1988). The lack of inhibition of these transporters by 
arprinocid and its metabolite suggests that these drugs may enter the host cells by 
diffusion. The diffusion gradient, however, would only lead to effective accumulation if 
the compound were subsequently salvaged from the host cell cytosol by a high affinity 
r. gondii transporter, after diffusion into the parasitophorous vacuole. Alternatively, 
arprinocid may accumulate within host cells by binding to intracellular organelles or 
membranes. It should also be recognised that perhaps arprinocid and arprinocid-1-N- 
oxide do not enter hRBC. In addition, erythrocytes are not good models of T. gondii 
host cells and further work using other cells, perhaps macrophages, is necessary. Both 
arprinocid and arprinocid-1-N-oxide inhibited TgATl, but not TglTl or TgHTl, with 
much higher affinity than its natural substrate, adenosine, suggesting these drugs may 
be substrates for the transporter -  leading to selective accumulation within the parasite.
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Conclusive evidence that arprinocid or arprinocid-1-N-oxide enters T. gondii via 
TgATl could not be obtained using dipyridamole (an inhibitor of adenosine transport) 
since this compound also inhibits the in vitro growth of the tachyzoites. The reason for 
this inhibition is not clear but is likely to involve inhibition of phosphodiesterase (PDE). 
The regulation of cAMP by adenylate cyclase and phosphodiesterase (PDE) is 
important in controlling the proliferation of T. gondii. PDE activators, for example 
imidazole, lower cAMP levels and inhibit growth of Toxoplasma, whereas PDE 
inhibitors, for example 3-isobutyl-1-methylxantine (IBMX), raise cAMP levels and 
promote growth of Toxoplasma (Choi et a l, 1990). Two classes of PDE enzymes have 
been identified in T. brucei (i) TbPDEl and (ii) TbPDE2. In contrast to the observations 
made by Choi et al, (1990), a mutant T. brucei isolate lacking the gene encoding for 
PDEl exhibited no phenotypic difference except for a marginal increase in growth rate. 
Whilst IBMX is a broad spectrum PDE inhibitor, dipyridamole is selective for type-2 
PDE enzymes (Seebeck et a l, 2001). Inhibition of T. gondii growth by dipyridamole 
would suggest that the parasite contains type-2 PDE or related enzymes. Trypanosoma 
brucei cyclic nucleotide-specific phosphodiesterase PDE2A (Accession number 
AF263280) sequence data was used in a BLASTn search of the T. gondii EST database 
and resulted in a match to the T. gondii consensus sequence Ctoxqual_4522 with 62 % 
homology (P = 1.5e-10). This indicats that T. gondii tachyzoites may contain a PDE2- 
related enzyme. Dipyridamole has been demonstrated to inhibit the in vitro growth of 
bloodstream T. brucei with an IC50 of 5 - 10 pM (Seebeck et al., 2001), a similar 
concentration to that shown to inhibit the proliferation of T. gondii tachyzoites. 
Currently, little is known about the role of PDE in T. gondii but it is evident that these 
enzymes are essential for normal metabolism and could be explored as potential 
chemotherapeutic targets.
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Results from chapter 3 (Section 3.4.5) led to the conclusion that both arprinocid and 
arprinocid-1-N-oxide act within a short period of time. In this chapter, it was 
demonstrated that arprinoeid (50 pM) and arprinocid-1-N-oxide (30 pM) reduce the rate 
of incorporation of ^H-uracil over a period of 120 s. This, perhaps, could explain the 
rapid action of the compounds. However, although there is a direct correlation between 
^H-uracil uptake and parasite growth (Chapter 3), the significance of a two-fold 
reduction in the rate of ^H-uracil uptake measured over a period of 120 s, considering 
that the tachyzoite replication cycle lasts approximately 4-6 h, is not known. In addition, 
the concentration of arprinocid-1-N-oxide used in the transport experiment is 490-fold 
greater than its I C 5 0  value, and hence the decreased rate of ^H-uracil uptake for 
arprinocid-1-N-oxide may not be significant.
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CHAPTER 7 
Final Discussion and Conclusions
The central theme of this study was to investigate the mode of action of two purine 
analogues, arprinocid and arprinocid-1-N-oxide, by comparing arprinocid-1 -N-oxide- 
sensitive and -resistant T. gondii lines. Two main approaches were taken:
• a global approach using two-dimensional electrophoresis and mass spectrometry 
(proteomics).
• a directed approach to test the hypothesis that arprinocid and arprinocid-1-N-oxide 
may exert their action by interfering with purine salvage and/or purine transport.
These approaches are discussed below in relation to their applicability to the drug 
discovery process and the results obtained in this work.
Initial work focussed on determining the efficacies of the compounds by using 
incorporation of ^H-uracil into tachyzoites as a measure of parasite abundance and 
viability. Although these investigations gave limited information on how the 
compounds work, the assays provided some details on basic properties of the 
compounds, such as the rapidity of their action, and in eliminating the hypothesis that 
hypoxanthine transport was involved in their mechanism of action. Further 
investigations of the rapidity of action of arprinocid and arprinocid-1-N-oxide showed
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that they caused a two-fold reduction in the rate of uptake of ^ H-uracil, but this was not 
thought to be significant. The adenosine transporter was found to be a possible mode of 
entry of the compounds into the parasites.
A major emphasis of this project was to apply techniques of proteomics to Toxoplasma. 
The ability to separate proteins in two dimensions has been in existence for over 25 
years. However, the recent improvements in both protein separation and mass 
spectrometry have enabled proteomics to become an important technology. Proteomics 
offers the distinct advantage over mRNA based techniques in that information regarding 
post-translational modifications or protein expression levels may be obtained. The study 
of genes alone cannot give this information, and given that there are over 400 possible 
chemical modifications that a protein may undergo (Pennington and Dunn, 2001), all 
with consequences to its function/activity, analysis of expressed gene products is vital. 
Changes in the structure and abundance of proteins are causes of disease and resistance 
to drugs. Ultimately, most therapeutic drugs are targeted against proteins and the design 
of new improved compounds requires increased knowledge of protein expression.
The use of proteomics in parasitology is in its infancy but the technique is applicable to 
the analysis of virulence factors, the analysis of protein changes as a consequence of 
genetic manipulation, and the analysis of protein expression changes between drug- 
sensitive and -resistant lines. These have been demonstrated in this work. Clearly, 
proteomics is also applicable to many other aspects of parasitology research, such as 
characterising the proteins specifically expressed in different T. gondii life stages. This 
could aid in understanding the mechanisms by which the parasite has evolved to be a 
successful intracellular pathogen.
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On a wider perspective, proteomics may be used in the drug discovery process, itself 
(Page et al., 1999). The drug discovery process has largely depended upon the screening 
of vast compound libraries but in recent years has frequently been initiated by the 
identification of a drug target by molecular, cellular or genomic approaches with 
experiments based on pre-determined hypotheses. For example, arprinocid being a 
purine analogue may inhibit purine salvage/transport. Working on this hypothesis a high 
affinity hypoxanthine transporter, TgHTl, was discovered, which itself may be a 
potential drug transporter. The next step would be to clone the gene, express it and 
target or characterise the transporter. In contrast to this approach, proteomics is 
"hypothesis-generating" and starts from the detection of a protein differentially 
expressed between diseased and healthy tissues/cells. The rapid identification of 
disease-specific proteins (or modifications of proteins) can be applied in the 
investigation of pathogenesis. Recently, comparative analysis of proteins from the 
brains of /j53-deficient mice (p53 is a tumour suppressor gene and mutations in this 
gene are known to account for more than 50 % of human cancers) and control mice 
revealed 7 proteins out of the 886 analysed that were specific to the p52> null mice 
(Araki et al., 2000).
The detection of differentially expressed proteins is insufficient to enable the start of the 
drug discovery process. The identification of these proteins by mass spectrometry and 
subsequent validation of their importance in the onset of disease is vital. For example, if 
the gene encoding the protein was deleted (by molecular methods) and resulted in a 
reversal of the disease phenotype, then this would validate the protein a drug-target. 
This is why proteomics is described as "hypothesis-generating''. Proteomics can also be 
of great advantage in assessing changes in metabolic pathways as a consequence of a
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drug directed against a particular protein and therefore provide information on potential 
toxic side-effects of this therapy.
Elucidating the mechanism of action of a compound is the next crucial part of the drug 
discovery process. This may be undertaken by analysing particular possible targets. In 
this study, T. gondii purine transporters were analysed using the oil-stop technique and 
this showed that the adenosine transporter might play a pivotal role in the mechanism of 
action of arprinocid and arprinocid-1-N-oxide. This possibility requires further 
investigation, perhaps by using an adenosine transporter Imockout line (Chiang et a l, 
1999). Proteomics also may be applied to mode-of-action studies, for example, in 
determining the up- or down-regulation of proteins in response to drug treatment. 
Treatment of hepatoma cells (Huh?) with IC50 doses of 5-fluorouracil identified 19 
proteins that were up-regulated by 5-fold or more (Page et ah, 1999). Several of these 
proteins were related to pyrimidine pathways and cell cycle/growth pathways, thus 
giving information on the mechanism of action of 5-fluorouracil. This approach could 
be an important method to determining (or comparing) the mechanisms of action of 
arprinocid and arprinocid-1-N-oxide, and potential toxicity pathways. In addition, it is 
conceivable that a protein involved in resistance may be minimally expressed under 
normal passage conditions, but up-regulated under drug pressure.
Although the reliable identification of proteins using mass spectrometry and EST 
databases was demonstrated, this failed to identify the protein that was differentially 
expressed between the arprinocid-1-N-oxide-sensitive and -resistant lines. The success 
of identification of proteins was, arguably, related to the fact that these samples were 
Coomassie-stained and that the failure to identify the differentially expressed protein 
may have been because it was silver-stained, which is much less compatible with mass
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spectrometry analysis. Since Sypro Ruby fluorescent staining is equal in sensitivity to 
silver-staining but more compatible with mass spectrometry analysis, this is, perhaps, 
the best strategy for future attempts to identify this and other proteins of interest. In 
addition Sypro Ruby staining allows more accurate assessment of subtle protein 
expression changes. However, the disadvantage of Sypro-staining is that an automated 
spot-picker is required for excising the protein from the gel. This equipment was not 
available during this study, but although expensive, is now commercially available.
It could be that even when using mass spectrometry-compatible protein staining 
methods together with the current status of the EST database, or even when full gene 
sequence information is available for T. gondii, that the differentially expressed protein 
would still remain unidentified. Certainly, not all the spots visualised with Coomassie- 
blue staining were identified. Thus the question needs to be asked, is proteomics a 
viable technique for identification of protein expression changes in organisms with 
limited genome information? The data presented suggest the answer is yes, and if 
further increases in the size of genome and protein databases are made, the possibility of 
proteins remaining unidentified should be minimised. Moreover, work in this thesis has 
demonstrated that proteins may be reliably identified from known proteins of other 
organisms (homology searching). These reasons for optimism are reinforced by the 
report that a proteomics approach was used successfully for the investigation of 
erythromycin-resistance in Streptococcus pneumoniae (Cash et al., 1999).
The techniques comprising proteomics are advancing very rapidly. In addition to the 
advances in 2-DE separation technology, improvements in fluorescent protein labelling 
(i.e. Cy " dyes) and analysis software (Beaumont et al., 2001) are further enhancing our 
ability to reproducibly and quantitatively analyse protein expression changes between
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two systems, with less manual input. The success of this "difference gel" electrophoresis 
(DIGE) technology is yet to be confirmed but the preliminary literature suggests that the 
techniques are very promising. One alternative to this technology is post-gel labelling, 
known as isotope-coded affinity tagging (ICAT). In this approach, proteins from two 
different cell states (A and B) are separated by 2-DE and protein spots of interest are 
excised. Proteins from A and B are digested and peptides labelled at the A-terminus 
with H4NicNHS (light isotope containing hydrogen) and D4NicNHS (heavy isotope 
containing deuterium), respectively. Mass spectrometric analysis of the combined 
digests then provides information on the expression levels of those proteins by 
comparison of H4/D4 ratios of individual peptides (Quadroni and James, 2001). All of 
the techniques mentioned above currently require 2-DE to separate proteins. However, 
recent improvements in HPLC analysis have meant the technique can be miniaturised to 
using capillary columns (Manabe, 1999; Jensen et a l, 2000). The advantage of this 
technique is that it is readily automatable and can be linked directly to a mass 
spectrometer (LC-MS). The ICAT technique described above, also may be performed 
using LC-MS without the need for 2-DE gel separation (Gygi et a l, 1999a). More 
recently, protein separation and digestion techniques have been miniaturised onto 'chips' 
containing fluid channels, measuring 50 \im (depth) x 30 jxm (width) x 16 cm (length), 
and reaction chambers (Figeys and Pinto, 2001). Thus, high-throughput proteomics is 
under development and will be available in the near future.
Microarray technology can rapidly identify disease-specific mRNAs but the lack of 
correlation between mRNA and protein expression limits its use for drug discovery. 
Micro array technology has been used in the identification of genes that are up- or down- 
regulated during the first 24 h of invasion of a cell by T. gondii (Blader et a l, 2001).
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Similar types of experiments should soon be possible using protein-array chips. The 
technique requires an interaction between a molecule and a protein moiety, and a 
method of detection of this interaction. Clearly molecular recognition of proteins in a 
similar fashion to that used for cDNA arrays has inherent problems. For example, 
fluorescently labelled proteins (for detection purposes) may alter the function of the 
protein or its active site and differences in the efficiency of labelling the same protein 
with different fluorophores may undermine quantitative analyses (Jenkins and 
Pennington, 2001). Thus problems remain to be overcome, but the potential advances 
are clear.
In conclusion, proteomics is at an early development 'proof of principle' stage and is 
currently limited by technology (Lee, 2001). However, with continued investment 
proteomics will become an important collection of tools for the investigation and 
characterisation of proteins in biological systems, including parasites and their 
interactions with host cells. It is certainly evident that proteomics is unrivalled in its 
ability to analyse simultaneously many thousands of proteins from complex mixtures. 
For the full potential of proteomics in parasitology to be realised, continued investment 
in biochemical and molecular techniques, and in genome-sequencing projects, are 
essential.
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